Rifampin	B
and	O
warfarin	B
:	O
a	O
drug	O
interaction	O
.	O

The	O
drug	O
interaction	O
between	O
warfarin	B
and	O
rifampin	B
is	O
not	O
well	O
known	O
.	O

Rifampin	B
has	O
been	O
reported	O
to	O
increase	O
the	O
warfarin	B
requirements	O
in	O
human	O
subjects	O
ingesting	O
these	O
agents	O
simultaneously	O
.	O

The	O
concomitant	O
administration	O
of	O
rifampin	B
and	O
warfarin	B
resulted	O
in	O
the	O
need	O
for	O
an	O
unusually	O
high	O
maintenance	O
dose	O
of	O
warfarin	B
(	O
20	O
mg	O
per	O
day	O
)	O
in	O
order	O
to	O
produce	O
a	O
therapeutic	O
effect	O
.	O

Withdrawal	O
of	O
rifampin	B
decreased	O
the	O
warfarin	B
requirement	O
by	O
50	O
%	O
.	O

This	O
effect	O
may	O
be	O
mediated	O
by	O
the	O
ability	O
of	O
rifampin	B
to	O
induce	O
microsomal	O
enzymes	O
and	O
,	O
thus	O
,	O
the	O
catabolism	O
of	O
warfarin	B
.	O

The	O
effect	O
of	O
rifampin	B
on	O
the	O
warfarin	B
requirement	O
of	O
our	O
patient	O
appeared	O
to	O
be	O
maximal	O
5	O
to	O
7	O
days	O
after	O
the	O
initiation	O
of	O
rifampin	B
and	O
extended	O
a	O
similar	O
length	O
of	O
time	O
after	O
rifampin	B
withdrawal	O
.	O

To	O
study	O
the	O
pancreatic	O
effects	O
of	O
other	O
agents	O
,	O
dynamic	O
insulin	O
and	O
glucagon	O
release	O
was	O
measured	O
from	O
the	O
in	O
vitro	O
perfused	O
pancreases	O
of	O
normal	O
and	O
diabetic	O
Chinese	O
hamsters	O
in	O
response	O
to	O
various	O
combinations	O
of	O
arginine	B
(	O
20mM	O
)	O
,	O
glucose	B
(	O
100	O
or	O
150	O
mg	O
.	O
per	O
100	O
ml	O
.	O
)	O
,	O
and	O
theophylline	B
(	O
10	O
mM	O
)	O
.	O

Glucose	B
,	O
alone	O
and	O
in	O
the	O
presence	O
of	O
theophylline	B
,	O
caused	O
subnormal	O
insulin	O
release	O
and	O
less	O
suppression	O
of	O
glucagon	O
release	O
in	O
the	O
diabectics	O
than	O
in	O
the	O
normals	O
.	O

Arginine	B
,	O
in	O
the	O
presence	O
of	O
glucose	B
and	O
theophylline	B
,	O
caused	O
excessive	O
glucagon	O
release	O
but	O
nearly	O
normal	O
insulin	O
release	O
in	O
the	O
diabetics	O
.	O

Arginine	B
,	O
in	O
the	O
absence	O
of	O
glucose	B
or	O
theophylline	B
,	O
caused	O
excessive	O
glucagon	O
release	O
in	O
the	O
diabetics	O
and	O
undetectable	O
insulin	O
release	O
in	O
either	O
diabetics	O
or	O
normals	O
.	O

Further	O
,	O
these	O
results	O
confirm	O
that	O
the	O
diabetic	O
Chinese	O
hamster	O
'	O
s	O
alpha	O
and	O
beta	O
cells	O
respond	O
normally	O
to	O
theophylline	B
,	O
but	O
are	O
relatively	O
insensitive	O
to	O
glucose	B
.	O

The	O
effects	O
of	O
ketamine	B
and	O
of	O
Innovar	B
anesthesia	O
on	O
digitalis	B
tolerance	O
in	O
dogs	O
.	O

In	O
a	O
comparison	O
of	O
digitalis	B
tolerance	O
in	O
dogs	O
anesthetized	O
with	O
ketamine	B
,	O
Innovar	B
Vet	I
,	O
or	O
pentobarbital	B
,	O
the	O
dosage	O
of	O
ouabain	B
needed	O
to	O
cause	O
ventricular	O
tachycardia	O
was	O
significantly	O
higher	O
,	O
as	O
was	O
the	O
LD50	O
of	O
ouabain	B
,	O
with	O
ketamine	B
or	O
Innovar	B
than	O
with	O
pentobarbital	B
.	O

Ventricular	O
tachycardia	O
induced	O
by	O
ouabain	B
was	O
generally	O
converted	O
to	O
sinus	O
rhythm	O
following	O
administration	O
of	O
Innovar	B
,	O
ketamine	B
,	O
or	O
droperidol	B
but	O
not	O
after	O
administration	O
of	O
fentayl	B
alone	O
or	O
after	O
pentobarbital	B
.	O

The	O
literature	O
provides	O
considerable	O
evidence	O
indicating	O
that	O
several	O
,	O
but	O
not	O
all	O
antihistaminics	B
,	O
are	O
indeed	O
analgesic	B
agents	I
and	O
some	O
are	O
analgesic	B
adjuvants	I
as	O
well	O
.	O

Those	O
for	O
which	O
effectiveness	O
is	O
reported	O
includes	O
diphenhydramine	B
,	O
hydroxyzine	B
,	O
orphenadrine	B
,	O
pyrilamine	B
,	O
phenyltoloxamine	B
,	O
promethazine	B
,	O
methdilazine	B
,	O
and	O
tripelennamine	B
.	O

[	O
The	O
GABA	O
-	O
ergic	O
system	O
and	O
brain	O
edema	O
]	O

[	O
Stimulation	O
by	O
cerulein	O
-	O
-	O
an	O
analog	O
of	O
the	O
octapeptide	O
cholecystokinin	O
-	O
-	O
of	O
3H	O
-	O
spiroperidol	O
binding	O
after	O
the	O
long	O
-	O
term	O
administration	O
of	O
neuroleptics	O
]	O

After	O
prolonged	O
administration	O
of	O
neuroleptics	B
the	O
displacing	O
effect	O
of	O
cerulein	B
,	O
an	O
analog	O
of	O
cholecystokinin	O
octapeptide	O
,	O
was	O
replaced	O
by	O
the	O
stimulant	O
action	O
on	O
3H	O
-	O
spiroperidol	O
binding	O
.	O

It	O
is	O
assumed	O
that	O
increased	O
interaction	O
between	O
3H	O
-	O
spiroperidol	O
and	O
high	O
affinity	O
binding	O
sites	O
for	O
apomorphine	B
on	O
dopamine2	O
-	O
and	O
serotonin2	O
-	O
receptors	O
underlies	O
the	O
antipsychotic	O
action	O
of	O
neuroleptics	B
after	O
their	O
prolonged	O
administration	O
.	O

Dual	O
effect	O
of	O
ouabain	B
on	O
the	O
palytoxin	B
-	O
induced	O
contraction	O
and	O
norepinephrine	O
release	O
in	O
the	O
guinea	O
-	O
pig	O
vas	O
deferens	O
.	O

Palytoxin	B
(	O
PTX	B
)	O
,	O
C129H223N3O54	O
,	O
isolated	O
from	O
marine	O
coelenterates	O
of	O
Palythoa	O
tuberculosa	O
,	O
caused	O
a	O
first	O
rapid	O
contraction	O
followed	O
by	O
the	O
slow	O
phasic	O
contraction	O
of	O
guinea	O
-	O
pig	O
vas	O
deferens	O
.	O

In	O
the	O
presence	O
of	O
ouabain	B
(	O
10	O
(	O
-	O
5	O
)	O
M	O
)	O
,	O
PTX	B
(	O
10	O
(	O
-	O
8	O
)	O
M	O
)	O
failed	O
to	O
cause	O
the	O
first	O
contraction	O
;	O

When	O
ouabain	B
was	O
applied	O
to	O
the	O
muscle	O
in	O
the	O
presence	O
of	O
phentolamine	B
,	O
both	O
first	O
and	O
second	O
contractile	O
responses	O
to	O
PTX	B
were	O
abolished	O
.	O

Exposure	O
of	O
the	O
muscle	O
to	O
ouabain	B
(	O
10	O
(	O
-	O
5	O
)	O
M	O
)	O
markedly	O
increased	O
the	O
PTX	B
-	O
induced	O
release	O
.	O

The	O
second	O
response	O
is	O
due	O
to	O
a	O
release	O
of	O
norepinephrine	O
from	O
nerves	O
and	O
was	O
potentiated	O
by	O
ouabain	B
through	O
the	O
increase	O
in	O
the	O
norepinephrine	O
release	O
,	O
whereas	O
the	O
first	O
response	O
was	O
not	O
due	O
to	O
the	O
norepinephrine	O
release	O
but	O
presumably	O
to	O
a	O
direct	O
action	O
on	O
smooth	O
muscle	O
cell	O
and	O
was	O
inhibited	O
by	O
ouabain	B
.	O

[	O
Quantitative	O
approach	O
to	O
treatment	O
with	O
incisive	O
neuroleptics	B
by	O
therapeutic	O
monitoring	O
]	O
;	O
The	O
problems	O
encountered	O
during	O
the	O
longterm	O
treatment	O
of	O
psychotic	O
patients	O
with	O
neuroleptics	B
are	O
illustrated	O
by	O
six	O
typical	O
case	O
reports	O
.	O

The	O
intestinal	O
absorption	O
of	O
arsenate	B
(	O
As	O
(	O
V	O
)	O
)	O
has	O
been	O
investigated	O
in	O
the	O
chick	O
by	O
means	O
of	O
the	O
in	O
situ	O
ligated	O
duodenal	O
loop	O
technique	O
.	O

By	O
this	O
procedure	O
,	O
it	O
was	O
observed	O
that	O
arsenate	B
is	O
rapidly	O
and	O
essentially	O
completely	O
absorbed	O
(	O
80	O
-	O
95	O
%	O
)	O
from	O
the	O
lumen	O
at	O
As	O
(	O
V	O
)	O
concentrations	O
up	O
to	O
5	O
mM	O
,	O
declining	O
to	O
about	O
50	O
%	O
absorption	O
at	O
50	O
mM	O
.	O

At	O
stable	O
As	O
(	O
V	O
)	O
concentrations	O
greater	O
than	O
1	O
mM	O
,	O
fractional	O
mucosal	O
cell	O
accumulation	O
of	O
As	O
(	O
V	O
)	O
remains	O
constant	O
,	O
while	O
fractional	O
transfer	O
to	O
the	O
body	O
declines	O
.	O

However	O
,	O
total	O
mucosal	O
accumulation	O
of	O
As	O
(	O
V	O
)	O
and	O
that	O
transferred	O
to	O
the	O
body	O
increase	O
in	O
a	O
linear	O
logarithmic	O
fashion	O
from	O
0	O
.	O
05	O
to	O
5	O
mm	O
As	O
(	O
V	O
)	O
.	O

Furthermore	O
,	O
arsenate	B
and	O
phosphate	B
do	O
not	O
appear	O
to	O
share	O
a	O
common	O
transport	O
pathway	O
in	O
the	O
duodenum	O
and	O
no	O
evidence	O
was	O
obtained	O
for	O
any	O
interaction	O
between	O
the	O
two	O
at	O
this	O
level	O
.	O

Vitamin	B
D3	I
administration	O
to	O
rachitic	O
chicks	O
was	O
effective	O
in	O
significantly	O
elevating	O
duodenal	O
arsenate	B
absorption	O
,	O
acting	O
primarily	O
to	O
enhance	O
serosal	O
transport	O
.	O

By	O
contrast	O
,	O
spermidine	B
(	O
1	O
mM	O
)	O
and	O
putrescine	B
(	O
1	O
mM	O
)	O
had	O
no	O
significant	O
effect	O
on	O
the	O
translocation	O
when	O
added	O
alone	O
.	O

Spermine	B
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
spermidine	B
,	O
enhanced	O
the	O
translocating	O
action	O
of	O
oleate	O
and	O
increased	O
its	O
effectiveness	O
in	O
transferring	O
the	O
phosphohydrolase	O
from	O
the	O
soluble	O
to	O
the	O
microsomal	O
fraction	O
.	O

Slow	O
-	O
channel	O
calcium	B
blockers	I
,	O
such	O
as	O
verapamil	B
,	O
diltiazem	B
and	O
nifedipine	B
,	O
inhibit	O
platelet	O
activation	O
in	O
vitro	O
,	O
and	O
decrease	O
platelet	O
adhesion	O
intravascularly	O
.	O

Differential	O
actions	O
of	O
intrathecal	O
naloxone	B
on	O
blocking	O
the	O
tail	O
-	O
flick	O
inhibition	O
induced	O
by	O
intraventricular	O
beta	O
-	O
endorphin	O
and	O
morphine	B
in	O
rats	O
.	O

The	O
blockade	O
of	O
the	O
spinal	O
endorphinergic	O
system	O
by	O
intrathecal	O
naloxone	B
on	O
the	O
production	O
of	O
tail	O
-	O
flick	O
inhibition	O
induced	O
by	O
intraventricular	O
beta	O
-	O
endorphin	O
and	O
morphine	B
was	O
then	O
studied	O
.	O

Intraventricular	O
injection	O
of	O
beta	O
-	O
endorphin	O
and	O
morphine	B
produced	O
an	O
inhibition	O
of	O
the	O
tail	O
-	O
flick	O
response	O
to	O
the	O
heat	O
stimulus	O
in	O
rats	O
.	O

Intrathecal	O
injection	O
of	O
naloxone	B
at	O
doses	O
of	O
0	O
.	O
4	O
to	O
40	O
micrograms	O
caused	O
a	O
dose	O
-	O
related	O
blockade	O
of	O
the	O
inhibition	O
of	O
the	O
tail	O
-	O
flick	O
response	O
induced	O
by	O
intraventricular	O
injection	O
of	O
beta	O
-	O
endorphin	O
,	O
and	O
a	O
high	O
dose	O
of	O
naloxone	B
(	O
40	O
micrograms	O
)	O
completely	O
blocked	O
the	O
tail	O
-	O
flick	O
inhibition	O
induced	O
by	O
intraventricular	O
beta	O
-	O
endorphin	O
(	O
16	O
micrograms	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
intrathecal	O
naloxone	B
(	O
12	O
-	O
120	O
micrograms	O
)	O
had	O
only	O
a	O
very	O
weak	O
effect	O
on	O
the	O
tail	O
-	O
flick	O
inhibition	O
induced	O
by	O
intraventricular	O
morphine	B
(	O
40	O
micrograms	O
)	O
.	O

Intraventricular	O
injection	O
of	O
naloxone	B
at	O
doses	O
of	O
1	O
.	O
2	O
to	O
12	O
micrograms	O
equally	O
antagonized	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
the	O
tail	O
-	O
flick	O
inhibition	O
induced	O
by	O
intraventricular	O
beta	O
-	O
endorphin	O
and	O
morphine	B
.	O

The	O
results	O
indicate	O
that	O
a	O
spinal	O
naloxone	B
-	O
sensitive	O
endorphinergic	O
system	O
is	O
involved	O
in	O
the	O
production	O
of	O
beta	O
-	O
endorphin	O
but	O
not	O
morphine	B
-	O
induced	O
tail	O
-	O
flick	O
inhibition	O
,	O
and	O
suggest	O
that	O
intraventricular	O
beta	O
-	O
endorphin	O
and	O
morphine	B
elicit	O
their	O
pharmacological	O
actions	O
via	O
the	O
activation	O
of	O
different	O
descending	O
pain	O
inhibitory	O
systems	O
;	O

descending	O
epsilon	O
and	O
mu	O
systems	O
for	O
beta	O
-	O
endorphin	O
and	O
morphine	B
,	O
respectively	O
,	O
are	O
proposed	O
.	O

Neurochemical	O
and	O
functional	O
consequences	O
following	O
1	O
-	O
methyl	O
-	O
4	O
-	O
phenyl	O
-	O
1	O
,	O
2	O
,	O
5	O
,	O
6	O
-	O
tetrahydropyridine	O
(	O
MPTP	B
)	O
and	O
methamphetamine	B
.	O

The	O
neurochemical	O
and	O
functional	O
consequences	O
following	O
MPTP	B
administration	O
to	O
the	O
rat	O
were	O
evaluated	O
and	O
compared	O
to	O
similar	O
effects	O
following	O
methamphetamine	B
administration	O
.	O

It	O
was	O
observed	O
that	O
MPTP	B
induced	O
long	O
lasting	O
depletions	O
of	O
striatal	O
dopamine	O
concentrations	O
and	O
this	O
neurotoxic	O
effect	O
could	O
be	O
prevented	O
by	O
pargyline	B
pretreatment	O
.	O

The	O
MPTP	B
-	O
induced	O
neuronal	O
damage	O
produced	O
a	O
tolerance	O
to	O
the	O
disruptive	O
effects	O
of	O
amphetamine	B
and	O
a	O
supersensitivity	O
to	O
the	O
disruptive	O
effects	O
of	O
apomorphine	B
in	O
rats	O
responding	O
in	O
a	O
schedule	O
controlled	O
paradigm	O
.	O

Methamphetamine	B
,	O
like	O
MPTP	B
,	O
produced	O
depletions	O
of	O
striatal	O
dopamine	O
but	O
these	O
actions	O
were	O
potentiated	O
by	O
pargyline	B
pretreatment	O
.	O

Dexamethasone	B
and	O
retinyl	B
acetate	I
similarly	O
inhibit	O
and	O
stimulate	O
EGF	B
-	O
or	O
insulin	B
-	O
induced	O
proliferation	O
of	O
prostatic	O
epithelium	O
.	O

Prostatic	O
epithelium	O
proliferates	O
in	O
a	O
defined	O
medium	O
consisting	O
of	O
basal	O
medium	O
RPMI1640	O
containing	O
transferrin	B
(	O
1	O
microgram	O
/	O
ml	O
)	O
,	O
EGF	B
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
and	O
insulin	B
(	O
3	O
.	O
7	O
micrograms	O
/	O
ml	O
or	O
0	O
.	O
1	O
IU	O
/	O
ml	O
)	O
.	O

Although	O
neither	O
dexamethasone	B
nor	O
retinyl	B
acetate	I
affected	O
the	O
proliferation	O
of	O
prostatic	O
epithelium	O
in	O
RPMI1640	O
containing	O
transferrin	B
alone	O
,	O
they	O
modify	O
the	O
mitogenic	O
effect	O
of	O
EGF	B
and	O
insulin	B
.	O

Dexamethasone	B
at	O
10	O
(	O
-	O
10	O
)	O
M	O
or	O
retinyl	B
acetate	I
at	O
about	O
3	O
X	O
10	O
(	O
-	O
9	O
)	O
M	O
inhibits	O
proliferation	O
stimulated	O
by	O
EGF	B
.	O

Higher	O
concentrations	O
of	O
dexamethasone	B
(	O
10	O
(	O
-	O
8	O
)	O
-	O
10	O
(	O
-	O
6	O
)	O
M	O
)	O
or	O
retinyl	B
acetate	I
(	O
3	O
X	O
10	O
(	O
-	O
8	O
)	O
-	O
10	O
(	O
-	O
7	O
)	O
M	O
)	O
enhance	O
the	O
mitogenic	O
activity	O
of	O
EGF	B
.	O

Dexamethasone	B
had	O
a	O
similar	O
effect	O
in	O
the	O
presence	O
of	O
insulin	B
.	O

However	O
,	O
retinyl	B
acetate	I
stimulated	O
,	O
but	O
did	O
not	O
significantly	O
inhibit	O
,	O
proliferation	O
in	O
the	O
presence	O
of	O
insulin	B
.	O

These	O
results	O
suggest	O
that	O
both	O
dexamethasone	B
and	O
retinyl	B
acetate	I
,	O
and	O
possibly	O
other	O
glucocorticoids	B
and	O
retinoids	B
,	O
may	O
regulate	O
the	O
proliferation	O
of	O
prostate	O
epithelium	O
by	O
a	O
dose	O
-	O
dependent	O
modification	O
of	O
the	O
activity	O
of	O
insulin	B
and	O
EGF	B
.	O

For	O
the	O
calcium	O
-	O
entry	O
blocking	B
agents	I
now	O
available	O
in	O
the	O
United	O
States	O
(	O
verapamil	B
,	O
nifedipine	B
and	O
diltiazem	B
)	O
,	O
these	O
data	O
appeared	O
well	O
after	O
clinical	O
patterns	O
of	O
use	O
evolved	O
.	O

by	O
the	O
nonlinear	O
kinetic	O
characteristics	O
for	O
verapamil	B
and	O
diltiazem	B
(	O
and	O
probably	O
for	O
nifedipine	B
,	O
as	O
well	O
)	O
and	O
the	O
derivative	O
implications	O
for	O
decreased	O
dosing	O
frequency	O
requirements	O
;	O

Selective	O
survival	O
in	O
pentazocine	B
and	O
tripelennamine	B
of	O
Pseudomonas	O
aeruginosa	O
serotype	O
O11	O
from	O
drug	O
addicts	O
.	O

The	O
growth	O
of	O
Pseudomonas	O
aeruginosa	O
,	O
particularly	O
serotype	O
O11	O
,	O
in	O
pentazocine	B
and	O
tripelennamine	B

Twelve	O
strains	O
of	O
Staphylococcus	O
aureus	O
(	O
a	O
frequent	O
cause	O
of	O
infection	O
in	O
heroin	B
,	O
but	O
not	O
in	O
pentazocine	B
and	O
tripelennamine	B
,	O
addicts	O
)	O
were	O
completely	O
inhibited	O
by	O
the	O
drug	O
combination	O
.	O

Dose	O
-	O
response	O
curves	O
(	O
derived	O
from	O
the	O
results	O
of	O
using	O
the	O
tablets	O
as	O
well	O
as	O
pure	O
powders	O
)	O
showed	O
that	O
tripelennamine	B
was	O
responsible	O
for	O
the	O
inhibitory	O
activity	O
,	O
which	O
was	O
partially	O
antagonized	O
by	O
pentazocine	B
.	O

aureus	O
,	O
to	O
survive	O
in	O
pentazocine	B
and	O
tripelennamine	B
may	O
explain	O
in	O
part	O
a	O
shift	O
from	O
S	O
.	O

Pharmacokinetic	O
evaluation	O
of	O
the	O
digoxin	B
-	O
amiodarone	B
interaction	O
.	O

Amiodarone	B
is	O
known	O
to	O
raise	O
serum	O
digoxin	B
levels	O
.	O

The	O
pharmacokinetic	O
variables	O
for	O
digoxin	B
were	O
determined	O
after	O
a	O
1	O
.	O
0	O
mg	O
intravenous	O
dose	O
of	O
digoxin	B
in	O
each	O
subject	O
,	O
before	O
and	O
after	O
oral	O
amiodarone	B
,	O
400	O
mg	O
daily	O
for	O
3	O
weeks	O
.	O

During	O
amiodarone	B
administration	O
,	O
systemic	O
clearance	O
of	O
digoxin	B
was	O
reduced	O
from	O
234	O
+	O
/	O
-	O
72	O
ml	O
/	O
min	O
(	O
mean	O
+	O
/	O
-	O
standard	O
deviation	O
)	O
to	O
172	O
+	O
/	O
-	O
33	O
ml	O
/	O
min	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Amiodarone	B
caused	O
a	O
three	O
-	O
to	O
fivefold	O
increase	O
in	O
serum	O
reverse	O
triiodothyronine	O
levels	O
,	O
but	O
changes	O
in	O
thyroid	O
function	O
were	O
not	O
quantitatively	O
related	O
to	O
the	O
changes	O
in	O
digoxin	B
pharmacokinetics	O
.	O

These	O
alterations	O
in	O
digoxin	B
pharmacokinetics	O
produced	O
by	O
amiodarone	B
explain	O
the	O
increase	O
in	O
serum	O
digoxin	B
level	O
that	O
has	O
been	O
observed	O
when	O
this	O
drug	O
combination	O
has	O
been	O
used	O
clinically	O
.	O

Misonidazole	B
protects	O
mouse	O
tumour	O
and	O
normal	O
tissues	O
from	O
the	O
toxicity	O
of	O
oral	O
CCNU	B
.	O

Because	O
the	O
nitrosourea	B
CCNU	I
is	O
given	O
exclusively	O
by	O
the	O
oral	O
route	O
in	O
man	O
,	O
we	O
have	O
carried	O
out	O
studies	O
in	O
mice	O
on	O
the	O
antitumour	O
activity	O
,	O
acute	O
toxicity	O
and	O
pharmacokinetics	O
of	O
oral	O
CCNU	B
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
the	O
chemosensitizer	O
misonidazole	B
.	O

Misonidazole	B
reduced	O
the	O
antitumour	O
activity	O
of	O
oral	O
CCNU	B
by	O
dose	O
modifying	O
factors	O
(	O
DMF	O
)	O
of	O
0	O
.	O
58	O
-	O
0	O
.	O
71	O
.	O

Misonidazole	B
has	O
a	O
complex	O
effect	O
on	O
oral	O
CCNU	B
pharmacokinetics	O
.	O

We	O
propose	O
these	O
pharmacokinetic	O
changes	O
to	O
be	O
the	O
underlying	O
mechanism	O
for	O
the	O
reduction	O
of	O
oral	O
CCNU	B
cytotoxicity	O
by	O
misonidazole	B
.	O

Enhanced	O
theophylline	B
clearance	O
secondary	O
to	O
phenytoin	B
therapy	O
.	O

This	O
report	O
describes	O
two	O
cases	O
in	O
which	O
theophylline	B
clearance	O
accelerated	O
markedly	O
with	O
concomitant	O
phenytoin	B
administration	O
.	O

With	O
combined	O
use	O
,	O
clinicians	O
should	O
be	O
aware	O
,	O
when	O
phenytoin	B
is	O
added	O
,	O
of	O
the	O
potential	O
for	O
reexacerbation	O
of	O
pulmonary	O
symptomatology	O
due	O
to	O
lowered	O
serum	O
theophylline	B
concentrations	O
.	O

The	O
behavioral	O
effects	O
of	O
the	O
stereoisomers	O
of	O
N	O
-	O
allylnormetazocine	O
(	O
NANM	B
)	O
were	O
compared	O
with	O
those	O
of	O
phencyclidine	B
(	O
PCP	B
)	O
in	O
pigeons	O
and	O
squirrel	O
monkeys	O
responding	O
under	O
a	O
multiple	O
fixed	O
-	O
interval	O
fixed	O
-	O
ratio	O
(	O
FI	O
FR	O
)	O
schedule	O
of	O
food	O
presentation	O
.	O

Intermediate	O
doses	O
of	O
(	O
+	O
)	O
-	O
NANM	O
or	O
PCP	B
produced	O
transient	O
increases	O
in	O
FI	O
responding	O
in	O
monkeys	O
and	O
sustained	O
increases	O
in	O
FI	O
responding	O
in	O
pigeons	O
;	O

In	O
monkeys	O
,	O
(	O
-	O
)	O
-	O
NANM	O
was	O
about	O
10	O
times	O
more	O
potent	O
than	O
(	O
+	O
)	O
-	O
NANM	O
in	O
decreasing	O
responding	O
,	O
whereas	O
in	O
pigeons	O
(	O
-	O
)	O
-	O
NANM	O
was	O
about	O
equipotent	O
with	O
(	O
+	O
)	O
-	O
NANM	O
.	O

In	O
both	O
species	O
,	O
(	O
-	O
)	O
-	O
NANM	O
,	O
but	O
not	O
(	O
+	O
)	O
-	O
NANM	O
,	O
antagonized	O
the	O
rate	O
-	O
decreasing	O
effects	O
of	O
morphine	B
on	O
FI	O
and	O
FR	O
responding	O
.	O

In	O
monkeys	O
,	O
the	O
effects	O
of	O
(	O
-	O
)	O
-	O
NANM	O
,	O
but	O
not	O
(	O
+	O
)	O
-	O
NANM	O
or	O
PCP	B
,	O
were	O
antagonized	O
by	O
naloxone	B
;	O

the	O
doses	O
of	O
naloxone	B
required	O
to	O
antagonize	O
the	O
effects	O
of	O
(	O
-	O
)	O
-	O
NANM	O
were	O
more	O
than	O
100	O
times	O
higher	O
than	O
those	O
required	O
to	O
antagonize	O
the	O
effects	O
of	O
morphine	B
.	O

In	O
pigeons	O
,	O
naloxone	B
did	O
not	O
systematically	O
alter	O
the	O
effects	O
of	O
(	O
-	O
)	O
-	O
NANM	O
,	O
(	O
+	O
)	O
-	O
NANM	O
or	O
PCP	B
.	O

Haloperidol	B
reduced	O
or	O
eliminated	O
the	O
increases	O
in	O
FI	O
responding	O
produced	O
by	O
intermediate	O
doses	O
of	O
either	O
(	O
+	O
)	O
-	O
NANM	B
or	O
PCP	B
in	O
pigeons	O
,	O
but	O
did	O
not	O
antagonize	O
the	O
decreases	O
in	O
FI	O
or	O
FR	O
responding	O
produced	O
by	O
high	O
doses	O
of	O
PCP	B
or	O
either	O
stereoisomer	O
of	O
NANM	B
.	O

Increased	O
hepatotoxicity	O
of	O
acetaminophen	B
by	O
concomitant	O
administration	O
of	O
caffeine	B
in	O
the	O
rat	O
.	O

Since	O
caffeine	B
is	O
frequently	O
co	O
-	O
administered	O
with	O
acetaminophen	B
,	O
it	O
is	O
of	O
clinical	O
interest	O
to	O
study	O
the	O
effect	O
of	O
caffeine	B
on	O
the	O
hepatotoxicity	O
of	O
acetaminophen	B
.	O

Careful	O
observations	O
on	O
hepatotoxicity	O
are	O
suggested	O
when	O
acetaminophen	B
is	O
prescribed	O
with	O
caffeine	B
.	O

High	O
-	O
dose	O
cisplatin	B
with	O
sodium	B
thiosulfate	I
protection	O
.	O

Sodium	B
thiosulfate	I
is	O
a	O
neutralizing	O
agent	O
for	O
cisplatin	B
that	O
protects	O
against	O
renal	O
damage	O
.	O

To	O
determine	O
whether	O
injection	O
of	O
thiosulfate	B
would	O
permit	O
larger	O
doses	O
of	O
cisplatin	B
to	O
be	O
administered	O
,	O
a	O
fixed	O
9	O
.	O
9	O
-	O
g	O
/	O
m2	O
dose	O
of	O
thiosulfate	B
was	O
given	O
intravenously	O
over	O
three	O
hours	O
concurrently	O
with	O
escalating	O
doses	O
of	O
cisplatin	B
.	O

Cisplatin	B
was	O
administered	O
over	O
the	O
last	O
two	O
hours	O
of	O
the	O
thiosulfate	B
infusion	O
.	O

Comparison	O
of	O
cisplatin	B
pharmacokinetics	O
in	O
patients	O
treated	O
with	O
202	O
.	O
5	O
mg	O
/	O
m2	O
plus	O
thiosulfate	B
to	O
those	O
in	O
patients	O
treated	O
with	O
100	O
mg	O
/	O
m2	O
without	O
thiosulfate	B
indicated	O
that	O
there	O
were	O
no	O
changes	O
in	O
the	O
elimination	O
rate	O
constant	O
,	O
volume	O
of	O
distribution	O
,	O
or	O
total	O
body	O
clearance	O
of	O
cisplatin	B
.	O

This	O
study	O
demonstrates	O
that	O
concurrent	O
administration	O
of	O
thiosulfate	B
permits	O
at	O
least	O
a	O
twofold	O
increase	O
in	O
dose	O
and	O
total	O
exposure	O
to	O
cisplatin	B
.	O

Failure	O
of	O
neomycin	B
to	O
modify	O
ACTH	B
induced	O
hypertension	O
in	O
sheep	O
.	O

Studies	O
in	O
rats	O
have	O
shown	O
that	O
neomycin	B
administration	O
attenuates	O
certain	O
types	O
of	O
adrenocortical	B
steroid	I
dependent	O
hypertension	O
,	O
including	O
ACTH	B
hypertension	O
.	O

The	O
effects	O
of	O
oral	O
neomycin	B
on	O
ACTH	B
induced	O
hypertension	O
were	O
examined	O
in	O
conscious	O
sheep	O
.	O

Neomycin	B
has	O
no	O
effect	O
on	O
the	O
blood	O
pressure	O
or	O
metabolic	O
responses	O
to	O
ACTH	B
in	O
sheep	O
.	O

Changes	O
in	O
urinary	O
homocysteine	O
following	O
synthetic	B
steroidal	I
estrogen	I
and	O
progestogen	B
administration	O
to	O
rats	O
.	O

The	O
present	O
work	O
involved	O
the	O
administration	O
of	O
both	O
ethynyl	B
estradiol	I
and	O
levonorgestrel	B
to	O
groups	O
of	O
rats	O
,	O
followed	O
by	O
determination	O
of	O
the	O
homocysteine	O
excretion	O
rate	O
in	O
urine	O
.	O

The	O
results	O
indicate	O
that	O
a	O
statistically	O
significant	O
difference	O
exists	O
between	O
the	O
excreted	O
levels	O
of	O
homocysteine	O
in	O
the	O
urine	O
of	O
both	O
control	O
and	O
levonorgestrel	B
-	O
treated	O
rats	O
and	O
the	O
levels	O
shown	O
by	O
rats	O
treated	O
with	O
ethynyl	B
estradiol	I
.	O

Thirty	O
male	O
rats	O
of	O
the	O
Fischer	O
-	O
344	O
strain	O
were	O
divided	O
into	O
three	O
equal	O
groups	O
and	O
were	O
given	O
injections	O
of	O
trimethyl	B
lead	I
(	O
TML	B
)	O
(	O
8	O
.	O
0	O
or	O
17	O
.	O
0	O
mg	O
/	O
kg	O
/	O
ml	O
SC	O
)	O
or	O
the	O
saline	O
vehicle	O
.	O

The	O
20	O
%	O
v	O
/	O
v	O
solution	O
of	O
alcohol	B
was	O
prepared	O
in	O
water	O
from	O
a	O
stock	O
solution	O
of	O
95	O
%	O
ethanol	B
.	O

These	O
results	O
suggest	O
that	O
exposure	O
to	O
environmental	O
lead	B
may	O
alter	O
the	O
biological	O
and	O
behavioral	O
responsiveness	O
of	O
an	O
animal	O
to	O
alcohol	B
.	O

Since	O
photic	O
evoked	O
potential	O
components	O
are	O
representations	O
of	O
neural	O
pathways	O
which	O
are	O
activated	O
during	O
photic	O
stimulation	O
,	O
study	O
of	O
the	O
effects	O
of	O
alcohol	B
on	O
these	O
components	O
may	O
help	O
to	O
trace	O
pathways	O
which	O
are	O
affected	O
by	O
alcohol	B
.	O

In	O
the	O
present	O
study	O
,	O
evoked	O
potentials	O
were	O
recorded	O
at	O
5	O
,	O
20	O
,	O
and	O
40	O
min	O
following	O
IP	O
injections	O
of	O
saline	O
,	O
ethanol	B
(	O
2	O
.	O
0	O
g	O
/	O
kg	O
)	O
,	O
physostigmine	B
(	O
0	O
.	O
6	O
mg	O
/	O
kg	O
)	O
or	O
atropine	B
(	O
15	O
.	O
0	O
mg	O
/	O
kg	O
)	O
on	O
separate	O
days	O
.	O

Physostigmine	B
pretreatment	O
augmented	O
the	O
depressant	O
effect	O
of	O
alcohol	B
on	O
the	O
early	O
components	O
P1	O
and	O
N1	O
,	O
while	O
attenuating	O
alcohol	B
'	O
s	O
influence	O
on	O
components	O
P2	O
and	O
P3	O
.	O

Atropine	B
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
alcohol	B
,	O
produced	O
approximately	O
the	O
same	O
degree	O
of	O
enhancement	O
of	O
component	O
P2	O
.	O

Hypothermia	O
as	O
an	O
index	O
of	O
the	O
disulfiram	B
-	O
ethanol	B
reaction	O
in	O
the	O
rat	O
.	O

Decreased	O
core	O
temperature	O
in	O
female	O
rats	O
was	O
investigated	O
as	O
one	O
possible	O
index	O
of	O
the	O
disulfiram	B
-	O
ethanol	B
reaction	O
(	O
DER	O
)	O
.	O

Core	O
temperature	O
was	O
decreased	O
in	O
rats	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
when	O
ethanol	B
was	O
administered	O
to	O
rats	O
treated	O
with	O
disulfiram	B
8	O
hours	O
before	O
the	O
ethanol	B
challenge	O
.	O

The	O
decrease	O
in	O
temperature	O
began	O
within	O
20	O
minutes	O
after	O
ethanol	B
administration	O
,	O
reaching	O
a	O
maximal	O
decrease	O
between	O
60	O
and	O
120	O
minutes	O
post	O
ethanol	B
.	O

Maximal	O
hypotension	O
was	O
found	O
120	O
minutes	O
post	O
ethanol	B
,	O
and	O
returned	O
to	O
normal	O
300	O
minutes	O
after	O
ethanol	B
.	O

Interaction	O
on	O
the	O
antinociceptive	O
effect	O
between	O
neurotensin	B
and	O
enkephalins	B
or	O
tuftsin	B
.	O

The	O
aim	O
of	O
this	O
paper	O
was	O
to	O
study	O
the	O
interaction	O
between	O
neurotensin	B
and	O
both	O
enkephalins	B
or	O
its	O
synthetic	O
analogue	O
D	O
-	O
Ala2	O
-	O
metenkephalinamide	O
,	O
or	O
tuftsin	B
,	O
on	O
the	O
antinonciceptive	O
effect	O
of	O
these	O
peptides	O
in	O
mice	O
after	O
intracisternal	O
injection	O
.	O

It	O
was	O
shown	O
that	O
neurotensin	B
antagonized	O
evidently	O
the	O
antinociceptive	O
effect	O
of	O
enkephalins	B
and	O
their	O
analogue	O
.	O

On	O
the	O
contrary	O
,	O
neurotensin	B
and	O
tuftsin	B
were	O
agonists	O
in	O
induction	O
of	O
analgesia	O
.	O

It	O
is	O
concluded	O
that	O
neurotensin	B
modulates	O
in	O
an	O
opposite	O
way	O
the	O
function	O
of	O
the	O
enkephalinergic	O
neurons	O
and	O
the	O
central	O
action	O
of	O
tuftsin	B
.	O

Among	O
the	O
risk	O
factors	O
studied	O
,	O
two	O
appear	O
to	O
increase	O
the	O
risk	O
of	O
ARE	O
:	O
the	O
prescription	O
of	O
thiabendazole	B
to	O
treat	O
strongyloidiasis	O
during	O
the	O
melarsoprol	B
cure	O
and	O
the	O
bad	O
general	O
clinical	O
conditions	O
of	O
patients	O
.	O

Recommendations	O
were	O
to	O
avoid	O
administration	O
of	O
diffusible	O
anti	O
-	O
helminthic	O
treatment	O
during	O
the	O
cure	O
,	O
and	O
to	O
improve	O
the	O
general	O
conditions	O
of	O
patients	O
before	O
the	O
cure	O
of	O
melarsoprol	B
.	O

Interactions	O
of	O
cobalt	B
and	O
iron	B
in	O
absorption	O
and	O
retention	O
.	O

The	O
effects	O
of	O
supplementary	O
oral	O
cobalt	B
and	O
iron	B
,	O
as	O
well	O
as	O
the	O
interaction	O
between	O
both	O
at	O
the	O
absorption	O
site	O
,	O
fecal	O
and	O
urinary	O
excretion	O
as	O
well	O
as	O
the	O
retention	O
of	O
these	O
trace	O
elements	O
were	O
determined	O
by	O
using	O
four	O
diets	O
containing	O
either	O
9	O
or	O
63	O
micrograms	O
/	O
kg	O
of	O
Co	B
and	O
48	O
or	O
446	O
mg	O
/	O
kg	O
of	O
Fe	B
over	O
a	O
period	O
of	O
19	O
days	O
in	O
a	O
total	O
of	O
24	O
rats	O
.	O

Cobalt	B
excretion	O
was	O
enhanced	O
by	O
supplementary	O
cobalt	B
;	O

Additional	O
iron	B
significantly	O
inhibited	O
the	O
absorption	O
of	O
cobalt	B
in	O
both	O
dietary	O
cobalt	B
treatments	O
.	O

The	O
lower	O
rate	O
of	O
absorption	O
in	O
the	O
groups	O
receiving	O
446	O
mg	O
Fe	B
instead	O
of	O
48	O
mg	O
of	O
Fe	B
per	O
kg	O
diet	O
resulted	O
in	O
a	O
decreased	O
renal	O
excretion	O
of	O
cobalt	B
.	O

Consequently	O
,	O
the	O
effect	O
of	O
iron	B
on	O
the	O
retention	O
of	O
cobalt	B
was	O
lower	O
than	O
on	O
absorption	O
.	O

Because	O
of	O
the	O
low	O
dietary	O
cobalt	B
concentration	O
as	O
compared	O
to	O
the	O
iron	B
contents	O
of	O
the	O
diets	O
,	O
no	O
effect	O
of	O
cobalt	B
on	O
iron	B
absorption	O
and	O
excretion	O
occurred	O
.	O

Differences	O
in	O
iron	B
balance	O
were	O
only	O
observed	O
between	O
both	O
dietary	O
concentrations	O
,	O
showing	O
a	O
higher	O
absolute	O
but	O
a	O
lower	O
relative	O
absorption	O
as	O
well	O
as	O
retention	O
in	O
the	O
groups	O
fed	O
further	O
Fe	B
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Effect	O
of	O
estradiol	B
on	O
endotoxin	B
-	O
induced	O
changes	O
in	O
steroid	O
hormone	O
levels	O
and	O
lethality	O
in	O
male	O
rats	O
.	O

We	O
examined	O
the	O
effect	O
of	O
exogenous	O
estradiol	B
on	O
the	O
changes	O
in	O
serum	O
steroid	O
hormone	O
levels	O
induced	O
by	O
a	O
nonlethal	O
dose	O
of	O
Escherichia	O
coli	O
endotoxin	B
in	O
male	O
rats	O
and	O
the	O
deaths	O
due	O
to	O
nonlethal	O
and	O
lethal	O
doses	O
of	O
endotoxin	B
.	O

Injection	O
of	O
estradiol	B
5	O
min	O
before	O
a	O
nonlethal	O
dose	O
of	O
endotoxin	B
changed	O
the	O
serum	O
sex	O
steroid	O
hormone	O
response	O
of	O
male	O
rats	O
to	O
endotoxin	B
.	O

The	O
serum	O
estrogen	O
concentrations	O
of	O
estradiol	B
+	O
endotoxin	B
-	O
treated	O
rats	O
decreased	O
by	O
50	O
%	O
,	O
while	O
those	O
of	O
the	O
endotoxin	B
-	O
treated	O
rats	O
increased	O
(	O
2	O
-	O
to	O
5	O
-	O
fold	O
)	O
.	O

The	O
serum	O
androgen	O
concentrations	O
of	O
estradiol	B
+	O
endotoxin	B
-	O
treated	O
rats	O
did	O
not	O
change	O
significantly	O
,	O
while	O
those	O
of	O
endotoxin	B
-	O
treated	O
rats	O
dropped	O
to	O
30	O
-	O
40	O
%	O

Exogenous	O
estradiol	B
also	O
appeared	O
to	O
influence	O
the	O
percentage	O
of	O
endotoxin	B
-	O
induced	O
deaths	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

These	O
results	O
,	O
together	O
with	O
the	O
known	O
relationships	O
between	O
estrogen	B
and	O
the	O
immune	O
response	O
,	O
suggest	O
that	O
estrogens	B
affect	O
the	O
course	O
of	O
septic	O
shock	O
in	O
a	O
complex	O
fashion	O
and	O
may	O
have	O
either	O
protective	O
or	O
deleterious	O
effect	O
.	O

The	O
16	O
,	O
16	O
-	O
dimethylprostaglandin	O
E2	B
(	O
dmPGE2	B
)	O
-	O
induced	O
diarrhea	O
was	O
analyzed	O
in	O
cecectomized	O
rats	O
prepared	O
by	O
resecting	O
the	O
cecum	O
and	O
its	O
vasculature	O
without	O
disturbing	O
the	O
ileocecal	O
junction	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
enhanced	O
secretion	O
of	O
colonic	O
fluid	O
by	O
dmPGE2	B
,	O
given	O
intraluminally	O
,	O
was	O
only	O
half	O
of	O
that	O
in	O
control	O
rats	O
,	O
whereas	O
the	O
colonic	O
transit	O
-	O
enhancing	O
effect	O
of	O
dmPGE2	B
in	O
cecectomized	O
rats	O
was	O
more	O
pronounced	O
than	O
in	O
control	O
rats	O
at	O
15	O
but	O
not	O
at	O
30	O
min	O
after	O
its	O
administration	O
.	O

Loperamide	B
and	O
morphine	B
(	O
0	O
.	O
1	O
and	O
1	O
.	O
0	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O

Loperamide	B
and	O
morphine	B
(	O
0	O
.	O
1	O
and	O
1	O
.	O
0	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
inhibited	O
the	O
dmPGE2	B
(	O
0	O
.	O
3	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
-	O
induced	O
diarrhea	O
in	O
cecectomized	O
rats	O
.	O

N	O
-	O
methyllevallorphan	O
(	O
5	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
completely	O
antagonized	O
the	O
inhibitory	O
effect	O
of	O
loperamide	B
and	O
partly	O
antagonized	O
the	O
effect	O
of	O
morphine	B
.	O

Therapeutic	O
drug	O
monitoring	O
can	O
avoid	O
iatrogenic	O
alterations	O
caused	O
by	O
99mTc	O
-	O
methylene	O
diphosphonate	B
(	O
MDP	O
)	O
-	O
gentamicin	B
interaction	O
.	O

Gentamicin	B
is	O
an	O
aminoglycoside	B
antibiotic	I
used	O
to	O
treat	O
a	O
wide	O
variety	O
of	O
infections	O
caused	O
by	O
gram	O
-	O
negative	O
organisms	O
,	O
but	O
it	O
is	O
potentially	O
toxic	O
to	O
the	O
kidneys	O
.	O

Due	O
to	O
its	O
nephrotoxicity	O
,	O
gentamicin	B
may	O
cause	O
abnormal	O
renal	O
uptake	O
to	O
be	O
seen	O
on	O
99mTc	O
-	O
MDP	O
bone	O
scintigraphy	O
.	O

Therapeutic	O
drug	O
monitoring	O
(	O
TDM	O
)	O
of	O
gentamicin	B
therapy	O
,	O
and	O
bone	O
scintigraphy	O
employing	O
99mTc	O
-	O
MDP	O
as	O
the	O
radiopharmaceutical	B
was	O
carried	O
out	O
in	O
22	O
patients	O
.	O

The	O
data	O
presented	O
here	O
demonstrate	O
that	O
with	O
serial	O
pharmacokinetic	O
dosing	O
of	O
gentamicin	B
,	O
the	O
iatrogenic	O
alteration	O
caused	O
by	O
gentamicin	B
therapy	O
can	O
be	O
avoided	O
.	O

This	O
article	O
looks	O
at	O
five	O
commonly	O
used	O
immunosuppressive	B
drugs	I
in	O
turn	O
(	O
corticosteroids	B
,	O
cyclosporin	B
,	O
azathioprine	B
,	O
methotrexate	B
,	O
cyclophosphamide	B
)	O
,	O
discussing	O
the	O
main	O
,	O
non	O
-	O
infection	O
,	O
unwanted	O
effects	O
,	O
ways	O
to	O
avoid	O
them	O
and	O
what	O
to	O
do	O
if	O
problems	O
arise	O
.	O

Little	O
has	O
been	O
studied	O
of	O
the	O
adverse	O
effects	O
of	O
the	O
exposure	O
of	O
the	O
liver	O
to	O
the	O
interaction	O
of	O
ethanol	B
with	O
its	O
congeners	O
and	O
acetaldehyde	B
,	O
coexisting	O
in	O
the	O
contents	O
of	O
alcoholic	O
beverages	O
.	O

Two	O
groups	O
(	O
SH	O
/	O
DA	O
;	O
SH	O
/	O
FA	O
)	O
were	O
submitted	O
to	O
daily	O
treatment	O
with	O
synthetic	O
hydroalcoholic	O
solutions	O
containing	O
ethanol	B
,	O
methanol	B
,	O
higher	O
alcohols	B
and	O
acetaldehyde	B
in	O
the	O
same	O
proportions	O
as	O
those	O
found	O
in	O
most	O
common	O
distilled	O
and	O
fermented	O
alcoholic	O
beverages	O
;	O

These	O
results	O
suggest	O
that	O
the	O
hepatoxicity	O
of	O
ethanol	B
in	O
alcoholic	O
beverages	O
is	O
enhanced	O
by	O
interaction	O
with	O
its	O
congeners	O
and	O
acetaldehyde	B
;	O

Induction	O
of	O
apoptosis	O
in	O
breast	O
cancer	O
cells	O
in	O
response	O
to	O
vitamin	B
D	I
and	O
antiestrogens	B
.	O

1	O
,	O
25	O
-	O
Dihydroxycholecalciferol	O
D3	B
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
,	O
the	O
active	O
metabolite	O
of	O
vitamin	B
D	I
,	O
is	O
a	O
potent	O
inhibitor	O
of	O
breast	O
cancer	O
cell	O
growth	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

In	O
the	O
experiments	O
reported	O
here	O
,	O
we	O
examined	O
the	O
interactions	O
between	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
the	O
antiestrogen	B
4	O
-	O
hydroxytamoxifen	O
(	O
TAM	B
)	O
,	O
which	O
also	O
induces	O
apoptosis	O
in	O
MCF	O
-	O
7	O
cells	O
.	O

Our	O
data	O
suggest	O
that	O
TAM	B
significantly	O
potentiates	O
the	O
reduction	O
in	O
cell	O
number	O
induced	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
alone	O
.	O

Combined	O
treatment	O
with	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
TAM	B
enhances	O
the	O
degree	O
of	O
apoptosis	O
assessed	O
using	O
morphological	O
markers	O
that	O
identify	O
chromatin	O
and	O
nuclear	O
matrix	O
protein	O
condensation	O
.	O

These	O
data	O
emphasize	O
that	O
apoptosis	O
can	O
be	O
induced	O
in	O
MCF	O
-	O
7	O
cells	O
either	O
by	O
activation	O
of	O
vitamin	O
-	O
D	O
-	O
mediated	O
signalling	O
or	O
disruption	O
of	O
estrogen	B
-	O
dependent	O
signalling	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
adenosine	O
receptor	O
antagonists	O
,	O
caffeine	B
,	O
theophylline	B
,	O
8	O
-	O
phenyltheophylline	O
,	O
and	O
8	O
-	O
cyclopentyl	O
-	O
1	O
,	O
3	O
-	O
dipropylxanthine	O
(	O
DPCPX	B
)	O
,	O
in	O
a	O
light	O
/	O
dark	O
test	O
in	O
mice	O
.	O

The	O
anxiogenic	O
effects	O
of	O
theophylline	B
were	O
reduced	O
by	O
pretreatment	O
with	O
CGS	B
21680	I
,	O
an	O
A2	O
-	O
selective	O
agonist	O
,	O
but	O
not	O
by	O
N6	O
-	O
cyclopentyladenosine	O
(	O
CPA	B
)	O
,	O
an	O
A1	O
-	O
selective	O
agonist	O
.	O

However	O
,	O
the	O
antagonism	O
of	O
the	O
theophylline	B
-	O
induced	O
anxiogenic	O
effects	O
by	O
CGS21680	B
was	O
only	O
observed	O
in	O
the	O
time	O
spent	O
in	O
the	O
light	O
zone	O
,	O
and	O
DPCPX	B
-	O
induced	O
anxiogenic	O
effects	O
were	O
neither	O
reversed	O
by	O
CGS	B
21680	I
nor	O
by	O
CPA	B
.	O

[	O
The	O
effect	O
of	O
sandimmune	O
on	O
the	O
activity	O
of	O
mixed	O
-	O
function	O
mono	O
-	O
oxidases	O
in	O
the	O
liver	O
microsomes	O
]	O

[	O
The	O
effect	O
of	O
cimetidine	O
on	O
the	O
renal	O
excretion	O
of	O
verografin	O
and	O
iodamide	O
in	O
dogs	O
]	O

The	O
higher	O
verografine	B
and	O
iodamide	B
excretion	O
was	O
due	O
to	O
their	O
increased	O
renal	O
tubular	O
secretion	O
.	O

In	O
dogs	O
,	O
cimetidine	B
unchanged	O
the	O
secretion	O
of	O
cardiotrast	B
,	O
a	O
test	O
agent	O
for	O
anionic	O
transport	O
.	O

Possible	O
extrarenal	O
mechanisms	O
of	O
action	O
of	O
cimetidine	B
on	O
verografine	B
and	O
iodamide	B
transport	O
were	O
also	O
examined	O
.	O

Two	O
different	O
types	O
of	O
therapy	O
with	O
magnesium	B
are	O
used	O
:	O
physiological	O
oral	O
magnesium	B
supplementation	O
which	O
is	O
totally	O
atoxic	O
since	O
it	O
palliates	O
magnesium	B
deficiencies	O
by	O
simply	O
normalizing	O
the	O
magnesium	B
intake	O
and	O
pharmacological	O
magnesium	B
therapy	O
which	O
may	O
induce	O
toxicity	O
since	O
it	O
creates	O
iatrogenic	O
magnesium	B
overload	O
.	O

Primary	O
and	O
secondary	O
magnesium	B
deficiencies	O
constitute	O
the	O
sole	O
indication	O
of	O
physiological	O
oral	O
magnesium	B
therapy	O
.	O

It	O
is	O
therefore	O
necessary	O
to	O
be	O
well	O
acquainted	O
with	O
the	O
clinical	O
and	O
paraclinical	O
pattern	O
of	O
magnesium	B
deficit	O
and	O
to	O
discriminate	O
between	O
magnesium	B
deficiency	O
due	O
to	O
an	O
insufficient	O
magnesium	B
intake	O
which	O
only	O
requires	O
oral	O
physiological	O
supplementation	O
and	O
magnesium	B
depletion	O
related	O
to	O
a	O
dysregulation	O
of	O
the	O
control	O
mechanisms	O
of	O
magnesium	B
status	O
which	O
requires	O
more	O
or	O
less	O
specific	O
regulation	O
of	O
its	O
causal	O
dysregulation	O
.	O

Physiological	O
oral	O
magnesium	B
load	O
constitutes	O
the	O
best	O
tool	O
for	O
diagnosis	O
of	O
magnesium	B
deficiency	O
and	O
the	O
first	O
step	O
of	O
its	O
treatment	O
.	O

Physiological	O
oral	O
magnesium	B
supplementation	O
(	O
5	O
mg	O
/	O
kg	O
/	O
day	O
)	O
is	O
easy	O
and	O
can	O
be	O
carried	O
out	O
in	O
the	O
diet	O
or	O
with	O
magnesium	B
salts	O
,	O
with	O
practically	O
only	O
one	O
contra	O
-	O
indication	O
:	O
overt	O
renal	O
failure	O
.	O

Specific	O
and	O
aspecific	O
treatments	O
of	O
magnesium	B
depletion	O
are	O
tricky	O
using	O
for	O
example	O
magnesium	B
sparing	I
diuretics	I
,	O
pharmacological	O
doses	O
of	O
vitamin	B
B6	I
,	O
physiological	O
doses	O
of	O
vitamin	B
D	I
and	O
of	O
selenium	B
.	O

There	O
are	O
3	O
types	O
of	O
indications	O
:	O
specific	O
(	O
for	O
the	O
treatment	O
of	O
some	O
forms	O
of	O
magnesium	B
deficit	O
i	O
.	O
e	O
.	O
acute	O
)	O
,	O
pharmacological	O
(	O
i	O
.	O
e	O
.	O
without	O
alterations	O
of	O
magnesium	B
status	O
)	O
and	O
mixed	O
-	O
-	O
pharmacological	O
and	O
aetiopathogenic	O
-	O
-	O
(	O
for	O
example	O
complications	O
of	O
chronic	O
alcoholism	O
)	O
.	O

Lastly	O
local	O
use	O
of	O
the	O
mucocutaneous	O
and	O
cytoprotective	O
properties	O
of	O
magnesium	B
is	O
still	O
valid	O
,	O
in	O
cardioplegic	B
solutions	I
and	O
for	O
preservation	O
of	O
transplants	O
particularly	O
.	O

Interaction	O
between	O
glycine	B
and	O
glutamate	B
in	O
the	O
development	O
of	O
spontaneous	O
motility	O
in	O
chick	O
embryos	O
.	O

The	O
successive	O
application	O
of	O
glycine	B
(	O
5	O
or	O
10	O
mg	O
/	O
kg	O
egg	O
weight	O
(	O
e	O
.	O
w	O
.	O
)	O
and	O
glutamate	B
(	O
15	O
mg	O
/	O
kg	O
e	O
.	O
w	O
.	O
)	O
in	O
a	O
10	O
min	O
interval	O
significantly	O
increased	O
the	O
activation	O
of	O
spontaneous	O
motility	O
of	O
17	O
-	O
day	O
-	O
old	O
chick	O
embryos	O
in	O
comparison	O
with	O
the	O
effect	O
of	O
glutamate	B
alone	O
.	O

The	O
EC50	O
values	O
for	O
isoproterenol	B
,	O
which	O
is	O
not	O
a	O
substrate	O
for	O
norepinephrine	B
uptake	O
-	O
1	O
,	O
were	O
reduced	O
in	O
myocardium	O
in	O
functional	O
classes	O
II	O
to	O
III	O
and	O
IV	O
compared	O
with	O
those	O
in	O
nonfailing	O
myocardium	O
.	O

The	O
uptake	O
inhibitors	O
cocaine	B
and	O
desipramine	B
(	O
3	O
mumol	O
/	O
liter	O
)	O
potentiated	O
the	O
positive	O
inotropic	O
effects	O
of	O
norepinephrine	B
in	O
nonfailing	O
myocardium	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
but	O
not	O
in	O
functional	O
class	O
IV	O
myocardium	O
.	O

Radioligand	O
binding	O
experiments	O
using	O
the	O
uptake	O
inhibitor	O
hydrogen	O
-	O
3	O
mazindol	B
revealed	O
a	O
significant	O
decrease	O
by	O
approximately	O
30	O
%	O
in	O
norepinephrine	B
uptake	O
-	O
1	O
carrier	O
density	O
in	O
functional	O
classes	O
II	O
to	O
III	O
and	O
IV	O
myocardium	O
versus	O
nonfailing	O
myocardium	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

This	O
defect	O
in	O
the	O
failing	O
heart	O
can	O
be	O
mimicked	O
by	O
the	O
effects	O
of	O
uptake	O
blocking	O
agents	O
,	O
such	O
as	O
cocaine	B
and	O
desipramine	B
,	O
in	O
the	O
nonfailing	O
heart	O
only	O
.	O

Compromised	O
norepinephrine	B
uptake	O
-	O
1	O
in	O
functional	O
class	O
IV	O
cannot	O
be	O
further	O
increased	O
by	O
cocaine	B
and	O
desipramine	B
.	O

[	O
A	O
pharmacological	O
analysis	O
of	O
the	O
effect	O
of	O
angiotensin	O
on	O
stimulated	O
gastric	O
secretion	O
]	O

It	O
was	O
established	O
that	O
both	O
angiotensins	O
inhibited	O
gastric	O
acid	O
secretion	O
stimulated	O
by	O
pentagastrin	B
but	O
not	O
by	O
histamine	B
.	O

Comparative	O
analysis	O
of	O
the	O
effects	O
of	O
stimulation	O
and	O
inhibition	O
of	O
cholino	O
-	O
and	O
adrenoreceptors	O
on	O
this	O
inhibitory	O
action	O
of	O
angiotensins	B
suggested	O
the	O
mediation	O
of	O
angiotensin	B
influence	O
through	O
the	O
modulation	O
of	O
cholinergic	O
reactions	O
of	O
parietal	O
cells	O
in	O
the	O
stomach	O
.	O

Antacids	B
and	O
kaolin	B
:	O
Antacids	B
and	O
kaolin	B
can	O
reduce	O
absorption	O
of	O
chloroquine	B
;	O

Cimetidine	B
:	O
Cimetidine	B
can	O
inhibit	O
the	O
metabolism	O
of	O
chloroquine	B
,	O
increasing	O
its	O
plasma	O
level	O
.	O

Ampicillin	B
:	O
In	O
a	O
study	O
of	O
healthy	O
volunteers	O
,	O
chloroquine	B
significantly	O
reduced	O
the	O
bioavailability	O
of	O
ampicillin	B
.	O

Cyclosporin	B
:	O
After	O
introduction	O
of	O
chloroquine	B
(	O
oral	O
form	O
)	O
,	O
a	O
sudden	O
increase	O
in	O
serum	O
cyclosporin	B
level	O
has	O
been	O
reported	O
.	O

Therefore	O
,	O
close	O
monitoring	O
of	O
serum	O
cyclosporin	B
level	O
is	O
recommended	O
and	O
,	O
if	O
necessary	O
,	O
chloroquine	B
should	O
be	O
discontinued	O
.	O

-	O
Alcohol	B
,	O
barbiturates	B
,	O
or	O
narcotics	B
:	O
Potentiation	O
of	O
otthostatic	O
hypotension	O
may	O
occur	O

-	O
Antidiabetic	B
drugs	I
:	O
(	O
Oral	O
agents	O
and	O
insulin	B
)	O
Dosage	O
adjustment	O
of	O
the	O
antidiabetic	B
drug	I
may	O
be	O
required	O

-	O
Cholestyramine	B
and	O
colestipol	B
resins	I
:	O
Cholestytamine	B
and	O
colestipol	B
resins	I
have	O
the	O
potential	O
of	O
binding	O
thiazide	B
diuretics	I
and	O
reducing	O
diuretic	B
absorption	O
from	O
the	O
gastrointestinal	O
tract	O

-	O
Corticosteroids	B
,	O
ACTH	B
:	O
Intensified	O
electrolyte	O
depletion	O
,	O
particularly	O
hypokalemia	O

-	O
Skeletal	B
muscle	I
relaxants	I
,	O
nondepolarizing	O
(	O
e	O
.	O
g	O
.	O
,	O
tubocurarine	B
)	O
:	O
Possible	O
increased	O
responsiveness	O
to	O
the	O
muscle	B
relaxant	I

-	O
Lithium	B
:	O
Generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	B
.	O

Diuretic	B
agents	I
reduce	O
the	O
renal	O
clearance	O
of	O
lithium	B
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B
toxicity	O
.	O

Refer	O
to	O
the	O
package	O
insert	O
for	O
lithium	B
preparations	O
before	O
use	O
of	O
such	O
preparations	O
with	O
chlorothiazide	B

-	O
Non	O
-	O
steroidal	O
Anti	O
-	O
inflammatory	O
Drugs	B
:	O
In	O
some	O
patients	O
,	O
the	O
administration	O
of	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
agent	B
can	O
reduce	O
the	O
diuretic	O
,	O
natriuretic	O
,	O
and	O
antihypertensive	O
effects	O
of	O
loop	B
,	O
potassium	O
-	O
sparing	O
and	O
thiazide	B
diuretics	I
.	O

Therefore	O
,	O
when	O
chlorothiazide	B
and	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
agents	B
are	O
used	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	B
is	O
obtained	O

Chlorotrianisene	B
may	O
interact	O
with	O
antidepressants	B
,	O
aspirin	B
,	O
barbiturates	B
,	O
bromocriptine	B
,	O
calcium	B
supplements	O
,	O
corticosteroids	B
,	O
corticotropin	B
,	O
cyclosporine	B
,	O
dantrolene	B
,	O
nicotine	B
,	O
somatropin	B
,	O
tamoxifen	B
,	O
and	O
warfarin	B
.	O

Increased	O
toxicity	O
(	O
CNS	B
depression	O
)	O
:	O
CNS	B
depressants	I
,	O
MAO	B
inhibitors	I
,	O
tricyclic	B
antidepressants	I
,	O
phenothiazines	B
.	O

Example	O
inhibitors	B
include	O
azole	B
antifungals	I
,	O
ciprofloxacin	B
,	O
clarithromycin	B
,	O
diclofenac	B
,	O
doxycycline	B
,	O
erythromycin	B
,	O
imatinib	B
,	O
isoniazid	B
,	O
nefazodone	B
,	O
nicardipine	B
,	O
propofol	B
,	O
protease	B
inhibitors	I
,	O
quinidine	B
,	O
and	O
verapamil	B
.	O

The	O
concurrent	O
use	O
of	O
two	O
or	O
more	O
drugs	O
with	O
anticholinergic	O
activity	O
-	O
-	O
such	O
as	O
an	O
antipsychotic	B
drug	I
(	O
eg	O
,	O
chlorpromazine	B
)	O
,	O
an	O
antiparkinsonian	B
drug	I
(	O
eg	O
,	O
trihexyphenidyl	B
)	O
,	O
and	O
/	O
or	O
a	O
tricyclic	B
antidepressant	I
(	O
eg	O
,	O
amitriptyline	B
)	O
-	O
-	O
commonly	O
results	O
in	O
excessive	O
anticholinergic	O
effects	O
,	O
including	O
dry	O
mouth	O
and	O
associated	O
dental	O
complications	O
,	O
blurred	O
vision	O
,	O
and	O
,	O
in	O
patients	O
exposed	O
to	O
high	O
temperature	O
and	O
humidity	O
,	O
hyperpyrexia	O
.	O

Interactions	O
may	O
also	O
occur	O
with	O
the	O
following	O
:	O
anti	O
-	O
depressants	O
/	O
anti	O
-	O
anxiety	O
drugs	B
,	O
drugs	B
used	O
to	O
treat	O
an	O
overactive	O
thyroid	O
,	O
beta	O
-	O
blockers	O
(	O
e	O
.	O
g	O
.	O
,	O
propranolol	B
)	O
,	O
sparfloxacin	B
,	O
grepafloxacin	B
,	O
guanethidine	B
,	O
guanadrel	B
,	O
metrizamide	B
,	O
cabergoline	B
,	O
lithium	B
,	O
narcotic	B
pain	O
medication	O
(	O
e	O
.	O
g	O
.	O
,	O
codeine	B
)	O
,	O
drugs	B
used	O
to	O
aid	O
sleep	O
,	O
drowsiness	O
-	O
causing	O
antihistamines	B
(	O
e	O
.	O
g	O
.	O
,	O
diphenhydramine	B
)	O
,	O
any	O
other	O
drugs	B
that	O
may	O
make	O
you	O
drowsy	O
.	O

The	O
hypoglycemic	O
action	O
of	O
sulfonylurea	B
may	O
be	O
potentiated	O
by	O
certain	O
drugs	O
including	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
agents	B
and	O
other	O
drugs	O
that	O
are	O
highly	O
protein	O
bound	O
,	O
salicylates	B
,	O
sulfonamides	B
,	O
chloramphenicol	B
,	O
probenecid	B
,	O
coumarins	B
,	O
monoamine	B
oxidase	I
inhibitors	I
,	O
and	O
beta	B
adrenergic	I
blocking	I
agents	I
.	O

These	O
drugs	B
include	O
the	O
thiazides	B
and	O
other	O
diuretics	B
,	O
corticosteroids	B
,	O
phenothiazines	B
,	O
thyroid	O
products	O
,	O
estrogens	B
,	O
oral	O
contraceptives	B
,	O
phenytoin	B
,	O
nicotinic	B
acid	I
,	O
sympathomimetics	B
,	O
calcium	B
channel	I
blocking	I
drugs	I
,	O
and	O
isoniazid	B
.	O

Since	O
animal	O
studies	O
suggest	O
that	O
the	O
action	O
of	O
barbiturates	B
may	O
be	O
prolonged	O
by	O
therapy	O
with	O
chlorpropamide	B
,	O
barbiturates	B
should	O
be	O
employed	O
with	O
caution	O
.	O

In	O
some	O
patients	O
,	O
a	O
disulfiram	B
-	O
like	O
reaction	O
may	O
be	O
produced	O
by	O
the	O
ingestion	O
of	O
alcohol	B
.	O

A	O
potential	O
interaction	O
between	O
oral	O
miconazole	B
and	O
oral	O
hypoglycemic	B
agents	I
leading	O
to	O
severe	O
hypoglycemia	O
has	O
been	O
reported	O
.	O

Chlorprothixene	B
may	O
increase	O
the	O
plasma	O
-	O
level	O
of	O
concomitantly	O
given	O
lithium	B
.	O

In	O
order	O
to	O
avoid	O
lithium	B
intoxication	O
,	O
lithium	B
plasma	O
levels	O
should	O
be	O
monitored	O
closely	O
.	O

If	O
chlorprothixene	B
is	O
given	O
concomitantly	O
with	O
opioids	B
,	O
the	O
opioid	B
dose	O
should	O
be	O
reduced	O
(	O
by	O
approx	O
.	O
50	O
%	O
)	O
,	O
because	O
chlorprothixene	B
amplifies	O
the	O
therapeutic	O
actions	O
and	O
side	O
-	O
effects	O
of	O
opioids	B
massively	O
.	O

Avoid	O
the	O
concomitant	O
use	O
of	O
chlorprothixene	B
and	O
tramadol	B
(	O
Ultram	B
)	O
.	O

Consider	O
additive	O
sedative	O
effects	O
and	O
confusional	O
states	O
to	O
emerge	O
,	O
if	O
chlorprothixene	B
is	O
given	O
with	O
benzodiazepines	B
or	O
barbituates	B
.	O

Exert	O
particular	O
caution	O
in	O
combining	O
chlorprothixene	B
with	O
other	O
anticholinergic	B
drugs	I
(	O
tricyclic	B
antidepressants	I
and	O
antiparkinsonian	B
agents	I
)	O
:	O
Particularly	O
the	O
elderly	O
may	O
develop	O
delirium	O
,	O
high	O
fever	O
,	O
severe	O
obstipation	O
,	O
even	O
ileus	O
and	O
glaucoma	O
.	O

Chlorthalidone	B
may	O
add	O
to	O
or	O
potentiate	O
the	O
action	O
of	O
other	O
antihypertensive	B
drugs	I
.	O

Chlorthalidone	B
and	O
related	O
drugs	O
may	O
increase	O
the	O
responsiveness	O
to	O
tubocurarine	B
.	O

Chlorthalidone	B
and	O
related	O
drugs	O
may	O
decrease	O
arterial	O
responsiveness	O
to	O
norepinephrine	B
.	O

The	O
concomitant	O
use	O
of	O
alcohol	B
or	O
other	O
central	B
nervous	I
system	I
depressants	I
may	O
have	O
an	O
additive	O
effect	O
.	O

Interactions	O
for	O
vitamin	B
D	I
analogues	O
(	O
Vitamin	B
D2	I
,	O
Vitamin	B
D3	I
,	O
Calcitriol	B
,	O
and	O
Calcidiol	B
)	O
:	O
Cholestyramine	B
:	O
Cholestyramine	B
has	O
been	O
reported	O
to	O
reduce	O
intestinal	O
absorption	O
of	O
fat	B
soluble	I
vitamins	I
;	O

Phenytoin	B
/	O
Phenobarbital	B
:	O
The	O
coadministration	O
of	O
phenytoin	B
or	O
phenobarbital	B
will	O
not	O
affect	O
plasma	O
concentrations	O
of	O
vitamin	B
D	I
,	O
but	O
may	O
reduce	O
endogenous	O
plasma	O
levels	O
of	O
calcitriol	B
/	O
ergocalcitriol	O
by	O
accelerating	O
metabolism	O
.	O

Since	O
blood	O
level	O
of	O
calcitriol	B
/	O
ergocalcitriol	O
will	O
be	O
reduced	O
,	O
higher	O
doses	O
of	O
Rocaltrol	B
may	O
be	O
necessary	O
if	O
these	O
drugs	O
are	O
administered	O
simultaneously	O
.	O

Thiazides	B
:	O
Thiazides	B
are	O
known	O
to	O
induce	O
hypercalcemia	O
by	O
the	O
reduction	O
of	O
calcium	O
excretion	O
in	O
urine	O
.	O

Some	O
reports	O
have	O
shown	O
that	O
the	O
concomitant	O
administration	O
of	O
thiazides	B
with	O
vitamin	B
D	I
causes	O
hypercalcemia	O
.	O

Digitalis	B
:	O
Vitamin	B
D	I
dosage	O
must	O
be	O
determined	O
with	O
care	O
in	O
patients	O
undergoing	O
treatment	O
with	O
digitalis	B
,	O
as	O
hypercalcemia	O
in	O
such	O
patients	O
may	O
precipitate	O
cardiac	O
arrhythmias	O
.	O

Ketoconazole	B
:	O
Ketoconazole	B
may	O
inhibit	O
both	O
synthetic	O
and	O
catabolic	O
enzymes	O
of	O
vitamin	B
D	I
.	O

However	O
,	O
in	O
vivo	O
drug	O
interaction	O
studies	O
of	O
ketoconazole	B
with	O
vitamin	B
D	I
have	O
not	O
been	O
investigated	O
.	O

Corticosteroids	B
:	O
A	O
relationship	O
of	O
functional	O
antagonism	O
exists	O
between	O
vitamin	B
D	I
analogues	O
,	O
which	O
promote	O
calcium	O
absorption	O
,	O
and	O
corticosteroids	B
,	O
which	O
inhibit	O
calcium	O
absorption	O
.	O

Vitamin	B
D	I
:	O
The	O
coadministration	O
of	O
any	O
of	O
the	O
vitamin	B
D	I
analogues	O
should	O
be	O
avoided	O
as	O
this	O
could	O
create	O
possible	O
additive	O
effects	O
and	O
hypercalcemia	O
.	O

Calcium	B
Supplements	O
:	O
Uncontrolled	O
intake	O
of	O
additional	O
calcium	B
-	O
containing	O
preparations	O
should	O
be	O
avoided	O
.	O

Magnesium	B
:	O
Magnesium	B
-	O
containing	O
preparations	O
(	O
eg	O
,	O
antacids	B
)	O
may	O
cause	O
hypermagnesemia	O
and	O
should	O
therefore	O
not	O
be	O
taken	O
during	O
therapy	O
with	O
vitamin	B
D	I
by	O
patients	O
on	O
chronic	O
renal	O
dialysis	O
.	O

Cholestyramine	B
resin	I
may	O
delay	O
or	O
reduce	O
the	O
absorption	O
of	O
concomitant	O
oral	O
medication	O
such	O
as	O
phenylbutazone	B
,	O
warfarin	B
,	O
thiazide	B
diuretics	I
(	O
acidic	O
)	O
or	O
propranolol	B
(	O
basic	O
)	O
,	O
as	O
well	O
as	O
tetracycline	B
penicillin	I
G	I
,	O
phenobarbital	B
,	O
thyroid	O
and	O
thyroxine	B
preparations	O
,	O
estrogens	B
and	O
progestins	B
,	O
and	O
digitalis	B
.	O

Cholestyramine	B
resin	I
may	O
interfere	O
with	O
the	O
pharmacokinetics	O
of	O
drugs	O
that	O
undergo	O
enterohepatic	O
circulation	O
,	O
The	O
discontinuance	O
of	O
cholestyramine	B
resin	I
could	O
pose	O
a	O
hazard	O
to	O
health	O
if	O
a	O
potentially	O
toxic	O
drug	O
such	O
as	O
digitalis	B
has	O
been	O
filtrated	O
to	O
a	O
maintenance	O
level	O
while	O
the	O
patient	O
was	O
taking	O
cholestyramine	B
resin	I
.	O

Because	O
cholestyramine	B
binds	O
bile	O
acids	O
,	O
cholestyramine	B
resin	I
may	O
interfere	O
with	O
normal	O
fat	B
digestion	O
and	O
absorption	O
and	O
thus	O
may	O
prevent	O
absorption	O
of	O
fat	B
soluble	I
vitamins	I
such	O
as	O
A	O
,	O
D	O
,	O
E	O
,	O
and	O
K	O
.	O

When	O
cholestyramine	B
resin	I
is	O
given	O
for	O
long	O
periods	O
of	O
time	O
,	O
concomitant	O
supplementation	O
with	O
water	O
-	O
miscible	O
(	O
or	O
parenteral	O
)	O
forms	O
of	O
fat	O
-	O
soluble	O
vitamins	B
should	O
be	O
considered	O
.	O

SINCE	O
CHOLESTYRAMINE	B
RESIN	I
MAY	O
BIND	O
OTHER	O
DRUGS	O
GIVEN	O
CONCURRENTLY	O
,	O
IT	O
IS	O
RECOMMENDED	O
THAT	O
PATIENTS	O
TAKE	O
OTHER	O
DRUGS	O
AT	O
LEAST	O
1	O
HOUR	O
BEFORE	O
OR	O
4	O
TO	O
6	O
HOURS	O
AFTER	O
CHOLESTYRAMINE	B
RESIN	I
(	O
OR	O
AT	O
AS	O
GREAT	O
AN	O
INTERVAL	O
AS	O
POSSIBLE	O
)	O
TO	O
AVOID	O
IMPEDING	O
THEIR	O
ABSORPTION	O
.	O

In	O
vitro	O
studies	O
demonstrated	O
that	O
the	O
plasma	O
protein	O
binding	O
of	O
des	O
-	O
ciclesonide	O
was	O
not	O
affected	O
by	O
warfarin	B
or	O
salicylic	B
acid	I
,	O
indicating	O
no	O
potential	O
for	O
protein	O
binding	O
-	O
based	O
drug	O
interactions	O
.	O

In	O
a	O
drug	O
interaction	O
study	O
,	O
co	O
-	O
administration	O
of	O
orally	O
inhaled	O
ciclesonide	B
and	O
oral	O
erythromycin	B
,	O
an	O
inhibitor	O
of	O
cytochrome	O
P450	O
3A4	O
,	O
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
either	O
des	O
-	O
ciclesonide	B
or	O
erythromycin	B
.	O

In	O
another	O
drug	O
interaction	O
study	O
,	O
co	O
-	O
administration	O
of	O
orally	O
inhaled	O
ciclesonide	B
and	O
oral	O
ketoconazole	B
,	O
a	O
potent	O
inhibitor	O
of	O
cytochrome	O
P450	O
3A4	O
,	O
increased	O
the	O
exposure	O
(	O
AUC	O
)	O
of	O
des	O
-	O
ciclesonide	B
by	O
approximately	O
3	O
.	O
6	O
-	O
fold	O
at	O
steady	O
state	O
,	O
while	O
levels	O
of	O
ciclesonide	B
remained	O
unchanged	O
.	O

Therefore	O
,	O
ketoconazole	B
should	O
be	O
administered	O
with	O
caution	O
with	O
intranasal	O
ciclesonide	B
.	O

Probenecid	B
:	O
Probenecid	B
is	O
known	O
to	O
interact	O
with	O
the	O
metabolism	O
or	O
renal	O
tubular	O
excretion	O
of	O
many	O
drugs	O
(	O
e	O
.	O
g	O
.	O
,	O
acetaminophen	B
,	O
acyclovir	B
,	O
angiotensin	O
-	O
converting	O
enzyme	B
inhibitors	I
,	O
aminosalicylic	B
acid	I
,	O
barbiturates	B
,	O
benzodiazepines	B
,	O
bumetanide	B
,	O
clofibrate	B
,	O
methotrexate	B
,	O
famotidine	B
,	O
furosemide	B
,	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
agents	O
,	O
theophylline	B
,	O
and	O
zidovudine	B
)	O
.	O

Zidovudine	B
should	O
either	O
be	O
temporarily	O
discontinued	O
or	O
decreased	O
by	O
50	O
%	O
when	O
coadministered	O
with	O
probenecid	B
on	O
the	O
day	O
of	O
VISTIDE	B
infusion	O
.	O

Nephrotoxic	O
agents	B
:	O
Concomitant	O
administration	O
of	O
VISTIDE	B
and	O
agents	B
with	O
nephrotoxic	O
potential	O
[	O
e	O
.	O
g	O
.	O
,	O
intravenous	O
aminoglycosides	B
(	O
e	O
.	O
g	O
.	O
,	O
tobramycin	B
,	O
gentamicin	B
,	O
and	O
amikacin	B
)	O
,	O
amphotericin	B
B	I
,	O
foscarnet	B
,	O
intravenous	O
pentamidine	B
,	O
vancomycin	B
,	O
and	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
agents	B
]	O
is	O
contraindicated	O
.	O

Since	O
PLETAL	B
is	O
extensively	O
metabolized	O
by	O
cytochrome	O
P	O
-	O
450	O
isoenzymes	O
,	O
caution	O
should	O
be	O
exercised	O
when	O
PLETAL	B
is	O
coadministered	O
with	O
inhibitors	O
of	O
C	O
.	O
P	O
.	O
A	O
.	O
such	O
as	O
ketoconazole	B
and	O
erythromycin	B
or	O
inhibitors	O
of	O
CYP2C19	O
such	O
as	O
omeprazole	B
.	O

Pharmacokinetic	O
studies	O
have	O
demonstrated	O
that	O
omeprazole	B
and	O
erythromycin	B
significantly	O
increased	O
the	O
systemic	O
exposure	O
of	O
cilostazol	B
and	O
/	O
or	O
its	O
major	O
metabolites	O
.	O

Population	O
pharmacokinetic	O
studies	O
showed	O
higher	O
concentrations	O
of	O
cilostazol	B
among	O
patients	O
concurrently	O
treated	O
with	O
diltiazem	B
,	O
an	O
inhibitor	O
of	O
C	O
.	O
P	O
.	O
A	O
.	O
.	O

Pletal	B
does	O
not	O
,	O
however	O
,	O
appear	O
to	O
cause	O
increased	O
blood	O
levels	O
of	O
drugs	O
metabolized	O
by	O
CYP3A4	O
,	O
as	O
it	O
had	O
no	O
effect	O
on	O
lovastatin	B
,	O
a	O
drug	O
with	O
metabolism	O
very	O
sensitive	O
to	O
C	O
.	O
P	O
.	O
A	O
.	O
inhibition	O
.	O

Tagamet	B
,	O
apparently	O
through	O
an	O
effect	O
on	O
certain	O
microsomal	O
enzyme	O
systems	O
,	O
has	O
been	O
reported	O
to	O
reduce	O
the	O
hepatic	O
metabolism	O
of	O
warfarin	O
-	O
type	O
anticoagulants	B
,	O
phenytoin	B
,	O
propranolol	B
,	O
nifedipine	B
,	O
chlordiazepoxide	B
,	O
diazepam	B
,	O
certain	O
tricyclic	B
antidepressants	I
,	O
lidocaine	B
,	O
theophylline	B
and	O
metronidazole	B
,	O
thereby	O
delaying	O
elimination	O
and	O
increasing	O
blood	O
levels	O
of	O
these	O
drugs	O
.	O

therefore	O
,	O
close	O
monitoring	O
of	O
prothrombin	O
time	O
is	O
recommended	O
,	O
and	O
adjustment	O
of	O
the	O
anticoagulant	B
dose	O
may	O
be	O
necessary	O
when	O
Tagamet	B
is	O
administered	O
concomitantly	O
.	O

Interaction	O
with	O
phenytoin	B
,	O
lidocaine	B
and	O
theophylline	B
has	O
also	O
been	O
reported	O
to	O
produce	O
adverse	O
clinical	O
effects	O
.	O

However	O
,	O
a	O
crossover	O
study	O
in	O
healthy	O
subjects	O
receiving	O
either	O
Tagamet	B
300	O
mg	O
q	O
.	O
i	O
.	O
d	O
.	O
or	O
800	O
mg	O
h	O
.	O
s	O
.	O
concomitantly	O
with	O
a	O
300	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
dosage	O
of	O
theophylline	B
(	O
Theo	O
-	O
Dur	O
,	O
Key	O
Pharmaceuticals	O
,	O
Inc	O
.	O
)	O
demonstrated	O
less	O
alteration	O
in	O
steady	O
-	O
state	O
theophylline	B
peak	O
serum	O
levels	O
with	O
the	O
800	O
mg	O
h	O
.	O
s	O
.	O
regimen	O
,	O
particularly	O
in	O
subjects	O
aged	O
54	O
years	O
and	O
older	O
.	O

Effect	O
of	O
Sensipar	B
on	O
other	O
drugs	O
:	O
Drugs	O
metabolized	O
by	O
cytochrome	O
P450	O
2D6	O
(	O
CYP2D6	O
)	O
:	O
Sensipar	B
is	O
a	O
strong	O
in	O
vitro	O
inhibitor	O
of	O
CYP2D6	O
.	O

Therefore	O
,	O
dose	O
adjustments	O
of	O
concomitant	O
medications	O
that	O
are	O
predominantly	O
metabolized	O
by	O
CYP2D6	O
and	O
have	O
a	O
narrow	O
therapeutic	O
index	O
(	O
e	O
.	O
g	O
.	O
,	O
flecainide	B
,	O
vinblastine	B
,	O
thioridazine	B
and	O
most	O
tricyclic	B
antidepressants	I
)	O
may	O
be	O
required	O
.	O

Amitriptyline	B
:	O
Concurrent	O
administration	O
of	O
25	O
mg	O
or	O
100	O
mg	O
cinacalcet	B
with	O
50	O
mg	O
amitriptyline	B
increased	O
amitriptyline	B
exposure	O
and	O
nortriptyline	B
(	O
active	O
metabolite	O
)	O
exposure	O
by	O
approximately	O
20	O
%	O
in	O
CYP2D6	O
extensive	O
metabolizers	O
.	O

Effect	O
of	O
other	O
drugs	O
on	O
Sensipar	B
:	O
Sensipar	B
is	O
metabolized	O
by	O
multiple	O
cytochrome	O
P450	O
enzymes	O
,	O
primarily	O
CYP3A4	O
,	O
CYP2D6	O
,	O
and	O
CYP1A2	O
.	O

Ketoconazole	B
:	O
Sensipar	B
is	O
metabolized	O
in	O
part	O
by	O
CYP3A4	O
.	O

Co	O
-	O
administration	O
of	O
ketoconazole	B
,	O
a	O
strong	O
inhibitor	O
of	O
CYP3A4	O
,	O
increased	O
cinacalcet	B
exposure	O
following	O
a	O
single	O
90	O
mg	O
dose	O
of	O
Sensipar	B
by	O
2	O
.	O
3	O
fold	O
.	O

Dose	O
adjustment	O
of	O
Sensipar	B
may	O
be	O
required	O
and	O
PTH	O
and	O
serum	O
calcium	O
concentrations	O
should	O
be	O
closely	O
monitored	O
if	O
a	O
patient	O
initiates	O
or	O
discontinues	O
therapy	O
with	O
a	O
strong	O
CYP3A4	O
inhibitor	O
(	O
e	O
.	O
g	O
.	O
,	O
ketoconazole	B
,	O
erythromycin	B
,	O
itraconazole	B
;	O

Elevated	O
plasma	O
levels	O
of	O
theophylline	B
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
some	O
quinolones	B
.	O

There	O
have	O
been	O
reports	O
of	O
theophylline	B
-	O
related	O
side	O
-	O
effects	O
in	O
patients	O
on	O
concomitant	O
theophylline	B
-	O
quinolone	B
therapy	O
.	O

Therefore	O
,	O
monitoring	O
of	O
theophylline	B
plasma	O
levels	O
should	O
be	O
considered	O
and	O
dosage	O
of	O
theophylline	B
adjusted	O
as	O
required	O
.	O

Quinolones	B
have	O
also	O
been	O
shown	O
to	O
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	B
.	O

Although	O
this	O
interaction	O
has	O
not	O
been	O
reported	O
with	O
cinoxacin	B
,	O
caution	O
should	O
be	O
exercised	O
when	O
cinoxacin	B
is	O
given	O
concomitantly	O
with	O
caffeine	B
-	O
containing	O
products	O
.	O

Antacids	B
or	O
sucralfate	B
substantially	O
interfere	O
with	O
the	O
absorption	O
of	O
some	O
quinolones	B
,	O
resulting	O
in	O
low	O
urine	O
levels	O
.	O

Also	O
,	O
concomitant	O
administration	O
of	O
quinolones	B
with	O
products	O
containing	O
iron	B
,	O
multivitamins	B
containing	O
zinc	B
,	O
or	O
Videx	B
(	O
didanosine	B
)	O
chewable	O
/	O
buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
may	O
result	O
in	O
low	O
urine	O
levels	O
.	O

Quinolones	B
,	O
including	O
cinoxacin	B
,	O
may	O
enhance	O
the	O
effects	O
of	O
oral	O
anticoagulants	B
,	O
such	O
as	O
warfarin	B
or	O
its	O
derivatives	O
.	O

Seizures	O
have	O
been	O
reported	O
in	O
patients	O
taking	O
another	O
quinolone	B
class	I
antimicrobial	I
and	O
the	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
drug	B
fenbufen	I
concurrently	O
.	O

Physicians	O
are	O
provided	O
this	O
information	O
to	O
increase	O
awareness	O
of	O
the	O
potential	O
for	O
serious	O
interactions	O
when	O
cinoxacin	B
and	O
certain	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
agents	B
are	O
administered	O
concomitantly	O
.	O

Elevated	O
cyclosporine	B
serum	O
levels	O
have	O
been	O
reported	O
with	O
the	O
concomitant	O
use	O
of	O
quinolones	B
and	O
cyclosporine	B
.	O

Some	O
quinolones	B
,	O
including	O
ciprofloxacin	B
,	O
have	O
also	O
been	O
shown	O
to	O
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	B
.	O

Some	O
quinolones	B
,	O
including	O
ciprofloxacin	B
,	O
have	O
been	O
associated	O
with	O
transient	O
elevations	O
in	O
serum	O
creatinine	O
in	O
patients	O
receiving	O
cyclosporine	B
concomitantly	O
.	O

Glyburide	B
:	O
The	O
concomitant	O
administration	O
of	O
ciprofloxacin	B
with	O
the	O
sulfonylurea	B
glyburide	I
has	O
,	O
on	O
rare	O
occasions	O
,	O
resulted	O
in	O
severe	O
hypoglycemia	O
.	O

Histamine	B
H2	O
-	O
receptor	O
antagonists	B
:	O
Histamine	B
H2	O
-	O
receptor	O
antagonists	B
appear	O
to	O
have	O
no	O
significant	O
effect	O
on	O
the	O
bioavailability	O
of	O
ciprofloxacin	B
.	O

Methotrexate	B
Renal	O
tubular	O
transport	O
of	O
methotrexate	B
may	O
be	O
inhibited	O
by	O
concomitant	O
administration	O
of	O
ciprofloxacin	B
,	O
potentially	O
leading	O
to	O
increased	O
plasma	O
levels	O
of	O
methotrexate	B
.	O

Therefore	O
,	O
patients	O
under	O
methotrexate	B
therapy	O
should	O
be	O
carefully	O
monitored	O
when	O
concomitant	O
ciprofloxacin	B
therapy	O
is	O
indicated	O
.	O

Multivalent	O
Cation	O
-	O
Containing	O
Products	O
:	O
Concurrent	O
administration	O
of	O
a	O
quinolone	B
,	O
including	O
ciprofloxacin	B
,	O
with	O
multivalent	O
cation	O
-	O
containing	O
products	O
such	O
as	O
magnesium	B
or	O
aluminum	B
antacids	I
,	O
sucralfate	B
,	O
VIDEX	B
chewable	O
/	O
buffered	O
tablets	O
or	O
pediatric	O
powder	O
,	O
or	O
products	O
containing	O
calcium	B
,	O
iron	B
,	O
or	O
zinc	B
may	O
substantially	O
decrease	O
the	O
absorption	O
of	O
ciprofloxacin	B
,	O
resulting	O
in	O
serum	O
and	O
urine	O
levels	O
considerably	O
lower	O
than	O
desired	O
.	O

This	O
time	O
window	O
is	O
different	O
than	O
for	O
other	O
oral	O
formulations	O
of	O
ciprofloxacin	B
,	O
which	O
are	O
usually	O
administered	O
2	O
hours	O
before	O
or	O
6	O
hours	O
after	O
antacids	B
.	O

Non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	B
(	O
but	O
not	O
aspirin	B
)	O
:	O
These	O
drugs	B
in	O
combination	O
with	O
very	O
high	O
doses	O
of	O
quinolones	B
have	O
been	O
shown	O
to	O
provoke	O
convulsions	O
in	O
pre	O
-	O
clinical	O
studies	O
.	O

Omeprazole	B
:	O
The	O
rate	O
and	O
extent	O
of	O
absorption	O
of	O
ciprofloxacin	B
was	O
bioequivalent	O
when	O
Proquin	B
XR	I
was	O
given	O
alone	O
or	O
when	O
Proquin	B
XR	I
was	O
given	O
2	O
hours	O
after	O
omeprazole	B
at	O
the	O
dose	O
that	O
maximally	O
suppresses	O
gastric	O
acid	O
secretion	O
.	O

Omeprazole	B
should	O
be	O
taken	O
as	O
directed	O
and	O
Proquin	B
XR	I
should	O
be	O
taken	O
with	O
a	O
main	O
meal	O
of	O
the	O
day	O
,	O
preferably	O
the	O
evening	O
meal	O
.	O
.	O

Phenytoin	B
:	O
Altered	O
serum	O
levels	O
of	O
phenytoin	B
(	O
increased	O
and	O
decreased	O
)	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
concomitant	O
ciprofloxacin	B
.	O

Probenecid	B
:	O
Probenecid	B
interferes	O
with	O
renal	O
tubular	O
secretion	O
of	O
ciprofloxacin	B
and	O
produces	O
an	O
increase	O
in	O
the	O
level	O
of	O
ciprofloxacin	B
in	O
serum	O
.	O

Theophylline	B
:	O
As	O
with	O
some	O
other	O
quinolones	B
,	O
concurrent	O
administration	O
of	O
ciprofloxacin	B
with	O
theophylline	B
may	O
lead	O
to	O
elevated	O
serum	O
concentrations	O
of	O
theophylline	B
and	O
prolongation	O
of	O
its	O
elimination	O
half	O
-	O
life	O
.	O

Warfarin	B
:	O
Quinolones	B
have	O
been	O
reported	O
to	O
enhance	O
the	O
effects	O
of	O
the	O
oral	O
anticoagulant	B
warfarin	I
or	O
its	O
derivatives	O
.	O

In	O
some	O
cases	O
where	O
serious	O
ventricular	O
arrhythmias	O
,	O
QT	O
prolongation	O
,	O
and	O
torsades	O
de	O
pointes	O
have	O
occurred	O
when	O
cisapride	B
was	O
taken	O
in	O
conjunction	O
with	O
one	O
of	O
the	O
cytochrome	O
P450	O
3A4	O
inhibitors	O
,	O
elevated	O
blood	O
cisapride	B
levels	O
were	O
noted	O
at	O
the	O
time	O
of	O
the	O
QT	O
prolongation	O
.	O

Antibiotics	B
:	O
In	O
vitro	O
and	O
/	O
or	O
in	O
vivo	O
data	O
show	O
that	O
clarithromycin	B
,	O
erythromycin	B
,	O
and	O
troleandomycin	B
markedly	O
inhibit	O
the	O
metabolism	O
of	O
cisapride	B
,	O
which	O
can	O
result	O
in	O
an	O
increase	O
in	O
plasma	O
cisapride	B
levels	O
and	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O

Anticholinergics	B
:	O
Concurrent	O
administration	O
of	O
certain	O
anticholinergic	B
compounds	I
,	O
such	O
as	O
belladonna	B
alkaloids	I
and	O
dicyclomine	B
,	O
would	O
be	O
expected	O
to	O
compromise	O
the	O
beneficial	O
effects	O
of	O
cisapride	B
.	O

Anticoagulants	B
(	O
Oral	O
)	O
:	O
In	O
patients	O
receiving	O
oral	O
anticoagulants	B
,	O
the	O
coagulation	O
times	O
were	O
increased	O
in	O
some	O
cases	O
.	O

It	O
is	O
advisable	O
to	O
check	O
coagulation	O
time	O
within	O
the	O
first	O
few	O
days	O
after	O
the	O
start	O
and	O
discontinuation	O
of	O
cisapride	B
therapy	O
,	O
with	O
an	O
appropriate	O
adjustment	O
of	O
the	O
anticoagulant	B
dose	O
,	O
if	O
necessary	O
.	O

Antidepressants	B
:	O
In	O
vitro	O
data	O
indicate	O
that	O
nefazodone	B
inhibits	O
the	O
metabolism	O
of	O
cisapride	B
,	O
which	O
can	O
result	O
in	O
an	O
increase	O
in	O
plasma	O
cisapride	B
levels	O
and	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O

Antifungals	B
:	O
In	O
vitro	O
and	O
/	O
or	O
in	O
vivo	O
data	O
indicate	O
that	O
fluconazole	B
,	O
itraconazole	B
,	O
and	O
oral	O
ketoconazole	B
markedly	O
inhibit	O
the	O
metabolism	O
of	O
cisapride	B
,	O
which	O
can	O
result	O
in	O
an	O
increase	O
in	O
plasma	O
cisapride	B
levels	O
and	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O

Human	O
pharmacokinetic	O
data	O
indicate	O
that	O
oral	O
ketoconazole	B
markedly	O
inhibits	O
the	O
metabolism	O
of	O
cisapride	B
,	O
resulting	O
in	O
a	O
mean	O
eight	O
-	O
fold	O
increase	O
in	O
AUC	O
of	O
cisapride	B
.	O

A	O
study	O
in	O
14	O
normal	O
male	O
and	O
female	O
volunteers	O
suggests	O
that	O
coadministration	O
of	O
cisapride	B
and	O
ketoconazole	B
can	O
result	O
in	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O

H2	B
Receptor	I
Antagonists	I
:	O
Cimetidine	B
coadministration	O
leads	O
to	O
an	O
increased	O
peak	O
plasma	O
concentration	O
and	O
AUC	O
of	O
cisapride	B
,	O
there	O
is	O
no	O
effect	O
on	O
cisapride	B
absorption	O
when	O
it	O
is	O
coadministered	O
with	O
ranitidine	B
.	O

The	O
gastrointestinal	O
absorption	O
of	O
cimetidine	B
and	O
ranitidine	B
is	O
accelerated	O
when	O
they	O
are	O
coadministered	O
with	O
cisapride	B
.	O

Protease	B
Inhibitors	I
:	O
In	O
vitro	O
data	O
indicate	O
that	O
indinavir	B
and	O
ritonavir	B
markedly	O
inhibit	O
the	O
metabolism	O
of	O
cisapride	B
which	O
can	O
result	O
in	O
an	O
increase	O
in	O
plasma	O
cisapride	B
levels	O
and	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O

Other	O
:	O
Coadministration	O
of	O
grapefruit	O
juice	O
with	O
cisapride	B
increases	O
the	O
bioavailability	O
of	O
cisapride	B
and	O
concomitant	O
use	O
should	O
be	O
avoided	O
.	O

Cisapride	B
should	O
not	O
be	O
used	O
concomitantly	O
with	O
other	O
drugs	O
known	O
to	O
prolong	O
the	O
QT	O
interval	O
:	O
certain	O
antiarrhythmics	B
,	O
including	O
those	O
of	O
Class	O
IA	O
(	O
such	O
as	O
quinidine	B
and	O
procainamide	B
)	O
and	O
Class	O
III	O
(	O
such	O
as	O
sotalol	B
)	O
;	O

tricyclic	B
antidepressants	I
(	O
such	O
as	O
amitriptyline	B
)	O
;	O

certain	O
tetracyclic	B
antidepressants	I
(	O
such	O
as	O
maprotiline	B
)	O
;	O

certain	O
antipsychotic	B
medications	I
(	O
such	O
as	O
sertindole	B
)	O
;	O

astemizole	B
,	O
bepridil	B
,	O
sparfloxacin	B
,	O
and	O
terodiline	B
.	O

Administration	O
of	O
0	O
.	O
1	O
-	O
mg	O
/	O
kg	O
(	O
2	O
x	O
ED95	O
)	O
NIMBEX	B
at	O
10	O
%	O
or	O
95	O
%	O
recovery	O
following	O
an	O
intubating	O
dose	O
of	O
succinylcholine	B
(	O
1	O
mg	O
/	O
kg	O
)	O
produced	O
95	O
%	O
neuromuscular	O
block	O
.	O

The	O
time	O
to	O
onset	O
of	O
maximum	O
block	O
following	O
NIMBEX	B
is	O
approximately	O
2	O
minutes	O
faster	O
with	O
prior	O
administration	O
of	O
succinylcholine	B
.	O

Prior	O
administration	O
of	O
succinylcholine	B
had	O
no	O
effect	O
on	O
the	O
duration	O
of	O
neuromuscular	O
block	O
following	O
initial	O
or	O
maintenance	O
bolus	O
doses	O
of	O
NIMBEX	B
.	O

Infusion	O
requirements	O
of	O
NIMBEX	B
in	O
patients	O
administered	O
succinylcholine	B
prior	O
to	O
infusions	O
of	O
NIMBEX	B
were	O
comparable	O
to	O
or	O
slightly	O
greater	O
than	O
when	O
succinylcholine	B
was	O
not	O
administered	O
.	O

The	O
use	O
of	O
NIMBEX	B
before	O
succinylcholine	B
to	O
attenuate	O
some	O
of	O
the	O
side	O
effects	O
of	O
succinylcholine	B
has	O
not	O
been	O
studied	O
.	O

Although	O
not	O
studied	O
systematically	O
in	O
clinical	O
trials	O
,	O
no	O
drug	O
interactions	O
were	O
observed	O
when	O
vecuronium	B
,	O
pancuronium	B
,	O
or	O
atracurium	B
were	O
administered	O
following	O
varying	O
degrees	O
of	O
recovery	O
from	O
single	O
doses	O
or	O
infusions	O
of	O
NIMBEX	B
.	O

Isoflurane	B
or	O
enflurane	B
administered	O
with	O
nitrous	B
oxide	I
/	O
oxygen	B
to	O
achieve	O
1	O
.	O
25	O
MAC	O
[	O
Minimum	O
Alveolar	O
Concentration	O
]	O
may	O
prolong	O
the	O
clinically	O
effective	O
duration	O
of	O
action	O
of	O
initial	O
and	O
maintenance	O
doses	O
of	O
NIMBEX	B
and	O
decrease	O
the	O
required	O
infusion	O
rate	O
of	O
NIMBEX	B
.	O

Fifteen	O
to	O
30	O
minutes	O
of	O
exposure	O
to	O
1	O
.	O
25	O
MAC	O
isoflurane	B
or	O
enflurane	B
had	O
minimal	O
effects	O
on	O
the	O
duration	O
of	O
action	O
of	O
initial	O
doses	O
of	O
NIMBEX	B
and	O
therefore	O
,	O
no	O
adjustment	O
to	O
the	O
initial	O
dose	O
should	O
be	O
necessary	O
when	O
NIMBEX	B
is	O
administered	O
shortly	O
after	O
initiation	O
of	O
volatile	O
agents	O
.	O

In	O
long	O
surgical	O
procedures	O
during	O
enflurane	B
or	O
isoflurane	B
anesthesia	O
,	O
less	O
frequent	O
maintenance	O
dosing	O
,	O
lower	O
maintenance	O
doses	O
,	O
or	O
reduced	O
infusion	O
rates	O
of	O
NIMBEX	B
may	O
be	O
necessary	O
.	O

In	O
clinical	O
studies	O
propofol	B
had	O
no	O
effect	O
on	O
the	O
duration	O
of	O
action	O
or	O
dosing	O
requirements	O
for	O
NIMBEX	B
.	O

Other	O
drugs	O
which	O
may	O
enhance	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
nondepolarizing	B
agents	I
such	O
as	O
NIMBEX	B
include	O
certain	O
antibiotics	B
(	O
e	O
.	O
g	O
.	O
,	O
aminoglycosides	B
,	O
tetracyclines	B
,	O
bacitracin	B
,	O
polymyxins	B
,	O
lincomycin	B
,	O
clindamycin	B
,	O
colistin	B
,	O
and	O
sodium	B
colistemethate	I
)	O
,	O
magnesium	B
salts	O
,	O
lithium	B
,	O
local	O
anesthetics	B
,	O
procainamide	B
,	O
and	O
quinidine	B
.	O

Resistance	O
to	O
the	O
neuromuscular	B
blocking	I
action	O
of	O
nondepolarizing	B
neuromuscular	I
blocking	I
agents	I
has	O
been	O
demonstrated	O
in	O
patients	O
chronically	O
administered	O
phenytoin	B
or	O
carbamazepine	B
.	O

While	O
the	O
effects	O
of	O
chronic	O
phenytoin	B
or	O
carbamazepine	B
therapy	O
on	O
the	O
action	O
of	O
NIMBEX	B
are	O
unknown	O
,	O
slightly	O
shorter	O
durations	O
of	O
neuromuscular	O
block	O
may	O
be	O
anticipated	O
and	O
infusion	O
rate	O
requirements	O
may	O
be	O
higher	O
.	O

Plasma	O
levels	O
of	O
anticonvulsant	B
agents	I
may	O
become	O
subtherapeutic	O
during	O
cisplatin	B
therapy	O
.	O

Central	B
nervous	I
system	I
depressant	I
(	O
CNS	O
)	O
drugs	O
including	O
alcohol	B
,	O
antidepressants	B
,	O
antihistamines	B
,	O
antipsychotics	B
,	O
blood	O
pressure	O
medications	O
(	O
reserpine	B
,	O
methyldopa	B
,	O
beta	O
-	O
blockers	O
)	O
,	O
motion	O
sickness	O
medications	O
,	O
muscle	B
relaxants	I
,	O
narcotics	B
,	O
sedatives	B
,	O
sleeping	O
pills	O
and	O
tranquilizers	B

The	O
concurrent	O
administration	O
of	O
allopurinol	B
and	O
ampicillin	B
increases	O
substantially	O
the	O
incidence	O
of	O
rashes	O
in	O
patients	O
receiving	O
both	O
drugs	O
as	O
compared	O
to	O
patients	O
receiving	O
ampicillin	B
alone	O
.	O

It	O
is	O
not	O
known	O
whether	O
this	O
potentiation	O
of	O
ampicillin	B
rashes	O
is	O
due	O
to	O
allopurinol	B
or	O
the	O
hyperuricemia	O
present	O
in	O
these	O
patients	O
.	O

In	O
controlled	O
clinical	O
trials	O
of	O
AUGMENTIN	B
XR	I
,	O
22	O
patients	O
received	O
concomitant	O
allopurinol	B
and	O
AUGMENTIN	B
XR	I
.	O

However	O
,	O
this	O
sample	O
size	O
is	O
too	O
small	O
to	O
allow	O
for	O
any	O
conclusions	O
to	O
be	O
drawn	O
regarding	O
the	O
risk	O
of	O
rashes	O
with	O
concomitant	O
AUGMENTIN	B
XR	I
and	O
allopurinol	B
use	O
.	O

In	O
common	O
with	O
other	O
broad	O
-	O
spectrum	O
antibiotics	B
,	O
AUGMENTIN	B
XR	I
may	O
reduce	O
the	O
efficacy	O
of	O
oral	O
contraceptives	B

Additive	O
CNS	B
depression	O
may	O
occur	O
when	O
antihistamines	B
are	O
administered	O
concomitantly	O
with	O
other	O
CNS	B
depressants	I
including	O
barbiturates	B
,	O
tranquilizers	B
,	O
and	O
alcohol	B
.	O

Patients	O
receiving	O
antihistamines	B
should	O
be	O
advised	O
against	O
the	O
concurrent	O
use	O
of	O
other	O
CNS	B
depressant	I
drugs	I
.	O

Monoamine	B
oxidase	I
(	O
MAO	O
)	O
inhibitors	B
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
effects	O
of	O
antihistamines	B
.	O

Amantadine	B
,	O
tricyclic	B
antidepressants	I
,	O
and	O
MAOIs	B
may	O
increase	O
anticholinergic	O
effect	O
of	O
clidinium	B
.	O

Clidinium	B
may	O
decrease	O
the	O
effect	O
of	O
phenothiazines	B
,	O
levodopa	B
,	O
and	O
ketoconazole	B
.	O

Clindamycin	B
has	O
been	O
shown	O
to	O
have	O
neuromuscular	B
blocking	I
properties	O
that	O
may	O
enhance	O
the	O
action	O
of	O
other	O
neuromuscular	B
blocking	I
agents	I
.	O

Antagonism	O
has	O
been	O
demonstrated	O
between	O
clindamycin	B
and	O
erythromycin	B
in	O
vitro	O
.	O

Alcohol	B
(	O
increases	O
bioavailability	O
by	O
50	O
%	O
)	O
,	O
cimetidine	B
,	O
and	O
valproates	O
.	O

Preliminary	O
data	O
which	O
suggest	O
that	O
dapsone	B
may	O
inhibit	O
the	O
anti	O
-	O
inflammatory	O
activity	O
of	O
Lamprene	B
have	O
not	O
been	O
confirmed	O
.	O

If	O
leprosy	O
-	O
associated	O
inflammatory	O
reactions	O
develop	O
in	O
patients	O
being	O
treated	O
with	O
dapsone	B
and	O
clofazimine	B
,	O
it	O
is	O
still	O
advisable	O
to	O
continue	O
treatment	O
with	O
both	O
drugs	O
.	O

Caution	O
should	O
be	O
exercised	O
when	O
anticoagulants	B
are	O
given	O
in	O
conjunction	O
with	O
Atromid	O
-	O
S	O
.	O

Atromid	O
-	O
S	O
may	O
displace	O
acidic	O
drugs	O
such	O
as	O
phenytoin	B
or	O
tolbutamide	B
from	O
their	O
binding	O
sites	O
.	O

The	O
hypoglycemic	O
effect	O
of	O
tolbutamide	B
has	O
been	O
reported	O
to	O
increase	O
when	O
Atromid	O
-	O
S	O
is	O
given	O
concurrently	O
.	O

Fulminant	O
rhabdomyolysis	O
has	O
been	O
seen	O
as	O
early	O
as	O
three	O
weeks	O
after	O
initiation	O
of	O
combined	O
therapy	O
with	O
another	O
fibrate	B
and	O
lovastatin	B
but	O
may	O
be	O
seen	O
after	O
several	O
months	O
.	O

For	O
these	O
reasons	O
,	O
it	O
is	O
felt	O
that	O
,	O
in	O
most	O
subjects	O
who	O
have	O
had	O
an	O
unsatisfactory	O
lipid	O
response	O
to	O
either	O
drug	O
alone	O
,	O
the	O
possible	O
benefits	O
of	O
combined	O
therapy	O
with	O
lovastatin	B
and	O
a	O
fibrate	B
do	O
not	O
outweigh	O
the	O
risks	O
of	O
severe	O
myopathy	O
,	O
rhabdomyolysis	O
,	O
and	O
acute	O
renal	O
failure	O
.	O

While	O
it	O
is	O
not	O
known	O
whether	O
this	O
interaction	O
occurs	O
with	O
fibrates	B
other	O
than	O
gemfibrozil	B
,	O
myopathy	O
and	O
rhabdomyolysis	O
have	O
occasionally	O
been	O
associated	O
with	O
the	O
use	O
of	O
fibrates	B
alone	O
,	O
including	O
clofibrate	B
.	O

Therefore	O
,	O
the	O
combined	O
use	O
of	O
lovastatin	B
with	O
fibrates	B
should	O
generally	O
be	O
avoided	O
.	O

Anafranil	B
should	O
not	O
be	O
used	O
with	O
MAO	B
inhibitors	I
.	O

Close	O
supervision	O
and	O
careful	O
adjustment	O
of	O
dosage	O
are	O
required	O
when	O
Anafranil	B
is	O
administered	O
with	O
anticholinergic	B
or	O
sympathomimetic	B
drugs	I
.	O

Several	O
tricyclic	B
antidepressants	I
have	O
been	O
reported	O
to	O
block	O
the	O
pharmacologic	O
effects	O
of	O
guanethidine	B
,	O
clonidine	B
,	O
or	O
similar	O
agents	O
,	O
and	O
such	O
an	O
effect	O
may	O
be	O
anticipated	O
with	O
CMI	B
because	O
of	O
its	O
structural	O
similarity	O
to	O
other	O
tricyclic	B
antidepressants	I
.	O

The	O
plasma	O
concentration	O
of	O
CMI	B
has	O
been	O
reported	O
to	O
be	O
increased	O
by	O
the	O
concomitant	O
administration	O
of	O
haloperidol	B
;	O

plasma	O
levels	O
of	O
several	O
closely	O
related	O
tricyclic	B
antidepressants	I
have	O
been	O
reported	O
to	O
be	O
increased	O
by	O
the	O
concomitant	O
administration	O
of	O
methylphenidate	B
or	O
hepatic	O
enzyme	O
inhibitors	O
(	O
e	O
.	O
g	O
.	O
,	O
cimetidine	B
,	O
fluoxetine	B
)	O
and	O
decreased	O
by	O
the	O
concomitant	O
administration	O
of	O
hepatic	O
enzyme	O
inducers	O
(	O
e	O
.	O
g	O
.	O
,	O
barbiturates	B
,	O
phenytoin	B
)	O
,	O
and	O
such	O
an	O
effect	O
may	O
be	O
anticipated	O
with	O
CMI	B
as	O
well	O
.	O

Administration	O
of	O
CMI	B
has	O
been	O
reported	O
to	O
increase	O
the	O
plasma	O
levels	O
of	O
phenobarbital	B
,	O
if	O
given	O
concomitantly	O
.	O

Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
lasma	O
concentrations	O
of	O
tricyclic	B
antidepressants	I
(	O
TCAs	B
)	O
when	O
given	O
usual	O
doses	O
.	O

cimetidine	B
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P450	O
2D6	O
(	O
many	O
other	O
antidepressants	B
,	O
phenothiazines	B
,	O
and	O
the	O
Type	B
1C	I
antiarrhythmics	I
propafenone	I
and	O
flecainide	B
)	O
.	O

While	O
all	O
the	O
selective	B
serotonin	I
reuptake	I
inhibitors	I
(	O
SSRIs	B
)	O
,	O
e	O
.	O
g	O
.	O
,	O
fluoxetine	B
,	O
sertraline	B
,	O
paroxetine	B
,	O
and	O
fluvoxamine	B
,	O
inhibit	O
P450	O
2D6	O
,	O
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O

Fluvoxamine	B
has	O
also	O
been	O
shown	O
to	O
inhibit	O
P450	O
1A2	O
,	O
an	O
isoform	O
also	O
involved	O
in	O
TCAmetabolism	O
.	O

The	O
extent	O
to	O
which	O
SSRI	B
-	O
TCAinteractions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	B
involved	O
.	O

Nevertheless	O
,	O
caution	O
is	O
indicated	O
in	O
the	O
co	O
-	O
administration	O
of	O
TCAs	B
with	O
any	O
of	O
the	O
SSRIs	B
and	O
also	O
in	O
switching	O
from	O
one	O
class	O
to	O
the	O
other	O
.	O

Of	O
particular	O
importance	O
,	O
sufficient	O
time	O
must	O
elapse	O
before	O
initiating	O
TCAtreatment	O
in	O
a	O
patient	O
being	O
withdrawn	O
from	O
fluoxetine	B
,	O
given	O
the	O
long	O
half	O
-	O
life	O
of	O
the	O
parent	O
and	O
active	O
metabolite	O
(	O
at	O
least	O
5	O
weeks	O
may	O
be	O
necessary	O
)	O
.	O

Concomitant	O
use	O
of	O
agents	O
in	O
the	O
tricyclic	B
antidepressant	I
class	I
(	O
which	O
includes	O
Anafranil	B
)	O
with	O
drugs	O
that	O
can	O
inhibit	O
cytochrome	O
P450	O
2D6	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	B
antidepressant	I
agent	I
or	O
the	O
other	O
drug	O
.	O

It	O
is	O
desirable	O
to	O
monitor	O
TCAplasma	O
levels	O
whenever	O
an	O
agent	O
of	O
the	O
tricyclic	B
antidepressant	I
class	I
including	O
Anafranil	B
is	O
going	O
to	O
be	O
co	O
-	O
administered	O
with	O
another	O
drug	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P450	O
2D6	O
(	O
and	O
/	O
or	O
P450	O
1A2	O
)	O
.	O

Because	O
Anafranil	B
is	O
highly	O
bound	O
to	O
serum	O
protein	O
,	O
the	O
administration	O
of	O
Anafranil	B
to	O
patients	O
taking	O
other	O
drugs	O
that	O
are	O
highly	O
bound	O
to	O
protein	O
(	O
e	O
.	O
g	O
.	O
,	O
warfarin	B
,	O
digoxin	B
)	O
may	O
cause	O
an	O
increase	O
in	O
plasma	O
concentrations	O
of	O
these	O
drugs	O
,	O
potentially	O
resulting	O
in	O
adverse	O
effects	O
.	O

Effect	O
of	O
Clonazepam	B
on	O
the	O
Pharmacokinetics	O
of	O
Other	O
Drugs	O
:	O
Clonazepam	B
does	O
not	O
appear	O
to	O
alter	O
the	O
pharmacokinetics	O
of	O
phenytoin	B
,	O
carbamazepine	B
,	O
or	O
phenobarbital	B
.	O

Effect	O
of	O
Other	O
Drugs	O
on	O
the	O
Pharmacokinetics	O
of	O
Clonazepam	B
:	O
Literature	O
reports	O
suggest	O
that	O
ranitidine	B
,	O
an	O
agent	O
that	O
decreases	O
stomach	O
acidity	O
,	O
does	O
not	O
greatly	O
alter	O
clonazepam	B
pharmacokinetics	O
.	O

In	O
a	O
study	O
in	O
which	O
the	O
2	O
mg	O
clonazepam	B
orally	O
disintegrating	O
tablet	O
was	O
administered	O
with	O
and	O
without	O
propantheline	B
(	O
an	O
anticholinergic	B
agent	I
with	O
multiple	O
effects	O
on	O
the	O
GI	O
tract	O
)	O
to	O
healthy	O
volunteers	O
,	O
the	O
AUC	O
of	O
clonazepam	B
was	O
10	O
%	O
lower	O
and	O
the	O
Cmax	O
of	O
clonazepam	B
was	O
20	O
%	O
lower	O
when	O
the	O
orally	O
disintegrating	O
tablet	O
was	O
given	O
with	O
propantheline	B
compared	O
to	O
when	O
it	O
was	O
given	O
alone	O
.	O

Fluoxetine	B
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
clonazepam	B
.	O

Cytochrome	O
P	O
-	O
450	O
inducers	O
,	O
such	O
as	O
phenytoin	B
,	O
carbamazepine	B
and	O
phenobarbital	B
,	O
induce	O
clonazepam	B
metabolism	O
,	O
causing	O
an	O
approximately	O
30	O
%	O
decrease	O
in	O
plasma	O
clonazepam	B
levels	O
.	O

Although	O
clinical	O
studies	O
have	O
not	O
been	O
performed	O
,	O
based	O
on	O
the	O
involvement	O
of	O
the	O
cytochrome	O
P	O
-	O
450	O
3A	O
family	O
in	O
clonazepam	B
metabolism	O
,	O
inhibitors	O
of	O
this	O
enzyme	O
system	O
,	O
notably	O
oral	O
antifungal	B
agents	I
,	O
should	O
be	O
used	O
cautiously	O
in	O
patients	O
receiving	O
clonazepam	B
.	O

Pharmacodynamic	O
Interactions	O
:	O
The	O
CNS	O
-	O
depressant	O
action	O
of	B
the	O
benzodiazepine	B
class	I
of	I
drugs	I
may	O
be	O
potentiated	O
by	O
alcohol	B
,	O
narcotics	B
,	O
barbiturates	B
,	O
nonbarbiturate	B
hypnotics	I
,	O
antianxiety	B
agents	I
,	O
the	O
phenothiazines	B
,	O
thioxanthene	B
and	O
butyrophenone	B
classes	I
of	I
antipsychotic	I
agents	I
,	O
monoamine	B
oxidase	I
inhibitors	I
and	O
the	O
tricyclic	B
antidepressants	I
,	O
and	O
by	O
other	O
anticonvulsant	B
drugs	I
.	O

Tablet	O
If	O
a	O
patient	O
receiving	O
clonidine	B
hydrochloride	I
is	O
also	O
taking	O
tricyclic	B
antidepressants	I
,	O
the	O
effect	O
of	O
clonidine	B
may	O
be	O
reduced	O
,	O
thus	O
necessitating	O
an	O
increase	O
in	O
dosage	O
.	O

Clonidine	B
hydrochloride	I
may	O
enhance	O
the	O
CNS	O
-	O
depressive	O
effects	O
of	O
alcohol	B
,	O
barbiturates	B
or	O
other	O
sedatives	B
.	O

Amitriptyline	B
in	O
combination	O
with	O
clonidine	B
enhances	O
the	O
manifestation	O
of	O
corneal	O
lesions	O
in	O
rats	O
Epidural	O
Injection	O
Clonidine	B
may	O
potentiate	O
the	O
CNS	O
-	O
depressive	O
effect	O
of	O
alcohol	B
,	O
barbiturates	B
or	O
other	O
sedating	B
drugs	I
.	O

Narcotic	B
analgesics	I
may	O
potentiate	O
the	O
hypotensive	O
effects	O
of	O
clonidine	B
.	O

Tricyclic	B
antidepressants	I
may	O
antagonize	O
the	O
hypotensive	O
effects	O
of	O
clonidine	B
.	O

The	O
effects	O
of	O
tricyclic	B
antidepressants	I
on	O
clonidines	O
analgesic	O
actions	O
are	O
not	O
known	O
.	O

Beta	B
blockers	I
may	O
exacerbate	O
the	O
hypertensive	O
response	O
seen	O
with	O
clonidine	B
withdrawl	O
.	O

Also	O
,	O
due	O
to	O
the	O
potential	O
for	O
additive	O
effects	O
such	O
as	O
bradycardia	O
and	O
AV	O
block	O
,	O
caution	O
is	O
warranted	O
in	O
patients	O
receiving	O
clonidine	B
with	O
agents	O
known	O
to	O
affect	O
sinus	O
node	O
function	O
or	O
AV	O
nodal	O
conduction	O
(	O
e	O
.	O
g	O
.	O
,	O
digitalis	B
,	O
calcium	B
channel	I
blockers	I
,	O
and	O
beta	O
-	O
blockers	B
.	O
)	O

There	O
is	O
one	O
reported	O
case	O
of	O
a	O
patient	O
with	O
acute	O
delirium	O
associated	O
with	O
the	O
simultaneous	O
use	O
of	O
fluphenazine	B
and	O
oral	O
clonidine	B
.	O

Symptoms	O
resolved	O
when	O
clonidine	B
was	O
withdrawn	O
and	O
recurred	O
when	O
the	O
patient	O
was	O
rechallenged	O
with	O
clonidine	B
.	O

Epidural	O
clonidine	B
may	O
prolong	O
the	O
duration	O
of	O
pharmacologic	O
effects	O
of	O
epidural	O
local	O
anesthetics	B
,	O
including	O
both	O
sensory	O
and	O
motor	O
blockade	O
.	O

Aspirin	B
,	O
warfarin	B
,	O
heparin	B
,	O
NSAIDs	B

Animal	O
experience	O
indicates	O
that	O
clorazepate	B
dipotassium	I
prolongs	O
the	O
sleeping	O
time	O
after	O
hexobarbital	B
or	O
after	O
ethyl	B
alcohol	I
,	O
increases	O
the	O
inhibitory	O
effects	O
of	O
chlorpromazine	B
,	O
but	O
does	O
not	O
exhibit	O
monoamine	O
oxidase	O
inhibition	O
.	O

The	O
actions	O
of	O
the	O
benzodiazepines	B
may	O
be	O
potentiated	O
by	O
barbiturates	B
,	O
narcotics	B
,	O
phenothiazines	B
,	O
monoamine	B
oxidase	I
inhibitors	I
or	O
other	O
antidepressants	B
.	O

In	O
bioavailability	O
studies	O
with	O
normal	O
subjects	O
,	O
the	O
concurrent	O
administration	O
of	O
antacids	B
at	O
therapeutic	O
levels	O
did	O
not	O
significantly	O
influence	O
the	O
bioavailability	O
of	O
TRANXENE	B
tablets	O
.	O

Given	O
the	O
primary	O
CNS	O
effects	O
of	O
Clozapine	B
,	O
caution	O
is	O
advised	O
in	O
using	O
it	O
concomitantly	O
with	O
other	O
CNS	O
-	O
active	O
drugs	O
or	O
alcohol	B
.	O

similar	O
events	O
have	O
been	O
reported	O
in	O
patients	O
taking	O
other	O
psychotropic	B
drugs	I
or	O
even	O
Clozapine	B
by	O
itself	O
.	O

Although	O
it	O
has	O
not	O
been	O
established	O
that	O
there	O
is	O
an	O
interaction	O
between	O
Clozapine	B
and	O
benzodiazepines	B
or	O
other	O
psychotropics	B
,	O
caution	O
is	O
advised	O
when	O
clozapine	B
is	O
initiated	O
in	O
patients	O
taking	O
a	O
benzodiazepine	B
or	O
any	O
other	O
psychotropic	B
drug	I
.	O

Clozapine	B
may	O
potentiate	O
the	O
hypotensive	O
effects	O
of	O
antihypertensive	B
drugs	I
and	O
the	O
anticholinergic	O
effects	O
of	O
atropine	B
-	O
type	O
drugs	B
.	O

The	O
administration	O
of	O
epinephrine	B
should	O
be	O
avoided	O
in	O
the	O
treatment	O
of	O
drug	O
induced	O
hypotension	O
because	O
of	O
a	O
possible	O
reverse	O
epinephrine	B
effect	O
.	O

Phenytoin	B
,	O
nicotine	B
,	O
and	O
rifampin	B
may	O
decrease	O
Clozapine	B
plasma	O
levels	O
,	O
resulting	O
in	O
a	O
decrease	O
in	O
effectiveness	O
of	O
a	O
previously	O
effective	O
Clozapine	B
dose	O
.	O

Cimetidine	B
,	O
caffeine	B
,	O
and	O
erythromycin	B
may	O
increase	O
plasma	O
levels	O
of	O
Clozapine	B
,	O
potentially	O
resulting	O
in	O
adverse	O
effects	O
.	O

Although	O
concomitant	O
use	O
of	O
Clozapine	B
and	O
carbamazepine	B
is	O
not	O
recommended	O
,	O
it	O
should	O
be	O
noted	O
that	O
discontinuation	O
of	O
concomitant	O
carbamazepine	B
administration	O
may	O
result	O
in	O
an	O
increase	O
in	O
Clozapine	B
plasma	O
levels	O
.	O

In	O
a	O
study	O
of	O
schizophrenic	O
patients	O
who	O
received	O
clozapine	B
under	O
steady	O
state	O
conditions	O
,	O
fluvoxamine	B
or	O
paroxetine	B
was	O
added	O
in	O
16	O
and	O
14	O
patients	O
,	O
respectively	O
.	O

After	O
14	O
days	O
of	O
co	O
-	O
administration	O
,	O
mean	O
trough	O
concentrations	O
of	O
clozapine	B
and	O
its	O
metabolites	O
,	O
N	O
-	O
desmethylclozapine	O
and	O
clozapine	B
N	O
-	O
oxide	O
,	O
were	O
elevated	O
with	O
fluvoxamine	B
by	O
about	O
three	O
-	O
fold	O
compared	O
to	O
baseline	O
concentrations	O
.	O

Paroxetine	B
produced	O
only	O
minor	O
changes	O
in	O
the	O
levels	O
of	O
clozapine	B
and	O
its	O
metabolites	O
.	O

However	O
,	O
other	O
published	O
reports	O
describe	O
modest	O
elevations	O
(	O
less	O
than	O
two	O
-	O
fold	O
)	O
of	O
clozapine	B
and	O
metabolite	O
concentrations	O
when	O
clozapine	B
was	O
taken	O
with	O
paroxetine	B
,	O
fluoxetine	B
,	O
and	O
sertraline	B
.	O

Therefore	O
,	O
such	O
combined	O
treatment	O
should	O
be	O
approached	O
with	O
caution	O
and	O
patients	O
should	O
be	O
monitored	O
closely	O
when	O
Clozapine	B
is	O
combined	O
with	O
these	O
drugs	O
,	O
particularly	O
with	O
fluvoxamine	B
.	O

Such	O
individuals	O
are	O
referred	O
to	O
as	O
poor	O
metabolizers	O
of	O
drugs	O
such	O
as	O
debrisoquin	B
,	O
dextromethorphan	B
,	O
the	O
tricyclic	B
antidepressants	I
,	O
and	O
clozapine	B
.	O

In	O
addition	O
,	O
certain	O
drugs	O
that	O
are	O
metabolized	O
by	O
this	O
isozyme	O
,	O
including	O
many	O
antidepressants	B
(	O
clozapine	B
,	O
selective	B
serotonin	I
reuptake	I
inhibitors	I
,	O
and	O
others	O
)	O
,	O
may	O
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	O
,	O
and	O
thus	O
may	O
make	O
normal	O
metabolizers	O
resemble	O
poor	O
metabolizers	O
with	O
regard	O
to	O
concomitant	O
therapy	O
with	O
other	O
drugs	O
metabolized	O
by	O
this	O
enzyme	O
system	O
,	O
leading	O
to	O
drug	O
interaction	O
.	O

Concomitant	O
use	O
of	O
clozapine	B
with	O
other	O
drugs	O
metabolized	O
by	O
cytochrome	O
P450	O
2D6	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
clozapine	B
or	O
the	O
other	O
drug	O
.	O

Therefore	O
,	O
co	O
-	O
administration	O
of	O
clozapine	B
with	O
other	O
drugs	O
that	O
are	O
metabolized	O
by	O
this	O
isozyme	O
,	O
including	O
antidepressants	B
,	O
phenothiazines	B
,	O
carbamazepine	B
,	O
and	O
Type	B
1C	I
antiarrhythmics	I
(	O
e	O
.	O
g	O
.	O
,	O
propafenone	B
,	O
flecainide	B
and	O
encainide	B
)	O
,	O
or	O
that	O
inhibit	O
this	O
enzyme	O
(	O
e	O
.	O
g	O
.	O
,	O
quinidine	B
)	O
,	O
should	O
be	O
approached	O
with	O
caution	O
.	O

The	O
risk	O
of	O
a	O
potential	O
interaction	O
between	O
NovoSeven	B
and	O
coagulation	B
factor	I
concentrates	O
has	O
not	O
been	O
adequately	O
evaluated	O
in	O
preclinical	O
or	O
clinical	O
studies	O
.	O

Simultaneous	O
use	O
of	O
activated	B
prothrombin	I
complex	I
concentrates	I
or	O
prothrombin	B
complex	I
concentrates	I
should	O
be	O
avoided	O
.	O

Although	O
the	O
specific	O
drug	O
interaction	O
was	O
not	O
studied	O
in	O
a	O
clinical	O
trial	O
,	O
there	O
have	O
been	O
more	O
than	O
50	O
episodes	O
of	O
concomitant	O
use	O
of	O
antifibrinolytic	O
therapies	O
(	O
i	O
.	O
e	O
.	O
,	O
tranexamic	B
acid	I
,	O
aminocaproic	B
acid	I
)	O
and	O
NovoSeven	B
.	O

Codeine	B
in	O
combination	O
with	O
other	O
narcotic	B
analgesics	I
,	O
general	O
anesthetics	B
,	O
phenothiazines	B
,	O
tranquilizers	B
,	O
sedative	O
-	O
hypnotics	O
,	O
or	O
other	O
CNS	B
depressants	I
(	O
including	O
alcohol	B
)	O
has	O
additive	O
depressant	O
effects	O
.	O

Colchicine	B
is	O
inhibited	O
by	O
acidifying	B
agents	I
.	O

The	O
action	O
of	O
colchicine	B
is	O
potentiated	O
by	O
alkalinizing	B
agents	I
.	O

Colchicine	B
may	O
increase	O
sensitivity	O
to	O
the	O
CNS	B
depressants	I
.	O

Response	O
to	O
sympathomimetic	B
agents	I
may	O
be	O
enhanced	O
by	O
colchicine	B
.	O

WelChol	B
was	O
found	O
to	O
have	O
no	O
significant	O
effect	O
on	O
the	O
bioavailability	O
of	O
digoxin	B
,	O
lovastatin	B
,	O
metoprolol	B
,	O
quinidine	B
,	O
valproic	B
acid	I
,	O
and	O
warfarin	B
.	O

WelChol	B
decreased	O
the	O
Cmax	O
and	O
AUC	O
of	O
sustained	O
-	O
release	O
verapamil	B
(	O
Calan	B
SR	I
)	O
by	O
approximately	O
31	O
%	O
and	O
11	O
%	O
,	O
respectively	O
.	O

In	O
clinical	O
studies	O
,	O
coadministration	O
of	O
WelChol	B
with	O
atorvastatin	B
,	O
lovastatin	B
,	O
or	O
simvastatin	B
did	O
not	O
interfere	O
with	O
the	O
lipid	O
-	O
lowering	O
activity	O
of	O
the	O
HMG	O
-	O
CoA	O
reductase	B
inhibitor	I
.	O

Since	O
colestipol	B
hydrochloride	I
is	O
an	O
anion	B
exchange	I
resin	I
,	O
it	O
may	O
have	O
a	O
strong	O
affinity	O
for	O
anions	O
other	O
than	O
the	O
bile	O
acids	O
.	O

Repeated	O
doses	O
of	O
colestipol	B
hydrochloride	I
given	O
prior	O
to	O
a	O
single	O
dose	O
of	O
propranolol	B
in	O
human	O
trials	O
have	O
been	O
reported	O
to	O
decrease	O
propranolol	B
absorption	O
.	O

However	O
,	O
in	O
a	O
follow	O
-	O
up	O
study	O
in	O
normal	O
subjects	O
,	O
single	O
-	O
dose	O
administration	O
of	O
colestipol	B
hydrochloride	I
and	O
propranolol	B
and	O
twice	O
-	O
a	O
-	O
day	O
administration	O
for	O
5	O
days	O
of	O
both	O
agents	O
did	O
not	O
affect	O
the	O
extent	O
of	O
propranolol	B
absorption	O
,	O
but	O
had	O
a	O
small	O
yet	O
statistically	O
significant	O
effect	O
on	O
its	O
rate	O
of	O
absorption	O
;	O

Therefore	O
,	O
patients	O
on	O
propranolol	B
should	O
be	O
observed	O
when	O
COLESTID	B
Tablets	O
are	O
either	O
added	O
or	O
deleted	O
from	O
a	O
therapeutic	O
regimen	O
.	O

Studies	O
in	O
humans	O
show	O
that	O
the	O
absorption	O
of	O
chlorothiazide	B
as	O
reflected	O
in	O
urinary	O
excretion	O
is	O
markedly	O
decreased	O
even	O
when	O
administered	O
one	O
hour	O
before	O
colestipol	B
hydrochloride	I
.	O

The	O
absorption	O
of	O
tetracycline	B
,	O
furosemide	B
,	O
penicillin	B
G	I
,	O
hydrochlorothiazide	B
,	O
and	O
gemfibrozil	B
was	O
significantly	O
decreased	O
when	O
given	O
simultaneously	O
with	O
colestipol	B
hydrochloride	I
;	O

No	O
depressant	O
effect	O
on	O
blood	O
levels	O
in	O
humans	O
was	O
noted	O
when	O
colestipol	B
hydrochloride	I
was	O
administered	O
with	O
any	O
of	O
the	O
following	O
drugs	O
:	O
aspirin	B
,	O
clindamycin	B
,	O
clofibrate	B
,	O
methyldopa	B
,	O
nicotinic	B
acid	I
(	O
niacin	B
)	O
,	O
tolbutamide	B
,	O
phenytoin	B
or	O
warfarin	B
.	O

Particular	O
caution	O
should	O
be	O
observed	O
with	O
digitalis	B
preparations	I
since	O
there	O
are	O
conflicting	O
results	O
for	O
the	O
effect	O
of	O
colestipol	B
hydrochloride	I
on	O
the	O
availability	O
of	O
digoxin	B
and	O
digitoxin	B
.	O

Discontinuing	O
colestipol	B
hydrochloride	I
could	O
pose	O
a	O
hazard	O
to	O
health	O
if	O
a	O
potentially	O
toxic	O
drug	O
that	O
is	O
significantly	O
bound	O
to	O
the	O
resin	B
has	O
been	O
titrated	O
to	O
a	O
maintenance	O
level	O
while	O
the	O
patient	O
was	O
taking	O
colestipol	B
hydrochloride	I
.	O

Bile	B
acid	I
binding	I
resins	I
may	O
also	O
interfere	O
with	O
the	O
absorption	O
of	O
oral	O
phosphate	B
supplements	O
and	O
hydrocortisone	B
.	O

Certain	O
other	O
antibiotics	B
(	O
aminoglycosides	B
and	O
polymyxin	B
)	O
have	O
also	O
been	O
reported	O
to	O
interfere	O
with	O
the	O
nerve	O
transmission	O
at	O
the	O
neuromuscular	O
junction	O
.	O

Curariform	B
muscle	I
relaxants	I
(	O
eg	O
,	O
tubocurarine	B
)	O
and	O
other	O
drugs	O
,	O
including	O
ether	O
,	O
succinylcholine	B
,	O
gallamine	B
,	O
decamethonium	B
and	O
sodium	B
citrate	I
,	O
potentiate	O
the	O
neuromuscular	O
blocking	O
effect	O
and	O
should	O
be	O
used	O
with	O
extreme	O
caution	O
in	O
patients	O
being	O
treated	O
with	O
Coly	O
-	O
Mycin	O
M	B
Parenteral	O
.	O

Sodium	B
cephalothin	I
may	O
enhance	O
the	O
nephrotoxicity	O
of	O
Coly	O
-	O
Mycin	O
M	B
Parenteral	O
.	O

The	O
concomitant	O
use	O
of	O
sodium	B
cephalothin	I
and	O
Coly	O
-	O
Mycin	O
M	B
Parenteral	O
should	O
be	O
avoided	O
.	O

Digoxin	B
:	O
Coadministration	O
of	O
digoxin	B
,	O
a	O
P	O
-	O
glycoprotein	O
substrate	O
,	O
with	O
oral	O
conivaptan	B
resulted	O
in	O
a	O
reduction	O
in	O
clearance	O
and	O
an	O
increase	O
in	O
digoxin	B
Cmax	O
and	O
AUC	O
values	O
.	O

Therefore	O
,	O
if	O
digoxin	B
is	O
administered	O
with	O
VAPRISOL	B
,	O
the	O
clinician	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
increases	O
in	O
digoxin	B
levels	O
.	O

decreased	O
levels	O
of	O
anti	O
-	O
factor	O
Xa	O
and	O
antithrombin	B
III	I
,	O
decreased	O
antithrombin	B
III	I
activity	O
;	O

increased	O
levels	O
of	O
fibrinogen	B
and	O
fibrinogen	B
activity	O
;	O

Other	O
binding	O
proteins	O
may	O
be	O
elevated	O
in	O
serum	O
,	O
(	O
i	O
.	O
e	O
.	O
,	O
corticosteroid	O
binding	O
globulin	O
(	O
CBG	O
)	O
,	O
sex	B
hormone	O
binding	O
globulin	O
(	O
SHBG	O
)	O
)	O
leading	O
to	O
increased	O
total	O
circulating	O
corticosteroids	B
and	O
sex	B
steroids	I
,	O
respectively	O
.	O

Corticotropin	B
may	O
accentuate	O
the	O
electrolyte	O
loss	O
associated	O
with	O
diuretic	B
therapy	O
.	O

Drugs	O
that	O
induce	O
hepatic	O
enzymes	O
such	O
as	O
phenobarbital	B
,	O
phenytoin	B
and	O
rifampin	B
may	O
increase	O
the	O
clearance	O
of	O
corticosteroids	B
and	O
may	O
require	O
increases	O
in	O
corticosteroid	B
dose	O
to	O
achieve	O
the	O
desired	O
response	O
.	O

Drugs	O
such	O
as	O
troleandomycin	B
and	O
ketoconazole	B
may	O
inhibit	O
the	O
metabolism	O
of	O
corticosteroids	B
and	O
thus	O
decrease	O
their	O
clearance	O
.	O

Corticosteroids	B
may	O
increase	O
the	O
clearance	O
of	O
chronic	O
high	O
dose	O
aspirin	B
.	O

This	O
could	O
lead	O
to	O
decreased	O
salicylate	B
serum	O
levels	O
or	O
increase	O
the	O
risk	O
of	O
salicylate	B
toxicity	O
when	O
corticosteroid	B
is	O
withdrawn	O
.	O

Aspirin	B
should	O
be	O
used	O
cautiously	O
in	O
conjunction	O
with	O
cortico	O
-	O
steroids	O
in	O
patients	O
suffering	O
from	O
hypopro	O
-	O
thrombinemia	O
.	O

The	O
effect	O
of	O
corticosteroids	B
on	O
oral	O
anticoagulants	B
is	O
variable	O
.	O

There	O
are	O
reports	O
of	O
enhanced	O
as	O
well	O
as	O
diminished	O
effects	O
of	O
anticoagulants	B
when	O
given	O
concurrently	O
with	O
corticosteroids	B
.	O

Corticotropin	B
may	O
accentuate	O
the	O
electrolyte	O
loss	O
associated	O
with	O
diuretic	B
therapy	O
.	O

Drug	O
Interaction	O
During	O
Pregnancy	O
:	O
Cromolyn	B
sodium	I
and	O
isoproterenol	B
were	O
studied	O
following	O
subcutaneous	O
injections	O
in	O
pregnant	O
mice	O
.	O

The	O
addition	O
of	O
540	O
mg	O
/	O
kg	O
/	O
day	O
of	O
cromolyn	B
sodium	I
(	O
approximately	O
340	O
times	O
the	O
maximum	O
recommended	O
daily	O
inhalation	O
dose	O
in	O
adults	O
on	O
a	O
mg	O
/	O
m2	O
basis	O
)	O
to	O
2	O
.	O
7	O
mg	O
/	O
kg	O
/	O
day	O
of	O
isoproterenol	B
(	O
approximately	O
7	O
times	O
the	O
maximum	O
recommended	O
daily	O
inhalation	O
dose	O
in	O
adults	O
on	O
a	O
mg	O
/	O
m2	O
basis	O
)	O
appears	O
to	O
have	O
increased	O
the	O
incidence	O
of	O
both	O
resorptions	O
and	O
malformations	O
.	O

Persons	O
taking	O
most	O
antibiotics	B
,	O
methotrexate	B
and	O
pyrimethamine	B
invalidate	O
folic	B
acid	I
and	O
vitamin	B
B12	I
diagnostic	O
blood	O
assays	O
.	O

Colchicine	B
para	O
-	O
aminosalicylic	O
acid	B
and	O
heavy	O
alcohol	B
intake	O
for	O
longer	O
than	O
2	O
weeks	O
may	O
produce	O
malabsorption	O
of	O
vitamin	B
B12	I
.	O

FLEXERIL	B
may	O
have	O
life	O
-	O
threatening	O
interactions	O
with	O
MAO	B
inhibitors	I
.	O

FLEXERIL	B
may	O
enhance	O
the	O
effects	O
of	O
alcohol	B
,	O
barbiturates	B
,	O
and	O
other	O
CNS	B
depressants	I
.	O

Tricyclic	B
antidepressants	I
may	O
block	O
the	O
antihypertensive	O
action	O
of	O
guanethidine	B
and	O
similarly	O
acting	O
compounds	O
.	O

Tricyclic	B
antidepressants	I
may	O
enhance	O
the	O
seizure	O
risk	O
in	O
patients	O
taking	O
tramadol	B

Cyclopentolate	B
may	O
interfere	O
with	O
the	O
anti	O
-	O
glaucoma	O
action	O
of	O
carbachol	B
or	O
pilocarpine	B
;	O

The	O
rate	O
of	O
metabolism	O
and	O
the	O
leukopenic	O
activity	O
of	O
cyclophosphamide	B
reportedly	O
are	O
increased	O
by	O
chronic	O
administration	O
of	O
high	O
doses	O
of	O
phenobarbital	B
.	O

The	O
physician	O
should	O
be	O
alert	O
for	O
possible	O
combined	O
drug	O
actions	O
,	O
desirable	O
or	O
undesirable	O
,	O
involving	O
cyclophosphamide	B
even	O
though	O
cyclophosphamide	B
has	O
been	O
used	O
successfully	O
concurrently	O
with	O
other	O
drugs	O
,	O
including	O
other	O
cytotoxic	O
drugs	O
.	O

Cyclophosphamide	B
treatment	O
,	O
which	O
causes	O
a	O
marked	O
and	O
persistent	O
inhibition	O
of	O
cholinesterase	O
activity	O
,	O
potentiates	O
the	O
effect	O
of	O
succinylcholine	B
chloride	I
.	O

May	O
interact	O
with	O
wthionamide	O
(	O
Trecator	O
-	O
SC	O
)	O
and	O
isoniazid	B
(	O
Nydrazid	B
)	O
.	O

MAO	B
inhibitors	I
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
effects	O
of	O
antihistamines	B
.	O

Antihistamines	B
may	O
have	O
additive	O
effects	O
with	O
alcohol	B
and	O
other	O
CNS	B
depressants	I
,	O
e	O
.	O
g	O
.	O
,	O
hypnotics	B
,	O
sedatives	B
,	O
tranquilizers	B
,	O
antianxiety	B
agents	I
.	O

Drug	O
/	O
LaboratoryTest	O
Interactions	O
Dactinomycin	B
may	O
interfere	O
with	O
bioassay	O
procedures	O
for	O
the	O
determination	O
of	O
antibacterial	B
drug	I
levels	O
.	O

However	O
,	O
neither	O
phenobarbital	B
nor	O
diazepam	B
appears	O
to	O
affect	O
Dantrium	B
metabolism	O
.	O

Binding	O
to	O
plasma	O
protein	O
is	O
not	O
significantly	O
altered	O
by	O
diazepam	B
,	O
diphenylhydantoin	B
,	O
or	O
phenylbutazone	B
.	O

Binding	O
to	O
plasma	O
proteins	O
is	O
reduced	O
by	O
warfarin	B
and	O
clotibrate	O
and	O
increased	O
by	O
tolbutamide	B
.	O

The	O
combination	O
of	O
therapeutic	O
doses	O
of	O
intravenous	O
dantrolene	B
sodium	I
and	O
verapamil	B
in	O
halothane	B
a	O
-	O
chloralose	O
anesthetized	O
swine	O
has	O
resulted	O
in	O
ventricular	O
fibrillation	O
and	O
cardiovascular	O
collapse	O
in	O
association	O
with	O
marked	O
hyperkalemia	O
.	O

It	O
is	O
recommended	O
that	O
the	O
combination	O
of	O
intravenous	O
dantrolene	B
sodium	I
and	O
calcium	B
channel	I
blockers	I
,	O
such	O
as	O
verapamil	B
,	O
not	O
be	O
used	O
together	O
during	O
the	O
management	O
of	O
malignant	O
hyperthermia	O
crisis	O
until	O
the	O
relevance	O
of	O
these	O
findings	O
to	O
humans	O
is	O
established	O
.	O

Administration	O
of	O
dantrolene	B
may	O
potentiate	O
vecuronium	B
-	O
induced	O
neuromuscular	O
block	O
.	O

A	O
drug	O
-	O
drug	O
interaction	O
study	O
evaluated	O
the	O
effect	O
of	O
the	O
use	O
of	O
ACZONE	B
Gel	O
,	O
5	O
%	O
,	O
in	O
combination	O
with	O
double	O
strength	O
(	O
160	O
mg	O
/	O
800	O
mg	O
)	O
trimethoprim	B
/	O
sulfamethoxazole	B
(	O
TMP	B
/	O
SMX	B
)	O
.	O

During	O
co	O
-	O
administration	O
,	O
systemic	O
levels	O
of	O
TMP	B
and	O
SMX	B
were	O
essentially	O
unchanged	O
.	O

Notably	O
,	O
systemic	O
exposure	O
(	O
AUC0	O
-	O
12	O
)	O
of	O
dapsone	B
hydroxylamine	I
(	O
DHA	B
)	O
was	O
more	O
than	O
doubled	O
in	O
the	O
presence	O
of	O
TMP	B
/	O
SMX	B
.	O

Exposure	O
from	O
the	O
proposed	O
topical	O
dose	O
is	O
about	O
1	O
%	O
of	O
that	O
from	O
the	O
100	O
mg	O
oral	O
dose	O
,	O
even	O
when	O
co	O
-	O
administered	O
with	O
TMP	B
/	O
SMX	B
.	O

Certain	O
concomitant	O
medications	O
(	O
such	O
as	O
rifampin	B
,	O
anticonvulsants	B
,	O
St	O
.	O

John	O
s	O
wort	O
)	O
may	O
increase	O
the	O
formation	O
of	O
dapsone	B
hydroxylamine	I
,	O
a	O
metabolite	O
of	O
dapsone	B
associated	O
with	O
hemolysis	O
.	O

With	O
oral	O
dapsone	B
treatment	O
,	O
folic	B
acid	I
antagonists	I
such	O
as	O
pyrimethamine	B
have	O
been	O
noted	O
to	O
possibly	O
increase	O
the	O
likelihood	O
of	O
hematologic	O
reactions	O

Warfarin	B
:	O
Concomitant	O
administration	O
of	O
daptomycin	B
(	O
6	O
mg	O
/	O
kg	O
once	O
every	O
24	O
hours	O
for	O
5	O
days	O
)	O
and	O
warfarin	B
(	O
25	O
mg	O
single	O
oral	O
dose	O
)	O
had	O
no	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
either	O
drug	O
,	O
and	O
the	O
INR	O
was	O
not	O
significantly	O
altered	O
.	O

HMG	O
-	O
CoA	O
Reductase	B
Inhibitors	I
:	O
Inhibitors	B
of	I
HMG	O
-	O
CoA	O
reductase	B
may	O
cause	O
myopathy	O
,	O
which	O
is	O
manifested	O
as	O
muscle	O
pain	O
or	O
weakness	O
associated	O
with	O
elevated	O
levels	O
of	B
CPK	O
.	O

There	O
were	O
no	O
reports	O
of	O
skeletal	O
myopathy	O
in	O
a	O
placebo	O
-	O
controlled	O
Phase	O
I	O
trial	O
in	O
which	O
10	O
healthy	O
subjects	O
on	O
stable	O
simvastatin	B
therapy	O
were	O
treated	O
concurrently	O
with	O
daptomycin	B
(	O
4	O
mg	O
/	O
kg	O
once	O
every	O
24	O
hours	O
)	O
for	O
14	O
days	O
.	O

Experience	O
with	O
co	O
-	O
administration	O
of	O
HMG	O
-	O
CoA	O
reductase	B
inhibitors	I
and	O
Fentanyl	B
in	O
patients	O
is	O
limited	O
,	O
therefore	O
,	O
consideration	O
should	O
be	O
given	O
to	O
temporarily	O
suspending	O
use	O
of	O
HMG	O
-	O
CoA	O
reductase	B
inhibitors	I
in	O
patients	O
receiving	O
Fentanyl	B
.	O

The	O
daily	O
dose	O
of	O
ENABLEX	B
should	O
not	O
exceed	O
7	O
.	O
5	O
mg	O
when	O
coadministered	O
with	O
potent	O
CYP3A4	O
inhibitors	O
(	O
e	O
.	O
g	O
.	O
,	O
ketoconazole	B
,	O
itraconazole	B
,	O
ritonavir	B
,	O
nelfinavir	B
,	O
clarithromycin	B
and	O
nefazadone	O
)	O
.	O

Caution	O
should	O
be	O
taken	O
when	O
ENABLEX	B
is	O
used	O
concomitantly	O
with	O
medications	O
that	O
are	O
predominantly	O
metabolized	O
by	O
CYP2D6	O
and	O
which	O
have	O
a	O
narrow	O
therapeutic	O
window	O
,	O
such	O
as	O
flecainide	B
,	O
thioridazine	B
and	O
tricyclic	B
antidepressants	I
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
)	O
.	O

The	O
concomitant	O
use	O
of	O
ENABLEX	B
with	O
other	O
anticholinergic	B
agents	I
may	O
increase	O
the	O
frequency	O
and	O
/	O
or	O
severity	O
of	O
dry	O
mouth	O
,	O
constipation	O
,	O
blurred	O
vision	O
and	O
other	O
anticholinergic	B
pharmacological	O
effects	O
.	O

Drugs	O
that	O
may	O
increase	O
dasatinib	B
plasma	O
concentrations	O
CYP3A4	O
Inhibitors	O
:	O
Dasatinib	B
is	O
a	O
CYP3A4	O
substrate	O
.	O

Concomitant	O
use	O
of	O
SPRYCEL	B
and	O
drugs	O
that	O
inhibit	O
CYP3A4	O
(	O
eg	O
,	O
ketoconazole	B
,	O
itraconazole	B
,	O
erythromycin	B
,	O
clarithromycin	B
,	O
ritonavir	B
,	O
atazanavir	B
,	O
indinavir	B
,	O
nefazodone	B
,	O
nelfinavir	B
,	O
saquinavir	B
,	O
telithromycin	B
)	O
may	O
increase	O
exposure	O
to	O
dasatinib	B
and	O
should	O
be	O
avoided	O
.	O

In	O
patients	O
receiving	O
treatment	O
with	O
SPRYCEL	B
,	O
close	O
monitoring	O
for	O
toxicity	O
and	O
a	O
SPRYCEL	B
dose	O
reduction	O
should	O
be	O
considered	O
if	O
systemic	O
administration	O
of	O
a	O
potent	O
CYP3A4	O
inhibitor	O
cannot	O
be	O
avoided	O
.	O

Drugs	O
that	O
may	O
decrease	O
dasatinib	B
plasma	O
concentrations	O
CYP3A4	O
Inducers	O
:	O
Drugs	O
that	O
induce	O
CYP3A4	O
activity	O
may	O
decrease	O
dasatinib	B
plasma	O
concentrations	O
.	O

In	O
patients	O
in	O
whom	O
CYP3A4	O
inducers	O
(	O
eg	O
,	O
dexamethasone	B
,	O
phenytoin	B
,	O
carbamazepine	B
,	O
rifampicin	B
,	O
phenobarbital	B
)	O
are	O
indicated	O
,	O
alternative	O
agents	O
with	O
less	O
enzyme	O
induction	O
potential	O
should	O
be	O
used	O
.	O

If	O
SPRYCEL	B
must	O
be	O
administered	O
with	O
a	O
CYP3A4	O
inducer	O
,	O
a	O
dose	O
increase	O
in	O
SPRYCEL	B
should	O
be	O
considered	O
.	O

Antacids	B
:	O
Nonclinical	O
data	O
demonstrate	O
that	O
the	O
solubility	O
of	O
dasatinib	B
is	O
pH	O
dependent	O
.	O

Simultaneous	O
administration	O
of	O
SPRYCEL	B
with	O
antacids	B
should	O
be	O
avoided	O
.	O

If	O
antacid	B
therapy	O
is	O
needed	O
,	O
the	O
antacid	B
dose	O
should	O
be	O
administered	O
at	O
least	O
2	O
hours	O
prior	O
to	O
or	O
2	O
hours	O
after	O
the	O
dose	O
of	O
SPRYCEL	B
.	O

H2	B
Blockers	I
/	O
Proton	B
Pump	I
Inhibitors	I
:	O
Long	O
-	O
term	O
suppression	O
of	O
gastric	O
acid	O
secretion	O
by	O
H2	B
blockers	I
or	O
proton	B
pump	I
inhibitors	I
(	O
eg	O
,	O
famotidine	B
and	O
omeprazole	B
)	O
is	O
likely	O
to	O
reduce	O
dasatinib	B
exposure	O
.	O

The	O
concomitant	O
use	O
of	O
H2	B
blockers	I
or	O
proton	B
pump	I
inhibitors	I
with	O
SPRYCEL	B
is	O
not	O
recommended	O
.	O

The	O
use	O
of	O
antacids	B
should	O
be	O
considered	O
in	O
place	O
of	O
H2	B
blockers	I
or	O
proton	B
pump	I
inhibitors	I
in	O
patients	O
receiving	O
SPRYCEL	B
therapy	O
.	O

Drugs	O
that	O
may	O
have	O
their	O
plasma	O
concentration	O
altered	O
by	O
dasatinib	B
CYP3A4	O
Substrates	O
:	O
Dasatinib	B
is	O
a	O
time	O
-	O
dependent	O
inhibitor	O
of	O
CYP3A4	O
.	O

Therefore	O
,	O
CYP3A4	O
substrates	O
known	O
to	O
have	O
a	O
narrow	O
therapeutic	O
index	O
such	O
as	O
alfentanil	B
,	O
astemizole	B
,	O
terfenadine	B
,	O
cisapride	B
,	O
cyclosporine	B
,	O
fentanyl	B
,	O
pimozide	B
,	O
quinidine	B
,	O
sirolimus	B
,	O
tacrolimus	B
,	O
or	O
ergot	B
alkaloids	I
(	O
ergotamine	B
,	O
dihydroergotamine	B
)	O
should	O
be	O
administered	O
with	O
caution	O
in	O
patients	O
receiving	O
SPRYCEL	B
.	O

Use	O
of	O
Cerubidine	B
in	O
a	O
patient	O
who	O
has	O
previously	O
received	O
doxorubicin	B
increases	O
the	O
risk	O
of	O
cardiotoxicity	O
.	O

Cerubidine	B
should	O
not	O
be	O
used	O
in	O
patients	O
who	O
have	O
previously	O
received	O
the	O
recommended	O
maximum	O
cumulative	O
doses	O
of	O
doxorubicin	B
or	O
Cerubidine	B
.	O

Cyclophosphamide	B
used	O
concurrently	O
with	O
Cerubidine	B
may	O
also	O
result	O
in	O
increased	O
cardiotoxicity	O
.	O

Anticholinesterases	B
(	O
neostgmine	O
,	O
physostigmine	B
)	O
,	O
lignocaine	B
,	O
quinine	B
,	O
procainamide	B
can	O
enhance	O
toxicity	O
and	O
cause	O
cardio	O
respiratory	O
depression	O
.	O

In	O
addition	O
,	O
neuromuscular	O
blocking	O
action	O
is	O
enhanced	O
by	O
general	O
anesthetics	B
,	O
local	O
anesthetics	B
like	O
lidocaine	B
,	O
procaine	B
,	O
beta	O
-	O
blockers	O
,	O
metaclopramide	B
,	O
lithium	B
carbonate	I
,	O
and	O
terbutaline	B
.	O

The	O
concomitant	O
administration	O
of	O
Exjade	B
and	O
aluminum	B
-	O
containing	O
antacid	B
preparations	I
has	O
not	O
been	O
formally	O
studied	O
.	O

Although	O
deferasirox	B
has	O
a	O
lower	O
affinity	O
for	O
aluminum	B
than	O
for	O
iron	B
,	O
Exjade	B
should	O
not	O
be	O
taken	O
with	O
aluminum	B
-	O
containing	O
antacid	B
preparations	I
.	O

In	O
healthy	O
volunteers	O
,	O
Exjade	B
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
digoxin	B
.	O

The	O
effect	O
of	O
digoxin	B
on	O
Exjade	B
pharmacokinetics	O
has	O
not	O
been	O
studied	O
.	O

The	O
concomitant	O
administration	O
of	O
Exjade	B
and	O
vitamin	B
C	I
has	O
not	O
been	O
formally	O
studied	O
.	O

The	O
interaction	O
of	O
Exjade	B
with	O
hydroxyurea	B
has	O
not	O
been	O
formally	O
studied	O
.	O

No	O
inhibition	O
of	O
deferasirox	B
metabolism	O
by	O
hydroxyurea	B
is	O
expected	O
based	O
on	O
the	O
results	O
of	O
an	O
in	O
vitro	O
study	O
.	O

Antiacid	O
,	O
clarithromycin	B
,	O
Didanosine	B
,	O
Fluconazole	B
,	O
Fluoxetine	B
,	O
Indanavir	O
,	O
Ketoconazole	B
,	O
Phenytoin	B
,	O
Phenobarbitol	O
,	O
carbamazepine	B
,	O
Rifabutin	B
,	O
Rifampin	B
,	O
Ritanovir	O
,	O
Saquinavir	B
.	O

Possible	O
drug	O
interactions	O
of	O
HUMORSOL	B
with	O
succinylcholine	B
or	O
with	O
other	O
anticholinesterase	B
agents	I
.	O

Because	O
the	O
tetracyclines	B
have	O
been	O
shown	O
to	O
depress	O
plasma	O
prothrombin	O
activity	O
,	O
patients	O
who	O
are	O
on	O
anticoagulant	B
therapy	O
may	O
require	O
downward	O
adjustment	O
of	O
their	O
anticoagulant	B
dosage	O
.	O

Since	O
bacteriostatic	O
drugs	O
,	O
such	O
as	O
the	O
tetracycline	B
class	I
of	O
antibiotics	B
,	O
may	O
interfere	O
with	O
the	O
bactericidal	O
action	O
of	O
penicillins	B
,	O
it	O
is	O
not	O
advisable	O
to	O
administer	O
these	O
drugs	O
concomitantly	O
.	O

Concurrent	O
use	O
of	O
tetracyclines	B
with	O
oral	O
contraceptives	B
may	O
render	O
oral	O
contraceptives	B
less	O
effective	O
.	O

Taking	O
a	O
rauwolfia	B
alkaloid	I
while	O
you	O
are	O
taking	O
or	O
within	O
2	O
weeks	O
of	O
taking	O
MAO	B
inhibitors	I
may	O
increase	O
the	O
risk	O
of	O
central	O
nervous	O
system	O
depression	O
or	O
may	O
cause	O
a	O
severe	O
high	O
blood	O
pressure	O
reaction	O
.	O

No	O
clinically	O
significant	O
adverse	O
interactions	O
with	O
commonly	O
used	O
preanesthetic	O
drugs	O
,	O
or	O
drugs	O
used	O
during	O
anesthesia	O
(	O
muscle	B
relaxants	I
,	O
intravenous	O
agents	B
,	O
and	O
local	O
anesthetic	B
agents	I
)	O
were	O
reported	O
in	O
clinical	O
trials	O
.	O

Like	O
isoflurane	B
,	O
desflurane	B
does	O
not	O
predispose	O
to	O
premature	O
ventricular	O
arrhythmias	O
in	O
the	O
presence	O
of	O
exogenously	O
infused	O
epinephrine	B
in	O
swine	O
.	O

Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	B
antidepressants	I
(	O
TCAs	B
)	O
when	O
given	O
usual	O
doses	O
.	O

cimetidine	B
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P450	O
2D6	O
(	O
many	O
other	O
antidepressants	B
,	O
phenothiazines	B
,	O
and	O
the	O
Type	O
1C	O
antiarrhythrnics	O
propatenone	O
and	O
flecainide	B
)	O
.	O

While	O
all	O
the	O
selective	B
serotonin	I
reuptake	I
inhibitors	I
(	O
SSRIs	B
)	O
,	O
e	O
.	O
g	O
.	O
,	O
fluoxetine	B
,	O
seriraline	O
,	O
and	O
paroxetine	B
,	O
inhibit	O
P450	O
2D6	O
,	O
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O

The	O
extent	O
to	O
which	O
SSRI	B
-	O
TCA	B
interactions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	B
involved	O
.	O

Nevertheless	O
,	O
caution	O
is	O
indicated	O
in	O
the	O
co	O
-	O
administration	O
of	O
T	O
.	O
A	O
.	O
with	O
any	O
of	O
the	O
SSRIs	B
and	O
also	O
in	O
switching	O
from	O
one	O
class	O
to	O
the	O
other	O
.	O

Concomitant	O
use	O
of	O
tricyclic	B
antidepressants	I
with	O
drugs	O
that	O
can	O
inhibit	O
cytochrome	O
P450	O
2D6	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	B
antidepressant	I
or	O
the	O
other	O
drug	O
.	O

It	O
is	O
desirable	O
to	O
monitor	O
TCA	B
plasma	O
levels	O
whenever	O
a	O
TCA	B
is	O
going	O
to	O
be	O
co	O
-	O
administered	O
with	O
another	O
drug	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P450	O
2D6	O
.	O

Close	O
supervision	O
and	O
careful	O
adjustment	O
of	O
dosage	O
are	O
required	O
when	O
this	O
drug	O
is	O
given	O
concomitantly	O
with	O
anticholinergic	B
or	O
sympathomimetic	B
drugs	I
.	O

If	O
desipramine	B
hydrochloride	I
is	O
to	O
be	O
combined	O
with	O
other	O
psychotropic	B
agents	I
such	O
as	O
tranquilizers	B
or	O
sedative	B
/	O
hypnotics	B
,	O
careful	O
consideration	O
should	O
be	O
given	O
to	O
the	O
pharmacology	O
of	O
the	O
agents	B
employed	O
since	O
the	O
sedative	B
effects	O
of	O
desipramine	B
and	O
benzodiazepines	B
(	O
e	O
.	O
g	O
.	O
,	O
chlordiazepoxide	B
or	O
diazepam	B
)	O
are	O
additive	O
.	O

Both	O
the	O
sedative	O
and	O
anticholinergic	O
effects	O
of	O
the	O
major	B
tranquilizers	I
are	O
also	O
additive	O
to	O
those	O
of	O
desipramine	B
.	O

Concurrent	O
administration	O
of	O
cimetidine	B
and	O
tricyclic	B
antidepressants	I
can	O
produce	O
clinically	O
significant	O
increases	O
in	O
the	O
plasma	O
levels	O
of	O
the	O
tricyclic	B
antidepressants	I
.	O

Conversely	O
,	O
decreases	O
in	O
plasma	O
levels	O
of	O
the	O
tricyclic	B
antidepressants	I
have	O
been	O
reported	O
upon	O
discontinuation	O
of	O
cimetidine	B
which	O
may	O
result	O
in	O
the	O
loss	O
of	O
the	O
therapeutic	O
efficacy	O
of	O
the	O
tricyclic	B
antidepressant	I
6	O
.	O

There	O
have	O
been	O
greater	O
than	O
two	O
-	O
fold	O
increases	O
of	O
previously	O
stable	O
plasma	O
levels	O
of	O
tricyclic	B
antidepressants	I
when	O
fluoxetine	B
has	O
been	O
administered	O
in	O
combination	O
with	O
these	O
agents	O
.	O

In	O
two	O
controlled	O
crossover	O
clinical	O
pharmacology	O
studies	O
in	O
healthy	O
male	O
(	O
n	O
=	O
12	O
in	O
each	O
study	O
)	O
a	O
nd	O
female	O
(	O
n	O
=	O
12	O
in	O
each	O
study	O
)	O
volunteers	O
,	O
desloratadine	B
7	O
.	O
5	O
mg	O
(	O
1	O
.	O
5	O
times	O
the	O
daily	O
dose	O
)	O
once	O
daily	O
was	O
coadministered	O
with	O
erythromycin	B
500	O
mg	O
every	O
8	O
hours	O
or	O
ketoconazole	B
200	O
mg	O
every	O
12	O
hours	O
for	O
10	O
days	O
.	O

In	O
three	O
separate	O
controlled	O
,	O
parallel	O
group	O
clinical	O
pharmacology	O
studies	O
,	O
desloratadine	B
at	O
the	O
clinical	O
dose	O
of	O
5	O
mg	O
has	O
been	O
coadministered	O
with	O
azithromycin	B
500	O
mg	O
followed	O
by	O
250	O
mg	O
once	O
daily	O
for	O
4	O
days	O
(	O
n	O
=	O
18	O
)	O
or	O
with	O
fluoxetine	B
20	O
mg	O
once	O
daily	O
for	O
7	O
days	O
after	O
a	O
23	O
day	O
pretreatment	O
period	O
with	O
fluoxetine	B
(	O
n	O
=	O
18	O
)	O
or	O
with	O
cimetidine	B
600	O
mg	O
every	O
12	O
hours	O
for	O
14	O
days	O
(	O
n	O
=	O
18	O
)	O
under	O
steady	O
state	O
conditions	O
to	O
normal	O
healthy	O
male	O
and	O
female	O
volunteers	O
.	O

Although	O
increased	O
plasma	O
concentrations	O
(	O
C	O
max	O
and	O
AUC	O
0	O
-	O
24	O
hrs	O
)	O
of	O
desloratadine	B
and	O
3	O
-	O
hydroxydesloratadine	O
were	O
observed	O
,	O
there	O
were	O
no	O
clinically	O
relevant	O
changes	O
in	O
the	O
safety	O
profile	O
of	O
desloratadine	B
,	O
as	O
assessed	O
by	O
electrocardiographic	O
parameters	O
(	O
including	O
the	O
corrected	O
QT	O
interval	O
)	O
,	O
clinical	O
laboratory	O
tests	O
,	O
vital	O
signs	O
,	O
and	O
adverse	O
events	O
.	O

Table	O
1	O
Changes	O
in	O
Desloratadine	B
and	O
3	O
-	O
Hydroxydesloratadine	O
Pharmacokinetics	O
in	O
Healthy	O
Male	O
and	O
Female	O
Volunteers	O

Desloratadine	B
3	O
-	O
Hydroxydesloratadine	O

Although	O
the	O
pressor	O
activity	O
of	O
Desmopressin	B
is	O
very	O
low	O
compared	O
to	O
its	O
antidiuretic	O
activity	O
,	O
large	O
doses	O
of	O
Desmopressin	B
Tablets	O
should	O
be	O
used	O
with	O
other	O
pressor	O
agents	O
only	O
with	O
careful	O
patient	O
monitoring	O
.	O

A	O
similar	O
association	O
,	O
though	O
less	O
marked	O
,	O
has	O
been	O
suggested	O
with	O
barbiturates	B
,	O
phenyl	O
-	O
butazone	O
,	O
phenytoin	B
sodium	I
,	O
carbamazepine	B
and	O
possibly	O
with	O
griseofulvin	B
,	O
ampicillin	B
,	O
and	O
tetracyclines	B
(	O
72	O
)	O

Aminoglutethimide	B
:	O
Aminoglutethimide	B
may	O
diminish	O
adrenal	O
suppression	O
by	O
corticosteroids	B
.	O

Amphotericin	B
B	I
injection	O
and	O
potassium	O
-	O
depleting	O
agents	O
:	O
When	O
corticosteroids	B
are	O
administered	O
concomitantly	O
with	O
potassium	O
-	O
depleting	O
agents	O
(	O
e	O
.	O
g	O
.	O
,	O
amphotericin	B
B	I
,	O
diuretics	B
)	O
,	O
patients	O
should	O
be	O
observed	O
closely	O
for	O
development	O
of	O
hypokalemia	O
.	O

In	O
addition	O
,	O
there	O
have	O
been	O
cases	O
reported	O
in	O
which	O
concomitant	O
use	O
of	O
amphotericin	B
B	I
and	O
hydrocortisone	B
was	O
followed	O
by	O
cardiac	O
enlargement	O
and	O
congestive	O
heart	O
failure	O
.	O

Antibiotics	B
:	O
Macrolide	B
antibiotics	I
have	O
been	O
reported	O
to	O
cause	O
a	O
significant	O
decrease	O
in	O
corticosteroid	B
clearance	O
.	O

Anticholinesterases	B
:	O
Concomitant	O
use	O
of	O
anticholinesterase	B
agents	I
and	O
corticosteroids	B
may	O
produce	O
severe	O
weakness	O
in	O
patients	O
with	O
myasthenia	O
gravis	O
.	O

If	O
possible	O
,	O
anticholinesterase	B
agents	I
should	O
be	O
withdrawn	O
at	O
least	O
24	O
hours	O
before	O
initiating	O
corticosteroid	B
therapy	O
.	O

Anticoagulants	B
,	O
oral	O
:	O
Co	O
-	O
administration	O
of	O
corticosteroids	B
and	O
warfarin	B
usually	O
results	O
in	O
inhibition	O
of	O
response	O
to	O
warfarin	B
,	O
although	O
there	O
have	O
been	O
some	O
conflicting	O
reports	O
.	O

Antidiabetics	B
:	O
Because	O
corticosteroids	B
may	O
increase	O
blood	O
glucose	O
concentrations	O
,	O
dosage	O
adjustments	O
of	O
antidiabetic	B
agents	I
may	O
be	O
required	O
.	O

Cholestyramine	B
:	O
Cholestyramine	B
may	O
increase	O
the	O
clearance	O
of	O
corticosteroids	B
.	O

Cyclosporine	B
:	O
Increased	O
activity	O
of	O
both	O
cyclosporine	B
and	O
corticosteroids	B
may	O
occur	O
when	O
the	O
two	O
are	O
used	O
concurrently	O
.	O

Digitalis	B
glycosides	I
:	O
Patients	O
on	O
digitalis	B
glycosides	I
may	O
be	O
at	O
increased	O
risk	O
of	O
arrhythmias	O
due	O
to	O
hypokalemia	O
.	O

Ephedrine	B
:	O
Ephedrine	B
may	O
enhance	O
the	O
metabolic	O
clearance	O
of	O
corticosteroids	B
,	O
resulting	O
in	O
decreased	O
blood	O
levels	O
and	O
lessened	O
physiologic	O
activity	O
,	O
thus	O
requiring	O
an	O
increase	O
in	O
corticosteroid	B
dosage	O
.	O

Estrogens	B
,	O
including	O
oral	O
contraceptives	B
:	O
Estrogens	B
may	O
decrease	O
the	O
hepatic	O
metabolism	O
of	O
certain	O
corticosteroids	B
,	O
thereby	O
increasing	O
their	O
effect	O
.	O

Hepatic	O
Enzyme	O
Inducers	O
,	O
Inhibitors	O
and	O
Substrates	O
:	O
Drugs	O
which	O
induce	O
cytochrome	O
P450	O
3A4	O
(	O
CYP	O
3A4	O
)	O
enzyme	O
activity	O
(	O
e	O
.	O
g	O
.	O
,	O
barbiturates	B
,	O
phenytoin	B
,	O
carbamazepine	B
,	O
rifampin	B
)	O
may	O
enhance	O
the	O
metabolism	O
of	O
corticosteroids	B
and	O
require	O
that	O
the	O
dosage	O
of	O
the	O
corticosteroid	B
be	O
increased	O
.	O

Drugs	O
which	O
inhibit	O
CYP	O
3A4	O
(	O
e	O
.	O
g	O
.	O
,	O
ketoconazole	B
,	O
macrolide	B
antibiotics	I
such	O
as	O
erythromycin	B
)	O
have	O
the	O
potential	O
to	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
corticosteroids	B
.	O

Co	O
-	O
administration	O
with	O
other	O
drugs	O
that	O
are	O
metabolized	O
by	O
CYP	O
3A4	O
(	O
e	O
.	O
g	O
.	O
,	O
indinavir	B
,	O
erythromycin	B
)	O
may	O
increase	O
their	O
clearance	O
,	O
resulting	O
in	O
decreased	O
plasma	O
concentration	O
.	O

Ketoconazole	B
:	O
Ketoconazole	B
has	O
been	O
reported	O
to	O
decrease	O
the	O
metabolism	O
of	O
certain	O
corticosteroids	B
by	O
up	O
to	O
60	O
%	O
,	O
leading	O
to	O
increased	O
risk	O
of	O
corticosteroid	B
side	O
effects	O
.	O

In	O
addition	O
,	O
ketoconazole	B
alone	O
can	O
inhibit	O
adrenal	O
corticosteroid	B
synthesis	O
and	O
may	O
cause	O
adrenal	O
insufficiency	O
during	O
corticosteroid	B
withdrawal	O
.	O

Nonsteroidal	B
anti	O
-	O
inflammatory	O
agents	B
(	O
NSAIDS	B
)	O
:	O
Concomitant	O
use	O
of	O
aspirin	B
(	O
or	O
other	O
nonsteroidal	B
antiinflammatory	I
agents	I
)	O
and	O
corticosteroids	B
increases	O
the	O
risk	O
of	O
gastrointestinal	O
side	O
effects	O
.	O

Aspirin	B
should	O
be	O
used	O
cautiously	O
in	O
conjunction	O
with	O
corticosteroids	B
in	O
hypoprothrombinemia	O
.	O

The	O
clearance	O
of	O
salicylates	B
may	O
be	O
increased	O
with	O
concurrent	O
use	O
of	O
corticosteroids	B
.	O

Phenytoin	B
:	O
In	O
post	O
-	O
marketing	O
experience	O
,	O
there	O
have	O
been	O
reports	O
of	O
both	O
increases	O
and	O
decreases	O
in	O
phenytoin	B
levels	O
with	O
dexamethasone	B
co	O
-	O
administration	O
,	O
leading	O
to	O
alterations	O
in	O
seizure	O
control	O
.	O

Thalidomide	B
:	O
Co	O
-	O
administration	O
with	O
thalidomide	B
should	O
be	O
employed	O
cautiously	O
,	O
as	O
toxic	O
epidermal	O
necrolysis	O
has	O
been	O
reported	O
with	O
concomitant	O
use	O
.	O

Vaccines	B
:	O
Patients	O
on	O
corticosteroid	B
therapy	O
may	O
exhibit	O
a	O
diminished	O
response	O
to	O
toxoids	O
and	O
live	B
or	O
inactivated	B
vaccines	I
due	O
to	O
inhibition	O
of	O
antibody	O
response	O
.	O

Corticosteroids	B
may	O
also	O
potentiate	O
the	O
replication	O
of	O
some	O
organisms	O
contained	O
in	O
live	B
attenuated	I
vaccines	I
.	O

Routine	O
administration	O
of	O
vaccines	B
or	O
toxoids	O
should	O
be	O
deferred	O
until	O
corticosteroid	B
therapy	O
is	O
discontinued	O
if	O
possible	O
.	O

Dexbrompheniramine	B
can	O
interact	O
with	O
alcohol	B
or	O
other	O
CNS	B
depressants	I
(	O
may	O
potentiate	O
the	O
CNS	B
depressant	O
effects	O
of	O
either	O
these	O
medications	O
or	O
antihistamines	B
)	O
,	O
anticholinergics	B
or	O
other	O
medications	O
with	O
anticholinergic	O
activity	O
(	O
anticholinergic	O
effects	O
may	O
be	O
potentiated	O
when	O
these	O
medications	O
are	O
used	O
concurrently	O
with	O
antihistamines	B
)	O
,	O
and	O
monoamine	B
oxidase	I
(	O
MAO	O
)	O
inhibitors	B
(	O
concurrent	O
use	O
with	O
antihistamines	B
may	O
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
and	O
CNS	B
depressant	O
effects	O
of	O
antihistamines	B
)	O
.	O

In	O
patients	O
receiving	O
nonselective	O
monoamine	B
oxidase	I
inhibitors	I
(	O
MAOIs	B
)	O
(	O
e	O
.	O
g	O
.	O
,	O
selegiline	B
hydrochloride	I
)	O
in	O
combination	O
with	O
serotoninergic	B
agents	I
(	O
e	O
.	O
g	O
.	O
,	O
fluoxetine	B
,	O
fluvoxamine	B
,	O
paroxetine	B
,	O
sertraline	B
,	O
venlafaxine	B
)	O
,	O
there	O
have	O
been	O
reports	O
of	O
serious	O
,	O
sometimes	O
fatal	O
,	O
reactions	O
.	O

Because	O
dexfenfluramine	B
is	O
a	O
serotonin	O
releaser	O
and	O
reuptake	O
inhibitor	B
,	O
dexfenfluramine	B
should	O
not	O
be	O
used	O
concomitantly	O
with	O
a	O
MAO	B
inhibitor	I
.	O

At	O
least	O
14	O
days	O
should	O
elapse	O
between	O
discontinuation	O
of	O
a	O
MAO	B
inhibitor	I
and	O
initiation	O
of	O
treatment	O
with	O
dexfenfluramine	B
.	O

At	O
least	O
3	O
weeks	O
should	O
elapse	O
between	O
discontinuation	O
of	O
dexfenfluramine	B
and	O
initiation	O
of	O
treatment	O
with	O
a	O
MAO	B
inhibitor	I
.	O

A	O
rare	O
,	O
but	O
serious	O
,	O
constellation	O
of	O
symptoms	O
,	O
termed	O
serotonin	B
syndrome	O
,	O
has	O
been	O
reported	O
with	O
the	O
concomitant	O
use	O
of	O
selective	B
serotonin	I
reuptake	I
inhibitors	I
(	O
SSRIs	B
)	O
and	O
agents	O
for	O
migraine	O
therapy	O
,	O
such	O
as	O
Imitrex	B
(	O
sumatriptan	B
succinate	I
)	O
and	O
dihydroergotamine	B
.	O

Dexfenfluramine	B
should	O
not	O
be	O
administered	O
with	O
other	O
serotoninergic	B
agents	I
.	O

Anesthetics	B
/	O
Sedatives	B
/	O
Hypnotics	B
/	O
Opioids	B
:	O
Co	O
-	O
administration	O
of	O
PRECEDEX	B
with	O
anesthetics	B
,	O
sedatives	B
,	O
hypnotics	B
,	O
and	O
opioids	B
is	O
likely	O
to	O
lead	O
to	O
an	O
enhancement	O
of	O
effects	O
.	O

Specific	O
studies	O
have	O
confirmed	O
these	O
effects	O
with	O
sevoflurane	B
,	O
isoflurane	B
,	O
propofol	B
,	O
alfentanil	B
,	O
and	O
midazolam	B
.	O

No	O
pharmacokinetic	O
interactions	O
between	O
dexmedetomidine	B
and	O
isoflurane	B
,	O
propofol	B
,	O
alfentanil	B
,	O
and	O
midazolam	B
have	O
been	O
demonstrated	O
.	O

However	O
,	O
due	O
to	O
possible	O
pharmacodynamic	O
interactions	O
,	O
when	O
co	O
-	O
administered	O
with	O
PRECEDEX	B
,	O
a	O
reduction	O
in	O
dosage	O
of	O
PRECEDEX	B
on	O
the	O
concomitant	O
anesthetic	B
,	O
sedative	B
,	O
hypnotic	B
or	O
opioid	B
may	O
be	O
required	O
.	O

Neuromuscular	B
Blockers	I
:	O
In	O
one	O
study	O
of	O
10	O
healthy	O
volunteers	O
,	O
administration	O
of	O
PRECEDEX	B
for	O
45	O
minutes	O
at	O
a	O
plasma	O
concentration	O
of	O
1	O
(	O
one	O
)	O
ng	O
/	O
mL	O
resulted	O
in	O
no	O
clinically	O
meaningful	O
increases	O
in	O
the	O
magnitude	O
or	O
neuromuscular	O
blockade	O
associated	O
with	O
rocuronium	B
administration	O
.	O

ZINECARD	B
does	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
doxorubicin	B
.	O

Acidifying	B
agents	I
:	O
Gastrointestinal	B
acidifying	I
agents	I
(	O
guanethidine	B
,	O
reserpine	B
,	O
glutamic	B
acid	I
HCl	I
,	O
ascorbic	B
acid	I
,	O
fruit	O
juices	O
,	O
etc	O
.	O
)	O
lower	O
absorption	O
of	O
amphetamines	B
.	O

Urinary	B
acidifying	I
agents	I
(	O
ammonium	B
chloride	I
,	O
sodium	B
acid	I
phosphate	I
,	O
etc	O
.	O
)	O
increase	O
the	O
concentration	O
of	O
the	O
ionized	O
species	O
of	O
the	O
amphetamine	B
molecule	O
,	O
thereby	O
increasing	O
urinary	O
excretion	O
.	O

Adrenergic	B
blockers	I
:	O
Adrenergic	B
blockers	I
are	O
inhibited	O
by	O
amphetamines	B
.	O

Alkalinizing	O
agents	O
:	O
Gastrointestinal	O
alkalinizing	O
agents	O
(	O
sodium	B
bicarbonate	I
,	O
etc	O
.	O
)	O
increase	O
absorption	O
of	O
amphetamines	B
.	O

Urinary	O
alkalinizing	O
agents	O
(	O
acetazolamide	B
,	O
some	O
thiazides	B
)	O
increase	O
the	O
concentration	O
of	O
the	O
non	O
-	O
ionized	O
species	O
of	O
the	O
amphetamine	B
molecule	O
,	O
thereby	O
decreasing	O
urinary	O
excretion	O
.	O

Antidepressants	B
,	O
tricyclic	B
:	O
Amphetamines	B
may	O
enhance	O
the	O
activity	O
of	O
tricyclic	B
or	O
sympathomimetic	B
agents	I
;	O

d	O
-	O
amphetamine	O
with	O
desipramine	B
or	O
protriptyline	B
and	O
possibly	O
other	O
tricyclics	B
cause	O
striking	O
and	O
sustained	O
increases	O
in	O
the	O
concentration	O
of	O
d	O
-	O
amphetamine	O
in	O
the	O
brain	O
;	O

MAO	B
inhibitors	I
:	O
MAOI	B
antidepressants	I
,	O
as	O
well	O
as	O
a	O
metabolite	O
of	O
furazolidone	B
,	O
slow	O
amphetamine	B
metabolism	O
.	O

Antihistamines	B
:	O
Amphetamines	B
may	O
counteract	O
the	O
sedative	O
effect	O
of	O
antihistamines	B
.	O

Antihypertensives	B
:	O
Amphetamines	B
may	O
antagonize	O
the	O
hypotensive	O
effects	O
of	O
antihypertensives	B
.	O

Chlorpromazine	B
:	O
Chlorpromazine	B
blocks	O
dopamine	O
and	O
norepinephrine	O
reuptake	O
,	O
thus	O
inhibiting	O
the	O
central	O
stimulant	O
effects	O
of	O
amphetamines	B
,	O
and	O
can	O
be	O
used	O
to	O
treat	O
amphetamine	B
poisoning	O
.	O

Ethosuximide	B
:	O
Amphetamines	B
may	O
delay	O
intestinal	O
absorption	O
of	O
ethosuximide	B
.	O

Haloperidol	B
:	O
Haloperidol	B
blocks	O
dopamine	O
and	O
norepinephrine	O
reuptake	O
,	O
thus	O
inhibiting	O
the	O
central	O
stimulant	O
effects	O
of	O
amphetamines	B
.	O

Lithium	B
carbonate	I
:	O
The	O
stimulatory	O
effects	O
of	O
amphetamines	B
may	O
be	O
inhibited	O
by	O
lithium	B
carbonate	I
.	O

Meperidine	B
:	O
Amphetamines	B
potentiate	O
the	O
analgesic	O
effect	O
of	O
meperidine	B
.	O

Methenamine	B
therapy	O
:	O
Urinary	O
excretion	O
of	O
amphetamines	B
is	O
increased	O
,	O
and	O
efficacy	O
is	O
reduced	O
,	O
by	O
acidifying	B
agents	I
used	O
in	O
methenamine	B
therapy	O
.	O

Norepinephrine	B
:	O
Amphetamines	B
enhance	O
the	O
adrenergic	O
effect	O
of	O
norepinephrine	B
.	O

Phenobarbital	B
:	O
Amphetamines	B
may	O
delay	O
intestinal	O
absorption	O
of	O
phenobarbital	B
;	O

Phenytoin	B
:	O
Amphetamines	B
may	O
delay	O
intestinal	O
absorption	O
of	O
phenytoin	B
;	O

Propoxyphene	B
:	O
In	O
cases	O
of	O
propoxyphene	B
overdosage	O
,	O
amphetamine	B
CNS	O
stimulation	O
is	O
potentiated	O
and	O
fatal	O
convulsions	O
can	O
occur	O
.	O

Veratrum	B
alkaloids	I
:	O
Amphetamines	B
inhibit	O
the	O
hypotensive	O
effect	O
of	O
veratrum	B
alkaloids	I
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
Amphetamines	B
can	O
cause	O
a	O
significant	O
elevation	O
in	O
plasma	O
corticosteroid	B
levels	O
.	O

Additive	O
depressant	O
effect	O
when	O
used	O
with	O
general	O
anesthetics	B
,	O
sedatives	B
,	O
antianxiety	B
drugs	I
,	O
hypnotics	B
,	O
alcohol	B
,	O
and	O
other	O
opiate	B
analgesics	I
.	O

May	O
interact	O
with	O
thyroid	O
medication	O
(	O
e	O
.	O
g	O
.	O
,	O
levothyroxine	B
)	O
,	O
iodine	B
-	O
containing	O
products	O
,	O
antacids	B
,	O
H2	O
-	O
antagonists	O
(	O
e	O
.	O
g	O
.	O
,	O
famotidine	B
,	O
ranitidine	B
)	O
,	O
and	O
proton	B
pump	I
inhibitors	I
(	O
e	O
.	O
g	O
.	O
,	O
lansoprazole	B
,	O
omeprazole	B
)	O
.	O

Caution	O
is	O
advised	O
in	O
patients	O
receiving	O
concomitant	O
high	O
-	O
dose	O
aspirin	B
and	O
carbonic	B
anhydrase	I
inhibitors	I
,	O
as	O
anorexia	O
,	O
tachypnea	O
,	O
lethargy	O
and	O
coma	O
have	O
been	O
rarely	O
reported	O
due	O
to	O
a	O
possible	O
drug	O
interaction	O
.	O

Aspirin	B
:	O
Concomitant	O
administration	O
of	O
diclofenac	B
and	O
aspirin	B
is	O
not	O
recommended	O
because	O
diclofenac	B
is	O
displaced	O
from	O
its	O
binding	O
sites	O
during	O
the	O
concomitant	O
administration	O
of	O
aspirin	B
,	O
resulting	O
in	O
lower	O
plasma	O
concentrations	O
,	O
peak	O
plasma	O
levels	O
,	O
and	O
AUC	O
values	O
.	O

Anticoagulants	B
:	O
While	O
studies	O
have	O
not	O
shown	O
diclofenac	B
to	O
interact	O
with	O
anticoagulants	B
of	I
the	I
warfarin	I
type	I
,	O
caution	O
should	O
be	O
exercised	O
,	O
nonetheless	O
,	O
since	O
interactions	O
have	O
been	O
seen	O
with	O
other	O
NSAIDs	B
.	O

Because	O
prostaglandins	O
play	O
an	O
important	O
role	O
in	O
hemostasis	O
,	O
and	O
NSAIDs	B
affect	O
platelet	O
function	O
as	O
well	O
,	O
concurrent	O
therapy	O
with	O
all	O
NSAIDs	B
,	O
including	O
diclofenac	B
,	O
and	O
warfarin	B
requires	O
close	O
monitoring	O
of	O
patients	O
to	O
be	O
certain	O
that	O
no	O
change	O
in	O
their	O
anticoagulant	B
dosage	O
is	O
required	O
.	O

Digoxin	B
,	O
Methotrexate	B
,	O
Cyclosporine	B
:	O
Diclofenac	B
,	O
like	O
other	O
NSAIDs	B
,	O
may	O
affect	O
renal	O
prostaglandins	O
and	O
increase	O
the	O
toxicity	O
of	O
certain	O
drugs	O
.	O

Ingestion	O
of	O
diclofenac	B
may	O
increase	O
serum	O
concentrations	O
of	O
digoxin	B
and	O
methotrexate	B
and	O
increase	O
cyclosporine	B
s	O
nephrotoxicity	O
.	O

Patients	O
who	O
begin	O
taking	O
diclofenac	B
or	O
who	O
increase	O
their	O
diclofenac	B
dose	O
or	O
any	O
other	O
NSAID	B
while	O
taking	O
digoxin	B
,	O
methotrexate	B
,	O
or	O
cyclosporine	B
may	O
develop	O
toxicity	O
characteristics	O
for	O
these	O
drugs	O
.	O

Lithium	B
:	O
Diclofenac	B
decreases	O
lithium	B
renal	O
clearance	O
and	O
increases	O
lithium	B
plasma	O
levels	O
.	O

In	O
patients	O
taking	O
diclofenac	B
and	O
lithium	B
concomitantly	O
,	O
lithium	B
toxicity	O
may	O
develop	O
.	O

Oral	O
Hypoglycemics	B
:	O
Diclofenac	B
does	O
not	O
alter	O
glucose	O
metabolism	O
in	O
normal	O
subjects	O
nor	O
does	O
it	O
alter	O
the	O
effects	O
of	O
oral	O
hypoglycemic	B
agents	I
.	O

There	O
are	O
rare	O
reports	O
,	O
however	O
,	O
from	O
marketing	O
experiences	O
,	O
of	O
changes	O
in	O
effects	O
of	O
insulin	B
or	O
oral	O
hypoglycemic	B
agents	I
in	O
the	O
presence	O
of	O
diclofenac	B
that	O
necessitated	O
changes	O
in	O
the	O
doses	O
of	O
such	O
agents	B
.	O

A	O
direct	O
causal	O
relationship	O
has	O
not	O
been	O
established	O
,	O
but	O
physicians	O
should	O
consider	O
the	O
possibility	O
that	O
diclofenac	B
may	O
alter	O
a	O
diabetic	O
patient	O
s	O
response	O
to	O
insulin	B
or	O
oral	O
hypoglycemic	B
agents	I
.	O

Diuretics	B
:	O
Diclofenac	B
and	O
other	O
NSAIDs	B
can	O
inhibit	O
the	O
activity	O
of	O
diuretics	B
.	O

Other	O
Drugs	O
:	O
In	O
small	O
groups	O
of	O
patients	O
(	O
7	O
-	O
10	O
/	O
interaction	O
study	O
)	O
,	O
the	O
concomitant	O
administration	O
of	O
azathioprine	B
,	O
gold	B
,	O
chloroquine	B
,	O
D	O
-	O
penicillamine	O
,	O
prednisolone	B
,	O
doxycycline	B
,	O
or	O
digitoxin	B
did	O
not	O
significantly	O
affect	O
the	O
peak	O
levels	O
and	O
AUC	O
values	O
of	O
diclofenac	B
.	O

Phenobarbital	B
toxicity	O
has	O
been	O
reported	O
to	O
have	O
occurred	O
in	O
a	O
patient	O
on	O
chronic	O
phenobarbital	B
treatment	O
following	O
the	O
initiation	O
of	O
diclofenac	B
therapy	O
.	O

Protein	O
Binding	O
In	O
vitro	O
,	O
diclofenac	B
interferes	O
minimally	O
or	O
not	O
at	O
all	O
with	O
the	O
protein	O
binding	O
of	O
salicylic	B
acid	I
(	O
20	O
%	O
decrease	O
in	O
binding	O
)	O
,	O
tolbutamide	B
,	O
prednisolone	B
(	O
10	O
%	O
decrease	O
in	O
binding	O
)	O
,	O
or	O
warfarin	B
.	O

Benzylpenicillin	B
,	O
ampicillin	B
,	O
oxacillin	B
,	O
chlortetracycline	B
,	O
doxycycline	B
,	O
cephalothin	B
,	O
erythromycin	B
,	O
and	O
sulfamethoxazole	B
have	O
no	O
influence	O
in	O
vitro	O
on	O
the	O
protein	O
binding	O
of	O
diclofenac	B
in	O
human	O
serum	O
.	O

Tetracycline	B
,	O
a	O
bacteriostatic	B
antibiotic	I
,	O
may	O
antagonize	O
the	O
bactercidal	O
effect	O
of	O
penicillin	B
and	O
concurrent	O
use	O
of	O
these	O
drugs	O
should	O
be	O
avoided	O
.	O

The	O
following	O
agents	B
may	O
increase	O
certain	O
actions	O
or	O
side	O
effects	O
of	O
anticholinergic	B
drugs	I
.	O
amantadine	B
antiarrhythmic	I
agents	I
of	O
class	O
(	O
e	O
.	O
g	O
.	O
quinidine	B
)	O
,	O
antihistamines	B
antipsychotic	I
agents	I
(	O
e	O
.	O
g	O
.	O
phenothiazines	B
)	O
,	O
benzodiazepines	B
.	O

MAO	B
inhibitors	I
,	O
narcotic	B
analgesics	I
(	O
e	O
.	O
g	O
.	O
,	O
meperidine	B
)	O
,	O
nitrates	B
and	O
nitrites	B
,	O
sympathomimetic	B
agents	I
,	O
tricyclic	B
antidepressants	I
,	O
and	O
other	O
drugs	O
having	O
anticholinergic	O
activity	O
.	O

Anticholinergics	B
antagonize	O
the	O
effects	O
of	O
antiglaucoma	B
agents	I
.	O

Anticholinergic	B
agents	I
may	O
affect	O
gastrointestinal	O
absorption	O
of	O
various	O
drugs	O
,	O
such	O
as	O
slowly	O
dissolving	O
dosage	O
forms	O
of	O
digoxin	B
;	O

Anticholinergic	B
drugs	I
may	O
antagonize	O
the	O
effects	O
of	O
the	O
drugs	B
that	O
alter	O
gastrointestinal	O
motility	O
,	O
such	O
as	O
metoclopramide	B
.	O

Because	O
antacids	B
may	O
interfere	O
with	O
the	O
absorption	O
of	O
anticholinergic	B
agents	I
,	O
simultaneous	O
use	O
of	O
these	O
drugs	O
should	O
be	O
avoided	O
.	O

Neuropathy	O
has	O
occurred	O
more	O
frequently	O
in	O
patients	O
with	O
a	O
history	O
of	O
neuropathy	O
or	O
neurotoxic	O
drug	O
therapy	O
,	O
including	O
stavudine	B
,	O
and	O
these	O
patients	O
may	O
be	O
at	O
increased	O
risk	O
of	O
neuropathy	O
during	O
VIDEX	B
therapy	O
(	O
see	O
ADVERSE	O
REACTIONS	O
)	O
.	O

Allopurinol	B
:	O
The	O
AUC	O
of	O
didanosine	B
was	O
increased	O
about	O
4	O
-	O
fold	O
when	O
allopurinol	B
at	O
300	O
mg	O
/	O
day	O
was	O
coadministered	O
with	O
a	O
single	O
200	O
-	O
mg	O
dose	O
of	O
VIDEX	B
to	O
two	O
patients	O
with	O
renal	O
impairment	O
(	O
CLcr	O
=	O
15	O
and	O
18	O
mL	O
/	O
min	O
)	O
.	O

The	O
effects	O
of	O
allopurinol	B
on	O
didanosine	B
pharmacokinetics	O
in	O
subjects	O
with	O
normal	O
renal	O
function	O
are	O
not	O
known	O
.	O

Antacids	B
:	O
Concomitant	O
administration	O
of	O
antacids	B
containing	O
magnesium	B
or	O
aluminum	B
with	O
VIDEX	B
Chewable	O
/	O
Dispersible	O
Buffered	O
Tablets	O
or	O
Pediatric	O
Powder	O
for	O
Oral	O
Solution	O
may	O
potentiate	O
adverse	O
events	O
associated	O
with	O
the	O
antacid	B
components	O
.	O

Drugs	O
Whose	O
Absorption	O
Can	O
Be	O
Affected	O
by	O
the	O
Level	O
of	O
Acidity	O
in	O
the	O
Stomach	O
:	O
Drugs	O
such	O
as	O
ketoconazole	B
and	O
itraconazole	B
should	O
be	O
administered	O
at	O
least	O
2	O
hours	O
prior	O
to	O
dosing	O
with	O
VIDEX	B
.	O

Ganciclovir	B
:	O
Administration	O
of	O
VIDEX	B
2	O
hours	O
prior	O
to	O
or	O
concurrent	O
with	O
oral	O
ganciclovir	B
was	O
associated	O
with	O
a	O
111	O
(	O
114	O
)	O
%	O
increase	O
in	O
the	O
steady	O
-	O
state	O
AUC	O
of	O
didanosine	B
(	O
n	O
=	O
12	O
)	O
.	O

A	O
21	O
(	O
17	O
)	O
%	O
decrease	O
in	O
the	O
steady	O
-	O
state	O
AUC	O
of	O
ganciclovir	B
was	O
observed	O
when	O
VIDEX	B
was	O
administered	O
2	O
hours	O
prior	O
to	O
ganciclovir	B
,	O
but	O
not	O
when	O
the	O
two	O
drugs	O
were	O
administered	O
simultaneously	O
(	O
n	O
=	O
12	O
)	O
.	O

Quinolone	B
Antibiotics	O
:	O
VIDEX	B
should	O
be	O
administered	O
at	O
least	O
2	O
hours	O
after	O
or	O
6	O
hours	O
before	O
dosing	O
with	O
ciprofloxacin	B
because	O
plasma	O
concentrations	O
of	O
ciprofloxacin	B
are	O
decreased	O
when	O
administered	O
with	O
antacids	B
containing	O
magnesium	B
,	O
calcium	B
,	O
or	O
aluminum	B
.	O

In	O
eight	O
HIV	O
-	O
infected	O
patients	O
,	O
the	O
steady	O
-	O
state	O
AUC	O
of	O
ciprofloxacin	B
was	O
decreased	O
an	O
average	O
of	O
26	O
%	O
(	O
95	O
%	O
CI	O
=	O
14	O
%	O
,	O
37	O
%	O
)	O
when	O
ciprofloxacin	B
was	O
administered	O
2	O
hours	O
prior	O
to	O
a	O
marketed	O
chewable	O
/	O
dispersible	O
tablet	O
formulation	O
of	O
VIDEX	B
.	O

The	O
AUC	O
of	O
ciprofloxacin	B
was	O
decreased	O
an	O
average	O
of	O
15	O
-	O
fold	O
in	O
12	O
healthy	O
subjects	O
given	O
ciprofloxacin	B
and	O
didanosine	B
-	O
placebo	O
tablets	O
concurrently	O
.	O

In	O
a	O
single	O
subject	O
given	O
one	O
dose	O
of	O
ciprofloxacin	B
2	O
hours	O
after	O
a	O
dose	O
of	O
didanosine	B
-	O
placebo	O
tablets	O
,	O
a	O
greater	O
than	O
50	O
%	O
reduction	O
in	O
the	O
AUC	O
of	O
ciprofloxacin	B
was	O
observed	O
.	O

Plasma	O
concentrations	O
of	O
quinolone	B
antibiotics	I
are	O
decreased	O
when	O
administered	O
with	O
antacids	B
containing	O
magnesium	B
,	O
calcium	B
,	O
or	O
aluminum	B
.	O

The	O
optimal	O
dosing	O
interval	O
for	O
coadministration	O
with	O
VIDEX	B
should	O
be	O
determined	O
by	O
consulting	O
the	O
appropriate	O
quinolone	B
package	O
insert	O
.	O

Interactions	O
with	O
Other	O
Antiretroviral	B
Drugs	I
:	O
Significant	O
decreases	O
in	O
the	O
AUC	O
of	O
delavirdine	B
(	O
20	O
%	O
)	O
and	O
indinavir	B
(	O
84	O
%	O
)	O
occurred	O
following	O
simultaneous	O
administration	O
of	O
these	O
agents	O
with	O
VIDEX	B
.	O

To	O
avoid	O
this	O
interaction	O
,	O
delavirdine	B
or	O
indinavir	B
should	O
be	O
given	O
1	O
hour	O
prior	O
to	O
dosing	O
with	O
VIDEX	B
.	O

The	O
pharmacokinetics	O
of	O
nelfinavir	B
are	O
not	O
altered	O
to	O
a	O
clinically	O
significant	O
degree	O
when	O
it	O
is	O
administered	O
with	O
a	O
light	O
meal	O
1	O
hour	O
after	O
VIDEX	B
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Certain	O
endocrine	O
and	O
liver	O
function	O
tests	O
may	O
be	O
affected	O
by	O
estrogen	B
-	O
containing	O
oral	O
contraceptives	B
.	O

Antidiabetic	B
drug	I
requirements	O
(	O
i	O
.	O
e	O
.	O
,	O
insulin	B
)	O
may	O
be	O
altered	O
.	O

conversely	O
,	O
diethylpropion	B
may	O
interfere	O
with	O
antihypertensive	B
drugs	I
(	O
i	O
.	O
e	O
.	O
,	O
guanethidine	B
,	O
a	O
-	O
methyldopa	O
)	O
.	O

Concurrent	O
use	O
of	O
phenothiazines	B
may	O
antagonize	O
the	O
anorectic	O
effect	O
of	O
diethylpropion	B
.	O

May	O
interact	O
anticoagulants	B
(	O
altered	O
hypo	O
-	O
prothrombinemic	O
effect	O
)	O
,	O
barbiturates	B
,	O
rifampin	B
and	O
other	O
inducers	O
of	O
hepatic	O
microsomal	O
enzyme	O
oxidation	O
system	O
(	O
decreased	O
effect	O
of	O
diethylstilbestrol	B
)	O
,	O
corticosteroids	B
(	O
increased	O
effect	O
of	O
corticosteroids	B
)	O
.	O

Oral	O
Anticoagulants	B
:	O
In	O
some	O
normal	O
volunteers	O
,	O
the	O
concomitant	O
administration	O
of	O
diflunisal	B
and	O
warfarin	B
,	O
acenocoumarol	B
,	O
or	O
phenprocoumon	B
resulted	O
in	O
prolongation	O
of	O
prothrombin	O
time	O
.	O

This	O
may	O
occur	O
because	O
diflunisal	B
competitively	O
displaces	O
coumarins	B
from	O
protein	O
binding	O
sites	O
.	O

Accordingly	O
,	O
when	O
diflunisal	B
is	O
administered	O
with	O
oral	O
anticoagulants	B
,	O
the	O
prothrombin	O
time	O
should	O
be	O
closely	O
monitored	O
during	O
and	O
for	O
several	O
days	O
after	O
concomitant	O
drug	O
administration	O
.	O

Tolbutamide	B
:	O
In	O
diabetic	O
patients	O
receiving	O
diflunisal	B
and	O
tolbutamide	B
,	O
no	O
significant	O
effects	O
were	O
seen	O
on	O
tolbutamide	B
plasma	O
levels	O
or	O
fasting	O
blood	O
glucose	O
.	O

Hydrochlorothiazide	B
:	O
In	O
normal	O
volunteers	O
,	O
concomitant	O
administration	O
of	O
diflunisal	B
and	O
hydrochlorothiazide	B
resulted	O
in	O
significantly	O
increased	O
plasma	O
levels	O
of	O
hydrochlorothiazide	B
.	O

Diflunisal	B
decreased	O
the	O
hyperuricemic	O
effect	O
of	O
hydrochlorothiazide	B
.	O

Furosemide	B
:	O
In	O
normal	O
volunteers	O
,	O
the	O
concomitant	O
administration	O
of	O
diflunisal	B
and	O
furosemide	B
had	O
no	O
effect	O
on	O
the	O
diuretic	O
activity	O
of	O
furosemide	B
.	O

Diflunisal	B
decreased	O
the	O
hyperuricemic	O
effect	O
of	O
furosemide	B
.	O

Antacids	B
:	O
Concomitant	O
administration	O
of	O
antacids	B
may	O
reduce	O
plasma	O
levels	O
of	O
diflunisal	B
.	O

This	O
effect	O
is	O
small	O
with	O
occasional	O
doses	O
of	O
antacids	B
,	O
but	O
may	O
be	O
clinically	O
significant	O
when	O
antacids	B
are	O
used	O
on	O
a	O
continuous	O
schedule	O
.	O

Acetaminophen	B
:	O
In	O
normal	O
volunteers	O
,	O
concomitant	O
administration	O
of	O
diflunisal	B
and	O
acetaminophen	B
resulted	O
in	O
an	O
approximate	O
50	O
%	O
increase	O
in	O
plasma	O
levels	O
of	O
acetaminophen	B
.	O

Acetaminophen	B
had	O
no	O
effect	O
on	O
plasma	O
levels	O
of	O
diflunisal	B
.	O

Since	O
acetaminophen	B
in	O
high	O
doses	O
has	O
been	O
associated	O
with	O
hepatotoxicity	O
,	O
concomitant	O
administration	O
of	O
diflunisal	B
and	O
acetaminophen	B
should	O
be	O
used	O
cautiously	O
,	O
with	O
careful	O
monitoring	O
of	O
patients	O
.	O

Concomitant	O
administration	O
of	O
diflunisal	B
and	O
acetaminophen	B
in	O
dogs	O
,	O
but	O
not	O
in	O
rats	O
,	O
at	O
approximately	O
2	O
times	O
the	O
recommended	O
maximum	O
human	O
therapeutic	O
dose	O
of	O
each	O
(	O
40	O
to	O
52	O
mg	O
/	O
kg	O
/	O
day	O
of	O
diflunisal	B
/	O
acetaminophen	B
)	O
resulted	O
in	O
greater	O
gastrointestinal	O
toxicity	O
than	O
when	O
either	O
drug	O
was	O
administered	O
alone	O
.	O

Methotrexate	B
:	O
Caution	O
should	O
be	O
used	O
if	O
diflunisal	B
is	O
administered	O
concomitantly	O
with	O
methotrexate	B
.	O

Nonsteroidal	B
anti	O
-	O
inflammatory	O
drugs	B
have	O
been	O
reported	O
to	O
decrease	O
the	O
tubular	O
secretion	O
of	O
methotrexate	B
and	O
to	O
potentiate	O
its	O
toxicity	O
.	O

Cyclosporine	B
:	O
Administration	O
of	O
nonsteroial	B
anti	O
-	O
inflammatory	O
drugs	B
concomitantly	O
with	O
cyclosporine	B
has	O
been	O
associated	O
with	O
an	O
increase	O
in	O
cyclosporine	B
-	O
induced	O
toxicity	O
,	O
possibly	O
due	O
to	O
decreased	O
synthesis	O
of	O
renal	O
prostacyclin	O
.	O

NSAIDs	B
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
taking	O
cyclosporine	B
,	O
and	O
renal	O
function	O
should	O
be	O
carefully	O
monitored	O
.	O

Nonsteroidal	B
Anti	O
-	O
Inflammatory	O
Drugs	B
:	O
The	O
administration	O
of	O
diflunisal	B
to	O
normal	O
volunteers	O
receiving	O
indomethacin	B
decreased	O
the	O
renal	O
clearance	O
and	O
significantly	O
increased	O
the	O
plasma	O
levels	O
of	O
indomethacin	B
.	O

In	O
some	O
patients	O
the	O
combined	O
use	O
of	O
indomethacin	B
and	O
diflunisal	B
has	O
been	O
associated	O
with	O
fatal	O
gastrointestinal	O
hemorrhage	O
.	O

Therefore	O
,	O
indomethacin	B
and	O
diflunisal	B
should	O
not	O
be	O
used	O
concomitantly	O
.	O

The	O
concomitant	O
use	O
of	O
diflunisal	B
tablets	O
and	O
other	O
NSAIDs	B
is	O
not	O
recommended	O
due	O
to	O
the	O
increased	O
possibility	O
of	O
gastrointestinal	O
toxicity	O
,	O
with	O
little	O
or	O
no	O
increase	O
in	O
efficacy	O
.	O

Aspirin	B
:	O
In	O
normal	O
volunteers	O
,	O
a	O
small	O
decrease	O
in	O
diflunisal	B
levels	O
was	O
observed	O
when	O
multiple	O
doses	O
of	O
diflunisal	B
and	O
aspirin	B
were	O
administered	O
concomitantly	O
.	O

Sulindac	B
:	O
The	O
concomitant	O
administration	O
of	O
diflunisal	B
and	O
sulindac	B
in	O
normal	O
volunteers	O
resulted	O
in	O
lowering	O
of	O
the	O
plasma	O
levels	O
of	O
the	O
active	O
sulindac	B
sulfide	O
metabolite	O
by	O
approximately	O
one	O
-	O
third	O
.	O

Naproxen	B
:	O
The	O
concomitant	O
administration	O
of	O
diflunisal	B
and	O
naproxen	B
in	O
normal	O
volunteers	O
had	O
no	O
effect	O
on	O
the	O
plasma	O
levels	O
of	O
naproxen	B
,	O
but	O
significantly	O
decreased	O
the	O
urinary	O
excretion	O
of	O
naproxen	B
and	O
its	O
glucuronide	O
metabolite	O
.	O

Naproxen	B
had	O
no	O
effect	O
on	O
plasma	O
levels	O
of	O
diflunisal	B
.	O

Potassium	O
-	O
depleting	O
diuretics	B
are	O
a	O
major	O
contributing	O
factor	O
to	O
digitalis	B
toxicity	O
.	O

Quinidine	B
,	O
verapamil	B
,	O
amiodarone	B
,	O
propafenone	B
,	O
indomethacin	B
,	O
itraconazole	B
,	O
alprazolam	B
,	O
and	O
spironolactone	B
raise	O
the	O
serum	O
digoxin	B
concentration	O
due	O
to	O
a	O
reduction	O
in	O
clearance	O
and	O
/	O
or	O
in	O
volume	O
of	O
distribution	O
of	O
the	O
drug	O
,	O
with	O
the	O
implication	O
that	O
digitalis	B
intoxication	O
may	O
result	O
.	O

Erythromycin	B
and	O
clarithromycin	B
(	O
and	O
possibly	O
other	O
macrolide	B
antibiotics	I
)	O
and	O
tetracycline	B
may	O
increase	O
digoxin	B
absorption	O
in	O
patients	O
who	O
inactivate	O
digoxin	B
by	O
bacterial	O
metabolism	O
in	O
the	O
lower	O
intestine	O
,	O
so	O
that	O
digitalis	B
intoxication	O
may	O
result	O
.	O

Propantheline	B
and	O
diphenoxylate	B
,	O
by	O
decreasing	O
gut	O
motility	O
,	O
may	O
increase	O
digoxin	B
absorption	O
.	O

Antacids	B
,	O
kaolin	B
-	O
pectin	O
,	O
sulfasalazine	B
,	O
neomycin	B
,	O
cholestyramine	B
,	O
certain	O
anticancer	O
drugs	O
,	O
and	O
metoclopramide	B
may	O
interfere	O
with	O
intestinal	O
digoxin	B
absorption	O
,	O
resulting	O
in	O
unexpectedly	O
low	O
serum	O
concentrations	O
.	O

Rifampin	B
may	O
decrease	O
serum	O
digoxin	B
concentration	O
,	O
especially	O
in	O
patients	O
with	O
renal	O
dysfunction	O
,	O
by	O
increasing	O
the	O
non	O
-	O
renal	O
clearance	O
of	O
digoxin	B
.	O

There	O
have	O
been	O
inconsistent	O
reports	O
regarding	O
the	O
effects	O
of	O
other	O
drugs	O
(	O
e	O
.	O
g	O
.	O
,	O
quinine	B
,	O
penicillamine	B
)	O
on	O
serum	O
digoxin	B
concentration	O
.	O

Thyroid	B
administration	O
to	O
a	O
digitalized	O
,	O
hypothyroid	O
patient	O
may	O
increase	O
the	O
dose	O
requirement	O
of	O
digoxin	B
.	O

Concomitant	O
use	O
of	O
digoxin	B
and	O
sympathomimetics	B
increases	O
the	O
risk	O
of	O
cardiac	O
arrhythmias	O
.	O

Although	O
beta	O
-	O
adrenergic	O
blockers	B
or	O
calcium	B
channel	I
blockers	I
and	O
digoxin	B
may	O
be	O
useful	O
in	O
combination	O
to	O
control	O
atrial	O
fibrillation	O
,	O
their	O
additive	O
effects	O
on	O
AV	O
node	O
conduction	O
can	O
result	O
in	O
advanced	O
or	O
complete	O
heart	O
block	O
.	O

Furthermore	O
,	O
caution	O
should	O
be	O
exercised	O
when	O
combining	O
digoxin	B
with	O
any	O
drug	O
that	O
may	O
cause	O
a	O
significant	O
deterioration	O
in	O
renal	O
function	O
,	O
since	O
a	O
decline	O
in	O
glomerular	O
filtration	O
or	O
tubular	O
secretion	O
may	O
impair	O
the	O
excretion	O
of	O
digoxin	B
.	O

Vasoconstrictors	B
:	O
D	O
.	O
H	O
.	O
E	O
.	O
45	B
(	O
dihydroergotamine	B
mesylate	I
)	O
Injection	O
,	O
USP	O
should	O
not	O
be	O
used	O
with	O
peripheral	B
vasoconstrictors	I
because	O
the	O
combination	O
may	O
cause	O
synergistic	O
elevation	O
of	O
blood	O
pressure	O
.	O

Sumatriptan	B
:	O
Sumatriptan	B
has	O
been	O
reported	O
to	O
cause	O
coronary	O
artery	O
vasospasm	O
,	O
and	O
its	O
effect	O
could	O
be	O
additive	O
with	O
D	O
.	O
H	O
.	O
E	O
.	O
45	B
(	O
dihydroergotamine	B
mesylate	I
)	O
Injection	O
,	O
USP	O
.	O

Sumatriptan	B
and	O
D	O
.	O
H	O
.	O
E	O
.	O
45	B
(	O
dihydroergotamine	B
mesylate	I
)	O
Injection	O
,	O
USP	O
should	O
not	O
be	O
taken	O
within	O
24	O
hours	O
of	O
each	O
other	O
.	O
.	O

Beta	B
Blockers	I
:	O
Although	O
the	O
results	O
of	O
a	O
clinical	O
study	O
did	O
not	O
indicate	O
a	O
safe	O
problem	O
associated	O
with	O
the	O
administration	O
of	O
D	O
.	O
H	O
.	O
E	O
.	O
45	B
(	O
dihydroergotamine	B
mesylate	I
)	O
Injection	O
,	O
USP	O
to	O
subjects	O
already	O
receiving	O
propranolol	B
,	O
there	O
have	O
been	O
reports	O
that	O
propranolol	B
may	O
potentiate	O
the	O
vasoconstrictive	O
action	O
of	O
ergotamine	B
by	O
blocking	O
the	O
vasodilating	O
property	O
of	O
epinephrine	O
.	O

Nicotine	B
:	O
Nicotine	B
may	O
provoke	O
vasoconstriction	O
in	O
some	O
patients	O
,	O
predisposing	O
to	O
a	O
greater	O
ischemic	O
response	O
to	O
ergot	B
therapy	O
.	O

Macrolide	B
Antibiotics	I
(	O
e	O
.	O
g	O
.	O
erythromycin	B
and	O
troleandomycin	B
)	O
:	O
Agents	O
of	O
the	O
ergot	B
alkaloid	I
class	I
,	O
of	O
which	O
D	O
.	O
H	O
.	O
E	O
.	O
45	B
(	O
dihydroergotamine	B
mesylate	I
)	O
Injection	O
,	O
USP	O
is	O
a	O
member	O
,	O
have	O
been	O
shown	O
to	O
interact	O
with	O
antibiotics	B
of	O
the	O
macrolide	B
class	I
,	O
resulting	O
in	O
increased	O
plasma	O
levels	O
of	O
unchanged	O
alkaloids	O
and	O
peripheral	O
vasoconstriction	O
.	O

Vasospastic	O
reactions	O
have	O
been	O
reported	O
with	O
therapeutic	O
doses	O
of	O
ergotamine	B
-	O
containing	O
drugs	O
when	O
co	O
-	O
administered	O
with	O
these	O
antibiotics	B
.	O

SSRIs	B
:	O
Weakness	O
hyperreflexia	O
,	O
and	O
incoordination	O
have	O
been	O
reported	O
rarely	O
when	O
5	O
-	O
HT1	O
agonists	B
have	O
been	O
co	O
-	O
administered	O
with	O
SSRIs	B
(	O
e	O
.	O
g	O
.	O

fluoxetine	B
,	O
fluvoxamine	B
,	O
paroxetine	B
,	O
sertraline	B
)	O
.	O

There	O
have	O
been	O
no	O
reported	O
cases	O
from	O
spontaneous	O
reports	O
of	O
drug	O
interaction	O
between	O
SSRIs	B
and	O
D	O
.	O
H	O
.	O
E	O
.	O
45	B
(	O
dihydroergotamine	B
mesylate	I
)	O
Injection	O
,	O
USP	O
.	O

Oral	O
Contraceptives	B
:	O
The	O
effect	O
of	O
oral	O
contraceptives	B
on	O
the	O
pharmacokinetics	O
of	O
D	O
.	O
H	O
.	O
E	O
.	O
45	B
(	O
dihydroergotamine	B
mesylate	I
)	O
Injection	O
,	O
USP	O
has	O
not	O
been	O
studied	O
.	O

Administration	O
of	O
thiazide	B
diuretics	I
to	O
hypoparathyroid	O
patients	O
who	O
are	O
concurrently	O
being	O
treated	O
with	O
dihydrotachysterol	B
may	O
cause	O
hypercalcemia	O
.	O

Pharmacologic	O
studies	O
indicate	O
that	O
there	O
may	O
be	O
additive	O
effects	O
in	O
prolonging	O
AV	O
conduction	O
when	O
using	O
beta	O
-	O
blockers	O
or	O
digitalis	B
concomitantly	O
with	O
Tiazac	B
.	O

Controlled	O
and	O
uncontrolled	O
domestic	O
studies	O
suggest	O
that	O
concomitant	O
use	O
of	O
diltiazem	B
hydrochloride	I
and	O
beta	O
-	O
blockers	O
is	O
usually	O
well	O
tolerated	O
,	O
but	O
available	O
data	O
are	O
not	O
sufficient	O
to	O
predict	O
the	O
effects	O
of	O
concomitant	O
treatment	O
in	O
patients	O
with	O
left	O
ventricular	O
dysfunction	O
or	O
cardiac	O
conduction	O
abnormalities	O
.	O

Administration	O
of	O
diltiazem	B
hydrochloride	I
concomitantly	O
with	O
propranolol	B
in	O
five	O
normal	O
volunteers	O
resulted	O
in	O
increased	O
propranolol	B
levels	O
in	O
all	O
subjects	O
and	O
bioavailability	O
of	O
propranolol	B
was	O
increased	O
approximately	O
50	O
%	O
.	O

In	O
vitro	O
,	O
propranolol	B
appears	O
to	O
be	O
displaced	O
from	O
its	O
binding	O
sites	O
by	O
diltiazem	B
.	O

If	O
combination	O
therapy	O
is	O
initiated	O
or	O
withdrawn	O
in	O
conjunction	O
with	O
propranolol	B
,	O
an	O
adjustment	O
in	O
the	O
propranolol	B
dose	O
may	O
be	O
warranted	O
.	O

A	O
study	O
in	O
six	O
healthy	O
volunteers	O
has	O
shown	O
a	O
significant	O
increase	O
in	O
peak	O
diltiazem	B
plasma	O
levels	O
(	O
58	O
%	O
)	O
and	O
AUC	O
(	O
53	O
%	O
)	O
after	O
a	O
1	O
-	O
week	O
course	O
of	O
cimetidine	B
1200	O
mg	O
/	O
day	O
and	O
a	O
single	O
dose	O
of	O
diltiazem	B
60mg	O
.	O

The	O
effect	O
may	O
be	O
mediated	O
by	O
cimetidines	O
known	O
inhibition	O
of	O
hepatic	O
cytochrome	O
P	O
-	O
450	O
,	O
the	O
enzyme	O
system	O
responsible	O
for	O
the	O
first	O
-	O
pass	O
metabolism	O
of	O
diltiazem	B
.	O

Patients	O
currently	O
receiving	O
diltiazem	B
therapy	O
should	O
be	O
carefully	O
monitored	O
for	O
a	O
change	O
in	O
pharmacological	O
effect	O
when	O
initiating	O
and	O
discontinuing	O
therapy	O
with	O
cimetidine	B
.	O

Administration	O
of	O
diltiazem	B
hydrochloride	I
with	O
digoxin	B
in	O
24	O
healthy	O
male	O
subjects	O
increased	O
plasma	O
digoxin	B
concentrations	O
approximately	O
20	O
%	O
.	O

Since	O
there	O
have	O
been	O
conflicting	O
results	O
regarding	O
the	O
effect	O
of	O
digoxin	B
levels	O
,	O
it	O
is	O
recommended	O
that	O
digoxin	B
levels	O
be	O
monitored	O
when	O
initiating	O
,	O
adjusting	O
,	O
and	O
discontinuing	O
diltiazem	B
hydrochloride	I
therapy	O
to	O
avoid	O
possible	O
over	O
-	O
or	O
under	O
-	O
digitalization	O
.	O

The	O
depression	O
of	O
cardiac	O
contractility	O
,	O
conductivity	O
,	O
and	O
automaticity	O
as	O
well	O
as	O
the	O
vascular	O
dilation	O
associated	O
with	O
anesthetics	B
may	O
be	O
potentiated	O
by	O
calcium	B
channel	I
blockers	I
.	O

When	O
used	O
concomitantly	O
,	O
anesthetics	B
and	O
calcium	B
channel	I
blockers	I
should	O
be	O
titrated	O
carefully	O
.	O

A	O
pharmacokinetic	O
interaction	O
between	O
diltiazem	B
and	O
cyclosporine	B
has	O
been	O
observed	O
during	O
studies	O
involving	O
renal	O
and	O
cardiac	O
transplant	O
patients	O
.	O

In	O
renal	O
and	O
cardiac	O
transplant	O
recipients	O
,	O
a	O
reduction	O
of	O
cyclosporine	B
dose	O
ranging	O
from	O
15	O
%	O
to	O
48	O
%	O
was	O
necessary	O
to	O
maintain	O
cyclosporine	B
trough	O
concentrations	O
similar	O
to	O
those	O
seen	O
prior	O
to	O
the	O
addition	O
of	O
diltiazem	B
.	O

If	O
these	O
agents	O
are	O
to	O
be	O
administered	O
concurrently	O
,	O
cyclosporine	B
concentrations	O
should	O
be	O
monitored	O
,	O
especially	O
when	O
diltiazem	B
therapy	O
is	O
initiated	O
,	O
adjusted	O
,	O
or	O
discontinued	O
.	O

The	O
effect	O
of	O
cyclosporine	B
on	O
diltiazem	B
plasma	O
concentrations	O
has	O
not	O
been	O
evaluated	O
.	O

Concomitant	O
administration	O
of	O
diltiazem	B
with	O
carbamazepine	B
has	O
been	O
reported	O
to	O
result	O
in	O
elevated	O
serum	O
levels	O
of	O
carbamazepine	B
(	O
40	O
%	O
to	O
72	O
%	O
increase	O
)	O
,	O
resulting	O
in	O
toxicity	O
in	O
some	O
cases	O
.	O

Studies	O
showed	O
that	O
diltiazem	B
increased	O
the	O
AUC	O
of	O
midazolam	B
and	O
triazolam	B
by	O
3	O
-	O
4	O
fold	O
and	O
the	O
Cmax	O
by	O
2	O
-	O
fold	O
,	O
compared	O
to	O
placebo	O
.	O

The	O
elimination	O
half	O
life	O
of	O
midazolam	B
and	O
triazolam	B
also	O
increased	O
(	O
1	O
.	O
5	O
-	O
2	O
.	O
5	O
fold	O
)	O
during	O
coadministration	O
with	O
diltiazem	B
.	O

These	O
pharmacokinetic	O
effects	O
seen	O
during	O
diltiazem	B
coadministration	O
can	O
result	O
in	O
increased	O
clinical	O
effects	O
(	O
e	O
.	O
g	O
.	O
,	O
prolonged	O
sodation	O
)	O
of	O
both	O
midazolam	B
and	O
triazolam	B
.	O

In	O
a	O
ten	O
-	O
subject	O
study	O
,	O
coadministration	O
of	O
diltiazem	B
(	O
120	O
mg	O
bid	O
)	O
with	O
lovastatin	B
resulted	O
in	O
a	O
3	O
-	O
4	O
times	O
increase	O
in	O
mean	O
lovastatin	B
AUC	O
and	O
Cmax	O
vs	O
.	O
lovastatin	B
alone	O
;	O

no	O
change	O
in	O
pravastatin	B
AUC	O
and	O
Cmax	O
was	O
observed	O
during	O
diltiazem	B
coadministration	O
.	O

Diltiazem	B
plasma	O
levels	O
were	O
not	O
significantly	O
affected	O
by	O
lovastatin	B
or	O
pravastatin	B
.	O

Coadministration	O
of	O
rifampin	B
with	O
diltiazem	B
lowered	O
the	O
diltiazem	B
plasma	O
concentrations	O
to	O
undetectable	O
levels	O
.	O

Coadministration	O
of	O
diltiazem	B
with	O
rifampin	B
or	O
any	O
known	O
CYP3A4	O
inducer	O
should	O
be	O
avoided	O
when	O
possible	O
,	O
and	O
alternative	O
therapy	O
considered	O
.	O

Dimenhydrinate	B
may	O
decrease	O
emetic	B
response	O
to	O
apomorphine	B
.	O

Oxytocin	B
or	O
other	O
oxytocics	B
(	O
concurrent	O
use	O
with	O
dinoprost	B
may	O
result	O
in	O
uterine	O
hypertonus	O
,	O
possibly	O
causing	O
uterine	O
rupture	O
or	O
cervical	O
laceration	O
,	O
especially	O
in	O
the	O
absence	O
of	O
adequate	O
cervical	O
dilatation	O
;	O

PROSTIN	B
E2	I
may	O
augment	O
the	O
activity	O
of	O
other	O
oxytocic	B
drugs	I
.	O

Diphenhydramine	B
hydrochloride	I
has	O
additive	O
effects	O
with	O
alcohol	B
and	O
other	O
CNS	B
depressants	I
(	O
hypnotics	B
,	O
sedatives	B
,	O
tranquilizers	B
,	O
etc	O
)	O
.	O

MAO	B
inhibitors	I
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
(	O
drying	O
)	O
effects	O
of	O
antihistamines	B
.	O

anticholinergics	B
or	O
other	O
medications	O
with	O
anticholinergic	O
activity	O
-	O
anticholinergic	O
effects	O
may	O
be	O
potentiated	O
when	O
these	O
medications	O
are	O
used	O
concurrently	O
with	O
diphenidol	B
;	O

apomorphine	B
-	O
prior	O
ingestion	O
of	O
diphenidol	B
may	O
decrease	O
the	O
emetic	B
response	O
to	O
apomorphine	B
in	O
the	O
treatment	O
of	O
poisoning	O
.	O

Known	O
drug	O
interactions	O
include	O
barbiturates	B
,	O
tranquilizers	B
,	O
and	O
alcohol	B
.	O

Diphenoxylate	B
HCl	I
and	O
atropine	B
sulfate	I
may	O
interact	O
with	O
MAO	B
inhibitors	I
In	O
studies	O
with	O
male	O
rats	O
,	O
diphenoxylate	B
hydrochloride	I
was	O
found	O
to	O
inhibit	O
the	O
hepatic	O
microsomal	O
enzyme	O
system	O
at	O
a	O
dose	O
of	O
2	O
mg	O
/	O
kg	O
/	O
day	O
.	O

This	O
drug	O
may	O
interact	O
with	O
alcohol	B
or	O
other	O
CNS	B
depressants	I
(	O
may	O
potentiate	O
the	O
CNS	B
depressant	O
effects	O
of	O
either	O
these	O
medications	O
or	O
antihistamines	B
)	O
,	O
anticholinergics	B
or	O
other	O
medications	O
with	O
anticholinergic	O
activity	O
(	O
anticholinergic	O
effects	O
may	O
be	O
potentiated	O
when	O
these	O
medications	O
are	O
used	O
concurrently	O
with	O
antihistamines	B
)	O
,	O
and	O
monoamine	B
oxidase	I
(	O
MAO	O
)	O
inhibitors	B
(	O
concurrent	O
use	O
with	O
antihistamines	B
may	O
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
and	O
CNS	B
depressant	O
effects	O
of	O
antihistamines	B
)	O
.	O

No	O
pharmacokinetic	O
drug	O
-	O
drug	O
interaction	O
studies	O
were	O
conducted	O
with	O
PERSANTINE	B
(	O
dipyridamole	B
USP	O
)	O
Tablets	O
.	O

Adenosine	B
:	O
Dipyridamole	B
has	O
been	O
reported	O
to	O
increase	O
the	O
plasma	O
levels	O
and	O
cardiovascular	O
effects	O
of	O
adenosine	B
.	O

Cholinesterase	B
Inhibitors	I
:	O
Dipyridamole	B
may	O
counteract	O
the	O
anticholinesterase	O
effect	O
of	O
cholinesterase	B
inhibitors	I
,	O
thereby	O
potentially	O
aggravating	O
myasthenia	O
gravis	O
.	O

Terfenadine	B
:	O
In	O
a	O
prospective	O
study	O
involving	O
six	O
-	O
healthy	O
-	O
male	O
volunteers	O
,	O
dirithromycin	B
did	O
not	O
affect	O
the	O
metabolism	O
of	O
terfenadine	B
.	O

These	O
six	O
volunteers	O
received	O
terfenadine	B
alone	O
(	O
60	O
mg	O
twice	O
daily	O
)	O
for	O
8	O
days	O
,	O
followed	O
by	O
terfenadine	B
in	O
combination	O
with	O
dirithromycin	B
(	O
500	O
mg	O
once	O
daily	O
)	O
for	O
10	O
days	O
.	O

The	O
pharmacokinetics	O
of	O
terfenadine	B
and	O
its	O
acid	O
metabolite	O
and	O
the	O
electrocardiographic	O
QT	O
c	O
interval	O
were	O
measured	O
during	O
both	O
periods	O
:	O
with	O
terfenadine	B
alone	O
,	O
and	O
with	O
terfenadine	B
plus	O
dirithromycin	B
.	O

in	O
one	O
man	O
,	O
the	O
C	O
max	O
of	O
terfenadine	B
was	O
8	O
.	O
1	O
ng	O
/	O
mL	O
with	O
terfenadine	B
alone	O
and	O
7	O
.	O
2	O
ng	O
/	O
mL	O
with	O
terfenadine	B
plus	O
dirithromycin	B
.	O

The	O
mean	O
QT	O
c	O
interval	O
(	O
msec	O
)	O
was	O
369	O
with	O
terfenadine	B
alone	O
and	O
367	O
with	O
terfenadine	B
plus	O
dirithromycin	B
.	O

Also	O
,	O
in	O
vitro	O
experiments	O
demonstrated	O
a	O
lack	O
of	O
interaction	O
between	O
dirithromycin	B
and	O
terfenadine	B
.	O

Thus	O
,	O
the	O
interaction	O
observed	O
between	O
erythromycin	B
and	O
terfenadine	B
is	O
not	O
expected	O
for	O
dirithromycin	B
.	O

Serious	O
cardiac	O
dysrhythmias	O
,	O
some	O
resulting	O
in	O
death	O
,	O
have	O
occurred	O
in	O
patients	O
receiving	O
terfenadine	B
concomitantly	O
with	O
other	O
macrolide	B
antibiotics	I
.	O

In	O
addition	O
,	O
most	O
macrolides	B
are	O
contraindicated	O
in	O
patients	O
receiving	O
terfenadine	B
therapy	O
who	O
have	O
pre	O
-	O
existing	O
cardiac	O
abnormalities	O
(	O
arrhythmia	O
,	O
bradycardia	O
,	O
QT	O
c	O
interval	O
prolongation	O
,	O
ischemic	O
heart	O
disease	O
,	O
congestive	O
heart	O
failure	O
,	O
etc	O
.	O
)	O
or	O
electrolyte	O
disturbances	O
.	O

Theophylline	B
:	O
Following	O
co	O
-	O
administration	O
of	O
two	O
250	O
-	O
mg	O
dirithromycin	B
tablets	O
administered	O
once	O
daily	O
with	O
200	O
-	O
mg	O
theophylline	B
tablets	O
administered	O
twice	O
daily	O
for	O
10	O
days	O
to	O
14	O
healthy	O
subjects	O
,	O
the	O
steady	O
-	O
state	O
plasma	O
concentration	O
of	O
theophylline	B
was	O
not	O
significantly	O
altered	O
.	O

In	O
general	O
,	O
most	O
patients	O
treated	O
with	O
dirithromycin	B
who	O
are	O
receiving	O
concomitant	O
theophylline	B
therapy	O
may	O
not	O
require	O
empiric	O
adjustment	O
of	O
theophylline	B
dosage	O
or	O
monitoring	O
of	O
theophylline	B
plasma	O
concentrations	O
.	O

However	O
,	O
theophylline	B
plasma	O
concentrations	O
should	O
be	O
monitored	O
,	O
with	O
dosage	O
adjustment	O
as	O
appropriate	O
,	O
in	O
patients	O
whose	O
pulmonary	O
disease	O
requires	O
maintaining	O
a	O
given	O
theophylline	B
plasma	O
concentration	O
for	O
optimal	O
pulmonary	O
function	O
or	O
in	O
patients	O
with	O
theophylline	B
concentrations	O
at	O
the	O
higher	O
end	O
of	O
the	O
therapeutic	O
range	O
.	O

Antacids	B
or	O
H	B
2	I
receptor	I
antagonists	I
:	O
When	O
dirithromycin	B
is	O
administered	O
immediately	O
following	O
antacids	B
or	O
H	B
2	I
-	O
receptor	B
antagonists	I
,	O
the	O
absorption	O
of	O
dirithromycin	B
is	O
slightly	O
enhanced	O
.	O

Triazolam	B
:	O
Erythromycin	B
has	O
been	O
reported	O
to	O
decrease	O
the	O
clearance	O
of	O
triazolam	B
and	O
,	O
thus	O
,	O
may	O
increase	O
the	O
pharmacologic	O
effect	O
of	O
triazolam	B
.	O

Digoxin	B
:	O
Concomitant	O
administration	O
of	O
erythromycin	B
and	O
digoxin	B
has	O
been	O
reported	O
to	O
result	O
in	O
elevated	O
digoxin	B
serum	O
levels	O
.	O

Anticoagulants	B
:	O
There	O
have	O
been	O
reports	O
of	O
increased	O
anticoagulant	O
effects	O
when	O
erythromycin	B
and	O
oral	O
anticoagulants	B
were	O
used	O
concomitantly	O
.	O

Ergotamine	B
:	O
Concurrent	O
use	O
of	O
erythromycin	B
and	O
ergotamine	B
or	O
dihydroergotamine	B
has	O
been	O
associated	O
in	O
some	O
patients	O
with	O
acute	O
ergot	O
toxicity	O
characterized	O
by	O
severe	O
peripheral	O
vasospasm	O
and	O
dysesthesia	O
.	O

Other	O
drugs	O
Drug	O
interactions	O
have	O
been	O
reported	O
with	O
concomitant	O
administration	O
of	O
erythromycin	B
and	O
other	O
medications	O
,	O
including	O
cyclosporine	B
,	O
hexobarbital	B
,	O
carbamazepine	B
,	O
alfentanil	B
,	O
disopyramide	B
,	O
phenytoin	B
,	O
bromocriptine	B
,	O
valproate	B
,	O
astemizole	B
,	O
and	O
lovastatin	B
.	O

If	O
phenytoin	B
or	O
other	O
hepatic	O
enzyme	O
inducers	O
are	O
taken	O
concurrently	O
with	O
Norpace	B
or	O
Norpace	B
CR	I
,	O
lower	O
plasma	O
levels	O
of	O
disopyramide	B
may	O
occur	O
.	O

Other	O
antiarrhythmic	B
drugs	I
(	O
eg	O
,	O
quinidine	B
,	O
procainamide	B
,	O
lidocaine	B
,	O
propranolol	B
)	O
have	O
occasionally	O
been	O
used	O
concurrently	O
with	O
Norpace	B
.	O

In	O
healthy	O
subjects	O
,	O
no	O
significant	O
drug	O
-	O
drug	O
interaction	O
was	O
observed	O
when	O
Norpace	B
was	O
coadministered	O
with	O
either	O
propranolol	B
or	O
diazepam	B
.	O

Concomitant	O
administration	O
of	O
Norpace	B
and	O
quinidine	B
resulted	O
in	O
slight	O
increases	O
in	O
plasma	O
disopyramide	B
levels	O
and	O
slight	O
decreases	O
in	O
plasma	O
quinidine	B
levels	O
.	O

Norpace	B
does	O
not	O
increase	O
serum	O
digoxin	B
levels	O
.	O

Patients	O
taking	O
disopyramide	B
phosphate	I
and	O
erythromycin	B
concomitantly	O
may	O
develop	O
increased	O
serum	O
concentrations	O
of	O
disopyramide	B
resulting	O
in	O
excessive	O
widening	O
of	O
the	O
QRS	O
complex	O
and	O
/	O
or	O
prolongation	O
of	O
the	O
Q	O
-	O
T	O
interval	O
.	O

Until	O
data	O
on	O
possible	O
interactions	O
between	O
verapamil	B
and	O
disopyramide	B
phosphate	I
are	O
obtained	O
,	O
disopyramide	B
should	O
not	O
be	O
administered	O
within	O
48	O
hours	O
before	O
or	O
24	O
hours	O
after	O
verapamil	B
administration	O
.	O

DISULFIRAM	B
SHOULD	O
BE	O
USED	O
WITH	O
CAUTION	O
IN	O
THOSE	O
PATIENTS	O
REVEIVING	O
PHENYTOIN	B
AND	O
ITS	O
CONGENERS	O
.	O

SINCE	O
THE	O
CONCOMITANT	O
ADMINISTRATION	O
OF	O
THESE	O
TWO	O
DRUGS	O
CAN	O
LEAD	O
TO	O
PHENYTOIN	B
INTOXICATION	O
,	O
PRIOR	O
TO	O
ADMINISTERING	O
DISULFIRAM	B
TO	O
A	O
PATIENT	O
ON	O
PHENYTOIN	B
THERAPY	O
,	O
A	O
BASELINE	O
PHENYTOIN	B
SERUM	O
LEVEL	O
SHOULD	O
BE	O
OBTAINED	O
.	O

It	O
may	O
be	O
necessary	O
to	O
adjust	O
the	O
dosage	O
of	O
oral	O
anticoagulants	B
upon	O
beginning	O
or	O
stopping	O
disulfiram	B
.	O
since	O
disulfiram	B
may	O
prolong	O
prothrombin	O
time	O
.	O

Patients	O
taking	O
isoniazid	B
when	O
disulfiram	B
is	O
given	O
should	O
be	O
observed	O
for	O
the	O
appearance	O
of	O
unsteady	O
gait	O
or	O
marked	O
changes	O
in	O
mental	O
status	O
;	O

In	O
rats	O
,	O
simultaneous	O
ingestion	O
of	O
disulfiram	B
and	O
nitrite	B
in	O
the	O
diet	O
for	O
78	O
weeks	O
has	O
been	O
reported	O
to	O
cause	O
tumors	O
,	O
and	O
it	O
has	O
been	O
suggested	O
that	O
disulfiram	B
may	O
react	O
with	O
nitrites	B
in	O
the	O
rat	O
stomach	O
to	O
form	O
a	O
nitrosamine	O
,	O
which	O
is	O
tumorigenic	O
.	O

Animal	O
studies	O
indicate	O
that	O
dobutamine	B
may	O
be	O
ineffective	O
if	O
the	O
patient	O
has	O
recently	O
received	O
a	O
b	O
-	O
blocking	O
drug	B
.	O

Preliminary	O
studies	O
indicate	O
that	O
the	O
concomitant	O
use	O
of	O
dobutamine	B
and	O
nitroprusside	B
results	O
in	O
a	O
higher	O
cardiac	O
output	O
and	O
,	O
usually	O
,	O
a	O
lower	O
pulmonary	O
wedge	O
pressure	O
than	O
when	O
either	O
drug	O
is	O
used	O
alone	O
.	O

There	O
was	O
no	O
evidence	O
of	O
drug	O
interactions	O
in	O
clinical	O
studies	O
in	O
which	O
dobutamine	B
was	O
administered	O
concurrently	O
with	O
other	O
drugs	O
,	O
including	O
digitalis	B
preparations	I
,	O
furosemide	B
,	O
spironolactone	B
,	O
lidocaine	B
,	O
glyceryl	B
trinitrate	I
,	O
isosorbide	B
dinitrate	I
,	O
morphine	B
,	O
atropine	B
,	O
heparin	B
,	O
protamine	B
,	O
potassium	B
chloride	I
,	O
folic	B
acid	I
,	O
and	O
acetaminophen	B
.	O

In	O
vitro	O
studies	O
have	O
shown	O
that	O
the	O
metabolism	O
of	O
docetaxel	B
may	O
be	O
modified	O
by	O
the	O
concomitant	O
administration	O
of	O
compounds	O
that	O
induce	O
,	O
inhibit	O
,	O
or	O
are	O
metabolized	O
by	O
cytochrome	O
P450	O
3A4	O
,	O
such	O
as	O
cyclosporine	B
,	O
terfenadine	B
,	O
ketoconazole	B
,	O
erythromycin	B
,	O
and	O
troleandomycin	B
.	O

Drug	O
-	O
Drug	O
Interactions	O
Cimetidine	B
:	O
Concomitant	O
use	O
of	O
cimetidine	B
is	O
contraindicated	O
.	O

Cimetidine	B
at	O
400	O
mg	O
BID	O
(	O
the	O
usual	O
prescription	O
dose	O
)	O
co	O
-	O
administered	O
with	O
TIKOSYN	B
(	O
500	O
mcg	O
BID	O
)	O
for	O
7	O
days	O
has	O
been	O
shown	O
to	O
increase	O
dofetilide	B
plasma	O
levels	O
by	O
58	O
%	O
.	O

Cimetidine	B
at	O
doses	O
of	O
100	O
mg	O
BID	O
(	O
OTC	O
dose	O
)	O
resulted	O
in	O
a	O
13	O
%	O
increase	O
in	O
dofetilide	B
plasma	O
levels	O
(	O
500	O
mcg	O
single	O
dose	O
)	O
.	O

If	O
a	O
patient	O
requires	O
TIKOSYN	B
and	O
anti	O
-	O
ulcer	O
therapy	O
,	O
it	O
is	O
suggested	O
that	O
omeprazole	B
,	O
ranitidine	B
,	O
or	O
antacids	B
(	O
aluminum	B
and	O
magnesium	B
hydroxides	O
)	O
be	O
used	O
as	O
alternatives	O
to	O
cimetidine	B
,	O
as	O
these	O
agents	O
have	O
no	O
effect	O
on	O
the	O
pharmacokinetic	O
profile	O
of	O
TIKOSYN	B
.	O

Verapamil	B
:	O
Concomitant	O
use	O
of	O
verapamil	B
is	O
contraindicated	O
.	O

Co	O
-	O
administration	O
of	O
TIKOSYN	B
with	O
verapamil	B
resulted	O
in	O
increases	O
in	O
dofetilide	B
peak	O
plasma	O
levels	O
of	O
42	O
%	O
,	O
although	O
overall	O
exposure	O
to	O
dofetilide	B
was	O
not	O
significantly	O
increased	O
.	O

In	O
an	O
analysis	O
of	O
the	O
supraventricular	O
arrhythmia	O
and	O
DIAMOND	O
patient	O
populations	O
,	O
the	O
concomitant	O
administration	O
of	O
verapamil	B
with	O
dofetilide	B
was	O
associated	O
with	O
a	O
higher	O
occurrence	O
of	O
torsade	O
de	O
pointes	O
.	O

Ketoconazole	B
:	O
Concomitant	O
use	O
of	O
ketoconazole	B
is	O
contraindicated	O
.	O

Ketoconazole	B
at	O
400	O
mg	O
daily	O
(	O
the	O
maximum	O
approved	O
prescription	O
dose	O
)	O
co	O
-	O
administered	O
with	O
TIKOSYN	B
(	O
500	O
mcg	O
BID	O
)	O
for	O
7	O
days	O
has	O
been	O
shown	O
to	O
increase	O
dofetilide	B
Cmax	O
by	O
53	O
%	O
in	O
males	O
and	O
97	O
%	O
in	O
females	O
,	O
and	O
AUC	O
by	O
41	O
%	O
in	O
males	O
and	O
69	O
%	O
in	O
females	O
.	O

Trimethoprim	B
Alone	O
or	O
in	O
Combination	O
with	O
Sulfamethoxazole	B
:	O
Concomitant	O
use	O
of	O
trimethoprim	B
alone	O
or	O
in	O
combination	O
with	O
sulfamethoxazole	B
is	O
contraindicated	O
.	O

Hydrochlorothiazide	B
(	O
HCTZ	B
)	O
Alone	O
or	O
in	O
Combination	O
with	O
Triamterene	B
:	O
Concomitant	O
use	O
of	O
HCTZ	B
alone	O
or	O
in	O
combination	O
with	O
triamterene	B
is	O
contraindicated	O
.	O

HCTZ	B
50	O
mg	O
QD	O
or	O
HCTZ	B
/	O
triamterene	B
50	O
/	O
100	O
mg	O
QD	O
was	O
co	O
-	O
administered	O
with	O
TIKOSYN	B
(	O
500	O
mcg	O
BID	O
)	O
for	O
5	O
days	O
(	O
following	O
2	O
days	O
of	O
diuretic	B
use	O
at	O
half	O
dose	O
)	O
.	O

In	O
patients	O
receiving	O
HCTZ	B
alone	O
,	O
dofetilide	B
AUC	O
increased	O
by	O
27	O
%	O
and	O
Cmax	O
by	O
21	O
%	O
.	O

In	O
the	O
DIAMOND	O
trials	O
,	O
1252	O
patients	O
were	O
treated	O
with	O
TIKOSYN	B
and	O
diuretics	B
concomitantly	O
of	O
whom	O
493	O
died	O
compared	O
to	O
508	O
deaths	O
among	O
the	O
1248	O
patients	O
receiving	O
placebo	O
and	O
diuretics	B
.	O

Of	O
the	O
229	O
patients	O
who	O
had	O
potassium	B
depleting	I
diuretics	I
added	O
to	O
their	O
concomitant	O
medications	O
in	O
the	O
DIAMOND	O
trials	O
,	O
the	O
patients	O
on	O
TIKOSYN	B
had	O
a	O
non	O
-	O
significantly	O
reduced	O
relative	O
risk	O
for	O
death	O
of	O
0	O
.	O
68	O
(	O
95	O
%	O
CI	O
0	O
.	O
376	O
,	O
1	O
.	O
230	O
)	O
.	O

In	O
addition	O
,	O
drugs	O
that	O
are	O
actively	O
secreted	O
via	O
this	O
route	O
(	O
e	O
.	O
g	O
.	O
,	O
triamterene	B
,	O
metformin	B
and	O
amiloride	B
)	O
should	O
be	O
co	O
-	O
administered	O
with	O
care	O
as	O
they	O
might	O
increase	O
dofetilide	B
levels	O
.	O

Inhibitors	O
of	O
this	O
isoenzyme	O
(	O
e	O
.	O
g	O
.	O
,	O
macrolide	B
antibiotics	I
,	O
azole	B
antifungal	I
agents	I
,	O
protease	B
inhibitors	I
,	O
serotonin	B
reuptake	I
inhibitors	I
,	O
amiodarone	B
,	O
cannabinoids	B
,	O
diltiazem	B
,	O
grapefruit	O
juice	O
,	O
nefazadone	B
,	O
norfloxacin	B
,	O
quinine	B
,	O
zafirlukast	B
)	O
should	O
be	O
cautiously	O
coadministered	O
with	O
TIKOSYN	B
as	O
they	O
can	O
potentially	O
increase	O
dofetilide	B
levels	O
.	O

Other	O
Drug	O
Interaction	O
Information	O
Digoxin	B
:	O
Studies	O
in	O
healthy	O
volunteers	O
have	O
shown	O
that	O
TIKOSYN	B
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
digoxin	B
.	O

In	O
patients	O
,	O
the	O
concomitant	O
administration	O
of	O
digoxin	B
with	O
dofetilide	B
was	O
associated	O
with	O
a	O
higher	O
occurrence	O
of	O
torsade	O
de	O
pointes	O
.	O

It	O
is	O
not	O
clear	O
whether	O
this	O
represents	O
an	O
interaction	O
with	O
TIKOSYN	B
or	O
the	O
presence	O
of	O
more	O
severe	O
structural	O
heart	O
disease	O
in	O
patients	O
on	O
digoxin	B
;	O

Other	O
Drugs	O
:	O
In	O
healthy	O
volunteers	O
,	O
amlodipine	B
,	O
phenytoin	B
,	O
glyburide	B
,	O
ranitidine	B
,	O
omeprazole	B
,	O
hormone	O
replacement	O
therapy	O
(	O
a	O
combination	O
of	O
conjugated	O
estrogens	B
and	O
medroxyprogesterone	B
)	O
,	O
antacid	B
(	O
aluminum	B
and	O
magnesium	B
hydroxides	O
)	O
and	O
theophylline	B
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
TIKOSYN	B
.	O

In	O
addition	O
,	O
studies	O
in	O
healthy	O
volunteers	O
have	O
shown	O
that	O
TIKOSYN	B
does	O
not	O
affect	O
the	O
pharmacokinetics	O
or	O
pharmacodynamics	O
of	O
warfarin	B
,	O
or	O
the	O
pharmacokinetics	O
of	O
propranolol	B
(	O
40	O
mg	O
twice	O
daily	O
)	O
,	O
phenytoin	B
,	O
theophylline	B
,	O
or	O
oral	O
contraceptives	B
.	O

Concomitant	O
medications	O
were	O
grouped	O
as	O
ACE	B
inhibitors	I
,	O
oral	O
anticoagulants	B
,	O
calcium	B
channel	I
blockers	I
,	O
beta	B
blockers	I
,	O
cardiac	B
glycosides	I
,	O
inducers	O
of	O
CYP3A4	O
,	O
substrates	O
and	O
inhibitors	B
of	O
CYP3A4	O
,	O
substrates	O
and	O
inhibitors	B
of	O
P	O
-	O
glycoprotein	O
,	O
nitrates	B
,	O
sulphonylureas	B
,	O
loop	B
diuretics	I
,	O
potassium	B
sparing	I
diuretics	I
,	O
thiazide	B
diuretics	I
,	O
substrates	O
and	O
inhibitors	B
of	O
tubular	O
organic	O
cation	O
transport	O
,	O
and	O
QTc	O
-	O
prolonging	O
drugs	O
.	O

The	O
mean	O
clearances	O
of	O
dofetilide	B
were	O
16	O
%	O
and	O
15	O
%	O
lower	O
in	O
patients	O
on	O
thiazide	B
diuretics	I
and	O
inhibitors	O
of	O
tubular	O
organic	O
cation	O
transport	O
,	O
respectively	O
.	O

The	O
potential	O
for	O
clinically	O
significant	O
drug	O
-	O
drug	O
interactions	O
posed	O
by	O
dolasetron	B
and	O
hydrodolasetron	B
appears	O
to	O
be	O
low	O
for	O
drugs	O
commonly	O
used	O
in	O
chemotherapy	O
or	O
surgery	O
,	O
because	O
hydrodolasetron	B
is	O
eliminated	O
by	O
multiple	O
routes	O
.	O

Blood	O
levels	O
of	O
hydrodolasetron	B
increased	O
24	O
%	O
when	O
dolasetron	B
was	O
coadministered	O
with	O
cimetidine	B
(	O
nonselective	O
inhibitor	O
of	O
cytochrome	O
P	O
-	O
450	O
)	O
for	O
7	O
days	O
,	O
and	O
decreased	O
28	O
%	O
with	O
coadministration	O
of	O
rifampin	B
(	O
potent	O
inducer	O
of	O
cytochrome	O
P	O
-	O
450	O
)	O
for	O
7	O
days	O
.	O

In	O
patients	O
taking	O
furosemide	B
,	O
nifedipine	B
,	O
diltiazem	B
,	O
ACE	B
inhibitors	I
,	O
verapamil	B
,	O
glyburide	B
,	O
propranolol	B
,	O
and	O
various	O
chemotherapy	O
agents	O
,	O
no	O
effect	O
was	O
shown	O
on	O
the	O
clearance	O
of	O
hydrodolasetron	B
.	O

Clearance	O
of	O
hydrodolasetron	B
decreased	O
by	O
about	O
27	O
%	O
when	O
dolasetron	B
mesylate	I
was	O
administered	O
intravenously	O
concomitantly	O
with	O
atenolol	B
.	O

Dolasetron	B
mesylate	I
did	O
not	O
inhibit	O
the	O
antitumor	O
activity	O
of	O
four	O
chemotherapeutic	B
agents	I
(	O
cisplatin	B
,	O
5	O
-	O
fluorouracil	O
,	O
doxorubicin	B
,	O
cyclophosphamide	B
)	O
in	O
four	O
murine	O
models	O
.	O

Because	O
dopamine	B
is	O
metabolized	O
by	O
monoamine	O
oxidase	O
(	O
MAO	O
)	O
,	O
inhibition	O
of	O
this	O
enzyme	O
prolongs	O
and	O
potentiates	O
the	O
effect	O
of	O
dopamine	B
.	O

Patients	O
who	O
have	O
been	O
treated	O
with	O
MAO	B
inhibitors	I
within	O
two	O
to	O
three	O
weeks	O
prior	O
to	O
the	O
administration	O
of	O
dopamine	B
HCl	I
should	O
receive	O
initial	O
doses	O
of	O
dopamine	B
HCl	I
no	O
greater	O
than	O
one	O
-	O
tenth	O
(	O
1	O
/	O
10	O
)	O
of	O
the	O
usual	O
dose	O
.	O

Concurrent	O
administration	O
of	O
low	O
-	O
dose	O
dopamine	B
HCl	I
and	O
diuretic	B
agents	I
may	O
produce	O
an	O
additive	O
or	O
potentiating	O
effect	O
on	O
urine	O
flow	O
.	O

Cardiac	O
effects	O
of	O
dopamine	B
are	O
antagonized	O
by	O
beta	O
-	O
adrenergic	O
blocking	B
agents	I
,	O
such	O
as	O
propranolol	B
and	O
metoprolol	B
.	O

The	O
peripheral	O
vasoconstriction	O
caused	O
by	O
high	O
doses	O
of	O
dopamine	B
HCl	I
is	O
antagonized	O
by	O
alpha	O
-	O
adrenergic	O
blocking	B
agents	I
.	O

Dopamine	B
-	O
induced	O
renal	O
and	O
mesenteric	O
vasodilation	O
is	O
not	O
antagonized	O
by	O
either	O
alpha	O
-	O
or	O
beta	O
-	O
adrenergic	O
blocking	B
agents	I
.	O

Butyrophenones	B
(	O
such	O
as	O
haloperidol	B
)	O
and	O
phenothiazines	B
can	O
suppress	O
the	O
dopaminergic	O
renal	O
and	O
mesenteric	O
vasodilation	O
induced	O
with	O
low	O
dose	O
dopamine	B
infusion	O
.	O

Cyclopropane	B
or	O
halogenated	B
hydrocarbon	I
anesthetics	I
increase	O
cardiac	O
autonomic	O
irritability	O
and	O
may	O
sensitize	O
the	O
myocardium	O
to	O
the	O
action	O
of	O
certain	O
intravenously	O
administered	O
catecholamines	B
,	O
such	O
as	O
dopamine	B
.	O

Therefore	O
,	O
EXTREME	O
CAUTION	O
should	O
be	O
exercised	O
when	O
administering	O
dopamine	B
HCl	I
to	O
patients	O
receiving	O
cyclopropane	B
or	O
halogenated	B
hydrocarbon	I
anesthetics	I
.	O

It	O
has	O
been	O
reported	O
that	O
results	O
of	O
studies	O
in	O
animals	O
indicate	O
that	O
dopamine	B
-	O
induced	O
ventricular	O
arrhythmias	O
during	O
anesthesia	O
can	O
be	O
reversed	O
by	O
propranolol	B
.	O

The	O
concomitant	O
use	O
of	O
vasopressors	O
,	O
vasoconstricting	O
agents	O
(	O
such	O
as	O
ergonovine	B
)	O
and	O
some	O
oxytocic	B
drugs	I
may	O
result	O
in	O
severe	O
hypertension	O
.	O

Administration	O
of	O
phenytoin	B
to	O
patients	O
receiving	O
dopamine	B
HCl	I
has	O
been	O
reported	O
to	O
lead	O
to	O
hypotension	O
and	O
bradycardia	O
.	O

It	O
is	O
suggested	O
that	O
in	O
patients	O
receiving	O
dopamine	B
HCl	I
,	O
alternatives	O
to	O
phenytoin	B
should	O
be	O
used	O
if	O
anticonvulsant	B
therapy	O
is	O
needed	O
.	O

Clinical	O
trials	O
have	O
indicated	O
that	O
Pulmozyme	B
can	O
be	O
effectively	O
and	O
safely	O
used	O
in	O
conjunction	O
with	O
standard	O
cystic	O
fibrosis	O
therapies	O
including	O
oral	O
,	O
inhaled	O
and	O
/	O
or	O
parenteral	O
antibiotics	B
,	O
bronchodilators	B
,	O
enzyme	O
supplements	O
,	O
vitamins	B
,	O
oral	O
or	O
inhaled	O
corticosteroids	B
,	O
and	O
analgesics	B
.	O

Although	O
acid	O
-	O
base	O
and	O
electrolyte	O
disturbances	O
were	O
not	O
reported	O
in	O
the	O
clinical	O
trials	O
with	O
dorzolamide	B
,	O
these	O
disturbances	O
have	O
been	O
reported	O
with	O
oral	O
carbonic	B
anhydrase	I
inhibitors	I
and	O
have	O
,	O
in	O
some	O
instances	O
,	O
resulted	O
in	O
drug	O
interactions	O
(	O
e	O
.	O
g	O
.	O
,	O
toxicity	O
associated	O
with	O
high	O
-	O
dose	O
salicylate	B
therapy	O
)	O
.	O

Prior	O
administration	O
of	O
succinylcholine	B
has	O
no	O
clinically	O
important	O
effect	O
on	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
NUROMAX	B
.	O

The	O
use	O
of	O
NUROMAX	B
before	O
succinylcholine	B
to	O
attenuate	O
some	O
of	O
the	O
side	O
effects	O
of	O
succinylcholine	B
has	O
not	O
been	O
studied	O
.	O

There	O
are	O
no	O
clinical	O
data	O
on	O
concomitant	O
use	O
of	O
NUROMAX	B
and	O
other	O
nondepolarizing	O
neuromuscular	B
blocking	I
agents	I
.	O

Isoflurane	B
,	O
enflurane	B
,	O
and	O
halothane	B
decrease	O
the	O
ED50	O
of	O
NUROMAX	B
by	O
30	O
%	O
to	O
45	O
%	O
.	O

Other	O
drugs	O
which	O
may	O
enhance	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
nondepolarizing	O
agents	O
such	O
as	O
NUROMAX	B
include	O
certain	O
antibiotics	B
(	O
e	O
.	O
g	O
.	O
,	O
aminoglycosides	B
,	O
tetracyclines	B
,	O
bacitracin	B
,	O
polymyxins	B
,	O
lincomycin	B
,	O
clindamycin	B
,	O
colistin	B
,	O
and	O
sodium	B
colistimethate	I
)	O
,	O
magnesium	B
salts	O
,	O
lithium	B
,	O
local	O
anesthetics	B
,	O
procainamide	B
,	O
and	O
quinidine	B
.	O

As	O
with	O
some	O
other	O
nondepolarizing	B
neuromuscular	I
blocking	I
agents	I
,	O
the	O
time	O
of	O
onset	O
of	O
neuromuscular	B
block	O
induced	O
by	O
NUROMAX	B
is	O
lengthened	O
and	O
the	O
duration	O
of	O
block	O
is	O
shortened	O
in	O
patients	O
receiving	O
phenytoin	B
or	O
carbamazepine	B
.	O

Administration	O
of	O
doxapram	B
to	O
patients	O
who	O
are	O
receiving	O
sympathomimetic	B
or	O
monoamine	B
oxidase	I
inhibiting	I
drugs	I
may	O
result	O
in	O
an	O
additive	O
pressor	O
effect	O
.	O

In	O
patients	O
who	O
have	O
received	O
muscle	B
relaxants	I
,	O
doxapram	B
may	O
temporarily	O
mask	O
the	O
residual	O
effects	O
of	O
muscle	B
relaxant	I
drugs	I
.	O

In	O
vitro	O
data	O
in	O
human	O
plasma	O
indicate	O
that	O
doxazosin	B
mesylate	I
has	O
no	O
effect	O
on	O
protein	O
binding	O
of	O
digoxin	B
,	O
warfarin	B
,	O
phenytoin	B
or	O
indomethacin	B
.	O

Doxazosin	B
mesylate	I
has	O
been	O
administered	O
without	O
any	O
evidence	O
of	O
an	O
adverse	O
drug	O
interaction	O
to	O
patients	O
receiving	O
thiazide	B
diuretics	I
,	O
beta	O
-	O
blocking	O
agents	O
,	O
and	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
drugs	B
.	O

In	O
a	O
placebo	O
-	O
controlled	O
trial	O
in	O
normal	O
volunteers	O
,	O
the	O
administration	O
of	O
a	O
single	O
1	O
mg	O
dose	O
of	O
doxazosin	B
on	O
day	O
1	O
of	O
a	O
four	O
-	O
day	O
regimen	O
of	O
oral	O
cimetidine	B
(	O
400	O
mg	O
twice	O
daily	O
)	O
resulted	O
in	O
a	O
10	O
%	O
increase	O
in	O
mean	O
AUC	O
of	O
doxazosin	B
(	O
p	O
=	O
0	O
.	O
006	O
)	O
,	O
and	O
a	O
slight	O
but	O
not	O
statistically	O
significant	O
increase	O
in	O
mean	O
Cmax	O
and	O
mean	O
half	O
-	O
life	O
of	O
doxazosin	B
.	O

Analgesic	B
/	O
anti	O
-	O
inflammatory	O
(	O
e	O
.	O
g	O
.	O
,	O
acetaminophen	B
,	O
aspirin	B
,	O
codeine	B
and	O
codeine	B
combinations	O
,	O
ibuprofen	B
,	O
indomethacin	B
)	O
.	O

Antibiotics	B
(	O
e	O
.	O
g	O
.	O
,	O
erythromycin	B
,	O
trimethoprim	B
and	O
sulfamethoxazole	B
,	O
amoxicillin	B
)	O
.	O

Antihistamines	B
(	O
e	O
.	O
g	O
.	O
,	O
chlorpheniramine	B
)	O
.	O

Cardiovascular	O
agents	O
(	O
e	O
.	O
g	O
.	O
,	O
atenolol	B
,	O
hydrochlorothiazide	B
,	O
propranolol	B
)	O
.	O

Sedatives	B
and	O
tranquilizers	B
(	O
e	O
.	O
g	O
.	O
,	O
diazepam	B
)	O
.	O

Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	B
antidepressants	I
(	O
TCAs	B
)	O
when	O
given	O
usual	O
doses	O
.	O

cimetidine	B
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P450	O
2D6	O
(	O
many	O
other	O
antidepressants	B
,	O
phenothiazines	B
,	O
and	O
the	O
Type	B
1C	I
antiarrhythmics	I
propafenone	I
and	O
flecainide	B
)	O
.	O

While	O
all	O
the	O
selective	B
serotonin	I
reuptake	I
inhibitors	I
(	O
SSRIs	B
)	O
,	O
e	O
.	O
g	O
.	O
,	O
citalopram	B
,	O
escitalopram	B
,	O
fluoxetine	B
,	O
sertraline	B
,	O
and	O
paroxetine	B
,	O
inhibit	O
P450	O
2D6	O
,	O
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O

The	O
extent	O
to	O
which	O
SSRI	B
-	O
TCA	B
interactions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	B
involved	O
.	O

Nevertheless	O
,	O
caution	O
is	O
indicated	O
in	O
the	O
co	O
-	O
administration	O
of	O
TCAs	B
with	O
any	O
of	O
the	O
SSRIs	B
and	O
also	O
in	O
switching	O
from	O
one	O
class	O
to	O
the	O
other	O
.	O

Concomitant	O
use	O
of	O
tricyclic	B
antidepressants	I
with	O
drugs	O
that	O
can	O
inhibit	O
cytochrome	O
P450	O
2D6	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	B
antidepressant	I
or	O
the	O
other	O
drug	O
.	O

It	O
is	O
desirable	O
to	O
monitor	O
TCA	B
plasma	O
levels	O
whenever	O
a	O
TCA	B
is	O
going	O
to	O
be	O
co	O
-	O
administered	O
with	O
another	O
drug	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P450	O
2D6	O
.	O

Inhibitors	O
or	O
substrates	O
of	O
CYP2D6	O
(	O
i	O
.	O
e	O
.	O
,	O
quinidine	B
,	O
selective	B
serotonin	I
reuptake	I
inhibitors	I
[	O
SSRIs	B
]	O
)	O
may	O
increase	O
the	O
plasma	O
concentration	O
of	O
doxepin	B
when	O
administered	O
concomitantly	O
.	O

MAO	B
Inhibitors	I
:	O
Serious	O
side	O
effects	O
and	O
even	O
death	O
have	O
been	O
reported	O
following	O
the	O
concomitant	O
use	O
of	O
certain	O
drugs	O
with	O
MAO	B
inhibitors	I
.	O

Therefore	O
,	O
MAO	B
inhibitors	I
should	O
be	O
discontinued	O
at	O
least	O
two	O
weeks	O
prior	O
to	O
the	O
cautious	O
initiation	O
of	O
therapy	O
with	O
SINEQUAN	B
.	O

Cimetidine	B
:	O
Cimetidine	B
has	O
been	O
reported	O
to	O
produce	O
clinically	O
significant	O
fluctuations	O
in	O
steady	O
-	O
state	O
serum	O
concentrations	O
of	O
various	O
tricyclic	B
antidepressants	I
.	O

Serious	O
anticholinergic	O
symptoms	O
(	O
i	O
.	O
e	O
.	O
,	O
severe	O
dry	O
mouth	O
,	O
urinary	O
retention	O
and	O
blurred	O
vision	O
)	O
have	O
been	O
associated	O
with	O
elevations	O
in	O
the	O
serum	O
levels	O
of	O
tricyclic	B
antidepressant	I
when	O
cimetidine	B
therapy	O
is	O
initiated	O
.	O

Additionally	O
,	O
higher	O
than	O
expected	O
tricyclic	B
antidepressant	I
levels	O
have	O
been	O
observed	O
when	O
they	O
are	O
begun	O
in	O
patients	O
already	O
taking	O
cimetidine	B
.	O

In	O
patients	O
who	O
have	O
been	O
reported	O
to	O
be	O
well	O
controlled	O
on	O
tricyclic	B
antidepressants	I
receiving	O
concurrent	O
cimetidine	B
therapy	O
,	O
discontinuation	O
of	O
cimetidine	B
has	O
been	O
reported	O
to	O
decrease	O
established	O
steady	O
-	O
state	O
serum	O
tricyclic	B
antidepressant	I
levels	O
and	O
compromise	O
their	O
therapeutic	O
effects	O
.	O

Alcohol	B
:	O
It	O
should	O
be	O
borne	O
in	O
mind	O
that	O
alcohol	B
ingestion	O
may	O
increase	O
the	O
danger	O
inherent	O
in	O
any	O
intentional	O
or	O
unintentional	O
SINEQUAN	B
overdosage	O
.	O

Tolazamide	B
:	O
A	O
case	O
of	O
severe	O
hypoglycemia	O
has	O
been	O
reported	O
in	O
a	O
type	O
II	O
diabetic	O
patient	O
maintained	O
on	O
tolazamide	B
(	O
1	O
gm	O
/	O
day	O
)	O
11	O
days	O
after	O
the	O
addition	O
of	O
doxepin	B
(	O
75	O
mg	O
/	O
day	O
)	O
.	O

DOXIL	B
may	O
interact	O
with	O
drugs	O
known	O
to	O
interact	O
with	O
the	O
conventional	O
formulation	O
of	O
doxorubicin	B
HCl	I
.	O

Because	O
tetracyclines	B
have	O
been	O
shown	O
to	O
depress	O
plasma	O
prothrombin	O
activity	O
,	O
patients	O
who	O
are	O
on	O
anticoagulant	B
therapy	O
may	O
require	O
downward	O
adjustment	O
of	O
their	O
anticoagulant	B
dosage	O
.	O

Since	O
bacteriostatic	O
drugs	O
may	O
interfere	O
with	O
the	O
bactericidal	O
action	O
of	O
penicillin	B
,	O
it	O
is	O
advisable	O
to	O
avoid	O
giving	O
tetracyclines	B
in	O
conjunction	O
with	O
penicillin	B
.	O

Absorption	O
of	O
tetracyclines	B
is	O
impaired	O
by	O
antacids	B
containing	O
aluminum	B
,	O
calcium	B
,	O
or	O
magnesium	B
,	O
and	O
iron	B
-	O
containing	O
preparations	O
.	O

Absorption	O
of	O
tetracycline	B
is	O
impaired	O
by	O
bismuth	B
subsalicylate	I
.	O

Barbiturates	B
,	O
carbamazepine	B
,	O
and	O
phenytoin	B
decrease	O
the	O
half	O
-	O
life	O
of	O
doxycycline	B
.	O

The	O
concurrent	O
use	O
of	O
tetracycline	B
and	O
Penthrane	B
(	O
methoxyflurane	B
)	O
has	O
been	O
reported	O
to	O
result	O
in	O
fatal	O
renal	O
toxicity	O
.	O

Concurrent	O
use	O
of	O
tetracycline	B
may	O
render	O
oral	O
contraceptives	B
less	O
effective	O
.	O

Potential	O
drug	O
interactions	O
for	O
doxylamine	B
include	O
,	O
increased	O
sedation	O
if	O
doxylamine	B
is	O
combined	O
with	O
other	O
CNS	B
depressant	I
drugs	I
.	O

Antihistamines	B
may	O
partially	O
counteract	O
the	O
anticoagulation	O
effects	O
of	O
heparin	B
or	O
warfarin	B
.	O

Doxylamine	B
may	O
enhance	O
the	O
effects	O
of	O
epinephrine	B
.	O

Concurrent	O
administration	O
of	O
oxyphenbutazone	B
and	O
androgens	B
may	O
result	O
in	O
elevated	O
serum	O
levels	O
of	O
oxyphenbutazone	B
.	O

In	O
diabetic	O
patients	O
,	O
the	O
metabolic	O
effects	O
of	O
androgens	B
may	O
decrease	O
blood	O
glucose	O
and	O
therefore	O
,	O
insulin	B
requirements	O
.	O

Other	O
CNS	B
depressant	I
drugs	I
(	O
e	O
.	O
g	O
.	O
barbiturates	B
,	O
tranquilizers	B
,	O
opioids	B
and	O
general	O
anesthetics	B
)	O
have	O
additive	O
or	O
potentiating	O
effects	O
with	O
INAPSINE	B
.	O

Following	O
the	O
administration	O
of	O
INAPSINE	B
,	O
the	O
dose	O
of	O
other	O
CNS	B
depressant	I
drugs	I
should	O
be	O
reduced	O
.	O

However	O
,	O
since	O
there	O
is	O
an	O
increased	O
risk	O
of	O
bleeding	O
with	O
Xigris	B
,	O
caution	O
should	O
be	O
employed	O
when	O
Xigris	B
is	O
used	O
with	O
other	O
drugs	O
that	O
affect	O
hemostasis	O
.	O

Approximately	O
2	O
/	O
3	O
of	O
the	O
patients	O
in	O
the	O
Phase	O
3	O
study	O
received	O
either	O
prophylactic	O
low	B
dose	O
heparin	B
(	O
unfractionated	B
heparin	I
up	O
to	O
15	O
,	O
000	O
units	O
/	O
day	O
)	O
or	O
prophylactic	O
doses	O
of	O
low	B
molecular	I
weight	I
heparins	I
as	O
indicated	O
in	O
the	O
prescribing	O
information	O
for	O
the	O
specific	O
products	O
.	O

Concomitant	O
use	O
of	O
prophylactic	O
low	O
dose	O
heparin	B
did	O
not	O
appear	O
to	O
affect	O
safety	O
,	O
however	O
,	O
its	O
effects	O
on	O
the	O
efficacy	O
of	O
Xigris	B
have	O
not	O
been	O
evaluated	O
in	O
an	O
adequate	O
and	O
well	O
-	O
controlled	O
clinical	O
trial	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interaction	O
Because	O
Xigris	B
may	O
affect	O
the	O
APTT	O
assay	O
,	O
Xigris	B
present	O
in	O
plasma	O
samples	O
may	O
interfere	O
with	O
one	O
-	O
stage	O
coagulation	O
assays	O
based	O
on	O
the	O
APTT	O
(	O
such	O
as	O
factor	O
VIII	O
,	O
IX	O
,	O
and	O
XI	O
assays	O
)	O
.	O

Potential	O
for	O
Other	O
Drugs	O
to	O
Affect	O
Duloxetine	B
:	O
Both	O
CYP1A2	O
and	O
CYP2D6	O
are	O
responsible	O
for	O
duloxetine	B
metabolism	O
.	O

Inhibitors	O
of	O
CYP1A2	O
:	O
Concomitant	O
use	O
of	O
duloxetine	B
with	O
fluvoxamine	B
,	O
an	O
inhibitor	O
of	O
CYP1A2	O
,	O
results	O
in	O
approximately	O
a	O
6	O
-	O
fold	O
increase	O
in	O
AUC	O
and	O
about	O
a	O
2	O
.	O
5	O
-	O
fold	O
increase	O
in	O
Cmax	O
of	O
duloxetine	B
.	O

Inhibitors	O
of	O
CYP2D6	O
:	O
Because	O
CYP2D6	O
is	O
involved	O
in	O
duloxetine	B
metabolism	O
,	O
concomitant	O
use	O
of	O
duloxetine	B
with	O
potent	O
inhibitors	O
of	O
CYP2D6	O
may	O
result	O
in	O
higher	O
concentrations	O
of	O
duloxetine	B
.	O

Paroxetine	B
(	O
20	O
mg	O
QD	O
)	O
increased	O
the	O
concentration	O
of	O
duloxetine	B
(	O
40	O
mg	O
QD	O
)	O
by	O
about	O
60	O
%	O
,	O
and	O
greater	O
degrees	O
of	O
inhibition	O
are	O
expected	O
with	O
higher	O
doses	O
of	O
paroxetine	B
.	O

Similar	O
effects	O
would	O
be	O
expected	O
with	O
other	O
potent	O
CYP2D6	O
inhibitors	O
(	O
e	O
.	O
g	O
.	O
,	O
fluoxetine	B
,	O
quinidine	B
)	O
.	O

Potential	O
for	O
Duloxetine	B
to	O
Affect	O
Other	O
Drugs	O
:	O
Drugs	O
Metabolized	O
by	O
CYP1A2	O
:	O
In	O
vitro	O
drug	O
interaction	O
studies	O
demonstrate	O
that	O
duloxetine	B
does	O
not	O
induce	O
CYP1A2	O
activity	O
,	O
and	O
it	O
is	O
unlikely	O
to	O
have	O
a	O
clinically	O
significant	O
effect	O
on	O
the	O
metabolism	O
of	O
CYP1A2	O
substrates	O
.	O

When	O
duloxetine	B
was	O
administered	O
(	O
at	O
a	O
dose	O
of	O
60	O
mg	O
BID	O
)	O
in	O
conjunction	O
with	O
a	O
single	O
50	O
-	O
mg	O
dose	O
of	O
desipramine	B
,	O
a	O
CYP2D6	O
substrate	O
,	O
the	O
AUC	O
of	O
desipramine	B
increased	O
3	O
-	O
fold	O
.	O

Therefore	O
,	O
co	O
-	O
administration	O
of	O
Duloxetine	B
with	O
other	O
drugs	O
that	O
are	O
extensively	O
metabolized	O
by	O
this	O
isozyme	O
and	O
which	O
have	O
a	O
narrow	O
therapeutic	O
index	O
,	O
including	O
certain	O
antidepressants	B
(	O
tricyclic	B
antidepressants	I
[	O
TCAs	B
]	O
,	O
such	O
as	O
nortriptyline	B
,	O
amitriptyline	B
,	O
and	O
imipramine	B
)	O
,	O
phenothiazines	B
and	O
Type	B
1C	I
antiarrhythmics	I
(	O
e	O
.	O
g	O
.	O
,	O
propafenone	B
,	O
flecainide	B
)	O
,	O
should	O
be	O
approached	O
with	O
caution	O
.	O

Plasma	O
TCA	B
concentrations	O
may	O
need	O
to	O
be	O
monitored	O
and	O
the	O
dose	O
of	O
the	O
TCA	B
may	O
need	O
to	O
be	O
reduced	O
if	O
a	O
TCA	B
is	O
co	O
-	O
administered	O
with	O
Duloxetine	B
.	O

Because	O
of	O
the	O
risk	O
of	O
serious	O
ventricular	O
arrhythmias	O
and	O
sudden	O
death	O
potentially	O
associated	O
with	O
elevated	O
plasma	O
levels	O
of	O
thioridazine	B
,	O
Duloxetine	B
and	O
thioridazine	B
should	O
not	O
be	O
co	O
-	O
administered	O
.	O

Duloxetine	B
May	O
Have	O
a	O
Clinically	O
Important	O
Interaction	O
with	O
the	O
Following	O
Other	O
Drugs	O
:	O
Alcohol	B
:	O
When	O
Duloxetine	B
and	O
ethanol	B
were	O
administered	O
several	O
hours	O
apart	O
so	O
that	O
peak	O
concentrations	O
of	O
each	O
would	O
coincide	O
,	O
Duloxetine	B
did	O
not	O
increase	O
the	O
impairment	O
of	O
mental	O
and	O
motor	O
skills	O
caused	O
by	O
alcohol	B
.	O

In	O
the	O
Duloxetine	B
clinical	O
trials	O
database	O
,	O
three	O
Duloxetine	B
-	O
treated	O
patients	O
had	O
liver	O
injury	O
as	O
manifested	O
by	O
ALT	O
and	O
total	O
bilirubin	O
elevations	O
,	O
with	O
evidence	O
of	O
obstruction	O
.	O

However	O
,	O
co	O
-	O
administration	O
of	O
Duloxetine	B
with	O
aluminum	B
-	O
and	O
magnesium	B
-	O
containing	O
antacids	B
(	O
51	O
mEq	O
)	O
or	O
Duloxetine	B
with	O
famotidine	B
,	O
had	O
no	O
significant	O
effect	O
on	O
the	O
rate	O
or	O
extent	O
of	O
duloxetine	B
absorption	O
after	O
administration	O
of	O
a	O
40	O
-	O
mg	O
oral	O
dose	O
.	O

It	O
is	O
unknown	O
whether	O
the	O
concomitant	O
administration	O
of	O
proton	B
pump	I
inhibitors	I
affects	O
duloxetine	B
absorption	O
.	O

Synergism	O
between	O
xanthine	B
bronchodilators	I
(	O
e	O
.	O
g	O
.	O
,	O
theophylline	B
)	O
,	O
ephedrine	B
,	O
and	O
other	O
sympathomimetic	B
bronchodilators	I
has	O
been	O
reported	O
.	O

Concurrent	O
administration	O
of	O
dyphylline	B
and	O
probenecid	B
,	O
which	O
competes	O
for	O
tubular	O
secretion	O
,	O
has	O
been	O
shown	O
to	O
increase	O
the	O
plasma	O
half	O
-	O
life	O
of	O
dyphylline	B
.	O

Phospholine	B
Iodide	I
potentiates	O
other	O
cholinesterase	B
inhibitors	I
such	O
as	O
succinylcholine	B
or	O
organophosphate	B
and	O
carbamate	B
insecticides	O
.	O

Steroids	B
enhance	O
the	O
renal	O
toxicity	O
of	O
edetate	B
calcium	I
disodium	I
in	O
animals	O
.	O
7	O
Edetate	B
calcium	I
disodium	I
interferes	O
with	O
the	O
action	O
of	O
zinc	B
insulin	I
preparations	O
by	O
chelating	O
the	O
zinc	B
.	O
7	O

RAPTIVA	B
should	O
not	O
be	O
used	O
with	O
other	O
immunosuppressive	B
drugs	I
.	O

Acellular	B
,	O
live	B
and	O
live	B
-	O
attenuated	O
vaccines	B
should	O
not	O
be	O
administered	O
during	O
RAPTIVA	B
treatment	O
.	O

Other	O
compounds	O
that	O
are	O
substrates	O
of	O
CYP3A4	O
may	O
have	O
decreased	O
plasma	O
concentrations	O
when	O
coadministered	O
with	O
SUSTIVA	B
(	O
efavirenz	B
)	O
.	O

In	O
vitro	O
studies	O
have	O
demonstrated	O
that	O
efavirenz	B
inhibits	O
2C9	O
,	O
2C19	O
,	O
and	O
3A4	O
isozymes	O
in	O
the	O
range	O
of	O
observed	O
efavirenz	B
plasma	O
concentrations	O
.	O

Drugs	O
which	O
induce	O
CYP3A4	O
activity	O
(	O
eg	O
,	O
phenobarbital	B
,	O
rifampin	B
,	O
rifabutin	B
)	O
would	O
be	O
expected	O
to	O
increase	O
the	O
clearance	O
of	O
efavirenz	B
resulting	O
in	O
lowered	O
plasma	O
concentrations	O
.	O

Antihistamines	B
:	O
Benzodiazepines	B
GI	O
Motility	O
Agents	O
Anti	O
-	O
Migraine	O
Antifungal	B

astemizole	B
midazolam	I
,	O
triazolam	B
cisapride	I
ergot	O
derivatives	O
voriconazole	B

When	O
coadministered	O
with	O
SUSTIVA	B
in	O
treatment	O
-	O
naive	O
patients	O
,	O
the	O
recommended	O
dose	O
of	O
atazanavir	B
is	O
300	O
mg	O
with	O
ritonavir	B
100	O
mg	O
and	O
SUSTIVA	B
600	O
mg	O
(	O
all	O
once	O
daily	O
)	O
.	O

Dosing	O
recommendations	O
for	O
SUSTIVA	B
and	O
atazanavir	B
in	O
treatment	O
-	O
experienced	O
patients	O
have	O
not	O
been	O
established	O
.	O

In	O
uninfected	O
volunteers	O
,	O
46	O
%	O
developed	O
rash	O
while	O
receiving	O
SUSTIVA	B
and	O
clarithromycin	B
.	O

No	O
dose	O
adjustment	O
of	O
SUSTIVA	B
is	O
recommended	O
when	O
given	O
with	O
clarithromycin	B
.	O

Alternatives	O
to	O
clarithromycin	B
,	O
such	O
as	O
azithromycin	B
,	O
should	O
be	O
considered	O
.	O

Other	O
macrolide	B
antibiotics	I
,	O
such	O
as	O
erythromycin	B
,	O
have	O
not	O
been	O
studied	O
in	O
combination	O
with	O
SUSTIVA	B
.	O

The	O
optimal	O
dose	O
of	O
indinavir	B
,	O
when	O
given	O
in	O
combination	O
with	O
SUSTIVA	B
,	O
is	O
not	O
known	O
.	O

Increasing	O
the	O
indinavir	B
dose	O
to	O
1000	O
mg	O
every	O
8	O
hours	O
does	O
not	O
compensate	O
for	O
the	O
increased	O
indinavir	B
metabolism	O
due	O
to	O
SUSTIVA	B
.	O

When	O
indinavir	B
at	O
an	O
increased	O
dose	O
(	O
1000	O
mg	O
every	O
8	O
hours	O
)	O
was	O
given	O
with	O
SUSTIVA	B
(	O
600	O
mg	O
once	O
daily	O
)	O
,	O
the	O
indinavir	B
AUC	O
and	O
Cmin	O
were	O
decreased	O
on	O
average	O
by	O
33	O
-	O
46	O
%	O
and	O
39	O
-	O
57	O
%	O
,	O
respectively	O
,	O
compared	O
to	O
when	O
indinavir	B
(	O
800	O
mg	O
every	O
8	O
hours	O
)	O
was	O
given	O
alone	O
.	O

Lopinavir	B
/	O
ritonavir	B

A	O
dose	O
increase	O
of	O
lopinavir	B
/	O
ritonavir	B
to	O
533	O
/	O
133	O
mg	O
(	O
4	O
capsules	O
or	O
6	O
.	O
5	O
mL	O
)	O
twice	O
daily	O
taken	O
with	O
food	O
is	O
recommended	O
when	O
used	O
in	O
combination	O
with	O
SUSTIVA	B
.	O

Coadministration	O
in	O
HIV	O
-	O
infected	O
individuals	O
with	O
a	O
history	O
of	O
injection	O
drug	O
use	O
resulted	O
in	O
decreased	O
plasma	O
levels	O
of	O
methadone	B
and	O
signs	O
of	O
opiate	B
withdrawal	O
.	O

Plasma	O
concentrations	O
increased	O
by	O
SUSTIVA	B
(	O
efavirenz	B
)	O
;	O

Because	O
the	O
potential	O
interaction	O
of	O
efavirenz	B
with	O
oral	O
contraceptives	B
has	O
not	O
been	O
fully	O
characterized	O
,	O
a	O
reliable	O
method	O
of	O
barrier	O
contraception	O
should	O
be	O
used	O
in	O
addition	O
to	O
oral	O
contraceptives	B
.	O

Consider	O
doubling	O
the	O
rifabutin	B
dose	O
in	O
regimens	O
where	O
rifabutin	B
is	O
given	O
2	O
or	O
3	O
times	O
a	O
week	O
.	O

Monitoring	O
of	O
liver	O
enzymes	O
is	O
recommended	O
when	O
SUSTIVA	B
is	O
used	O
in	O
combination	O
with	O
ritonavir	B
.	O

Should	O
not	O
be	O
used	O
as	O
sole	O
protease	B
inhibitor	I
in	O
combination	O
with	O
SUSTIVA	B
.	O

Anticoagulants	B
:	O
Warfarin	B

Anticonvulsants	B
:	O
Phenytoin	B
Phenobarbital	I
Carbamazepine	I

Potential	O
for	O
reduction	O
in	O
anticonvulsant	B
and	O
/	O
or	O
efavirenz	B
plasma	O
levels	O
;	O

Antifungals	B
:	O
Itraconazole	B
Ketoconazole	I

Drug	O
interaction	O
studies	O
with	O
SUSTIVA	B
and	O
these	O
imidazole	B
and	O
triazole	B
antifungals	I
have	O
not	O
been	O
conducted	O
.	O

SUSTIVA	B
has	O
the	O
potential	O
to	O
decrease	O
plasma	O
concentrations	O
of	O
itraconazole	B
and	O
ketoconazole	B
.	O

Anti	O
-	O
HIV	O
protease	B
inhibitors	I
:	O
Saquinavir	B
/	O
ritonavir	B
combination	O

Expected	O
to	O
substantially	O
decrease	O
plasma	O
levels	O
of	O
efavirenz	B
;	O
has	O
not	O
been	O
studied	O
in	O
combination	O
with	O
SUSTIVA	B
.	O

Other	O
Drugs	O
:	O
Based	O
on	O
the	O
results	O
of	O
drug	O
interaction	O
studies	O
,	O
no	O
dosage	O
adjustment	O
is	O
recommended	O
when	O
SUSTIVA	B
(	O
efavirenz	B
)	O
is	O
given	O
with	O
the	O
following	O
:	O
aluminum	O
/	O
magnesium	O
hydroxide	B
antacids	I
,	O
azithromycin	B
,	O
cetirizine	B
,	O
famotidine	B
,	O
fluconazole	B
,	O
lamivudine	B
,	O
lorazepam	B
,	O
nelfinavir	B
,	O
paroxetine	B
,	O
and	O
zidovudine	B
.	O

Specific	O
drug	O
interaction	O
studies	O
have	O
not	O
been	O
performed	O
with	O
SUSTIVA	B
and	O
NRTIs	B
other	O
than	O
lamivudine	B
and	O
zidovudine	B
.	O

Clinically	O
significant	O
interactions	O
would	O
not	O
be	O
expected	O
since	O
the	O
NRTIs	B
are	O
metabolized	O
via	O
a	O
different	O
route	O
than	O
efavirenz	B
and	O
would	O
be	O
unlikely	O
to	O
compete	O
for	O
the	O
same	O
metabolic	O
enzymes	O
and	O
elimination	O
pathways	O
.	O

The	O
potential	O
for	O
drug	O
interactions	O
with	O
EMTRIVA	B
has	O
been	O
studied	O
in	O
combination	O
with	O
indinavir	B
,	O
stavudine	B
,	O
famciclovir	B
,	O
and	O
tenofovir	B
disoproxil	I
fumarate	I
.	O

Hypotension	O
:	O
Patients	O
on	O
Diuretic	O
Therapy	O
:	O
Patients	O
on	O
diuretics	B
and	O
especially	O
those	O
in	O
whom	O
diuretic	O
therapy	O
was	O
recently	O
instituted	O
,	O
may	O
occasionally	O
experience	O
an	O
excessive	O
reduction	O
of	O
blood	O
pressure	O
after	O
initiation	O
of	O
therapy	O
with	O
enalapril	B
or	O
enalaprilat	B
.	O

The	O
possibility	O
of	O
hypotensive	O
effects	O
with	O
enalapril	B
or	O
enalaprilat	B
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	B
or	O
increasing	O
the	O
salt	O
intake	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
enalapril	B
or	O
enalaprilat	B
.	O

Agents	O
Causing	O
Renin	O
Release	O
:	O
The	O
antihypertensive	B
effect	O
of	O
enalapril	B
and	O
enalapril	B
IV	O
is	O
augmented	O
by	O
antihypertensive	B
agents	I
that	O
cause	O
renin	O
release	O
(	O
e	O
.	O
g	O
.	O
,	O
diuretics	B
)	O
.	O

Non	O
-	O
steroidal	O
Anti	O
-	O
inflammatory	O
Agents	B
:	O
In	O
some	O
patients	O
with	O
compromised	O
renal	O
function	O
who	O
are	O
being	O
treated	O
with	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
drugs	B
,	O
the	O
co	O
-	O
administration	O
of	O
enalapril	B
may	O
result	O
in	O
a	O
further	O
deterioration	O
of	O
renal	O
function	O
.	O

In	O
a	O
clinical	O
pharmacology	O
study	O
,	O
indomethacin	B
or	O
sulindac	B
was	O
administered	O
to	O
hypertensive	O
patients	O
receiving	O
VASOTEC	B
.	O

However	O
,	O
reports	O
suggest	O
that	O
NSAIDs	B
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
ACE	B
inhibitors	I
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
NSAIDs	B
concomitantly	O
with	O
ACE	B
inhibitors	I
.	O

Other	O
Cardiovascular	O
Agents	O
:	O
Enalapril	B
and	O
enalapril	B
IV	O
have	O
been	O
used	O
concomitantly	O
with	O
beta	B
adrenergic	O
-	O
blocking	O
agents	B
,	O
methyldopa	B
,	O
nitrates	B
,	O
calcium	O
-	O
blocking	O
agents	B
,	O
hydralazine	B
,	O
prazosin	B
and	O
digoxin	B
without	O
evidence	O
of	O
clinically	O
significant	O
adverse	O
interactions	O
.	O

Enalapril	B
IV	O
has	O
been	O
used	O
concomitantly	O
with	O
digitalis	B
without	O
evidence	O
of	O
clinically	O
significant	O
adverse	O
reactions	O
.	O

Agents	O
Increasing	O
Serum	O
Potassium	O
:	O
Enalapril	B
and	O
enalapril	B
IV	O
attenuate	O
potassium	O
loss	O
caused	O
by	O
thiazide	O
-	O
type	O
diuretics	B
.	O

Potassium	O
-	O
sparing	O
diuretics	B
(	O
e	O
.	O
g	O
.	O
,	O
spironolactone	B
,	O
triamterene	B
,	O
or	O
amiloride	B
)	O
,	O
potassium	B
supplements	O
,	O
or	O
potassium	B
-	O
containing	O
salt	O
substitutes	O
may	O
lead	O
to	O
significant	O
increases	O
in	O
serum	O
potassium	B
.	O

Lithium	B
:	O
Lithium	B
toxicity	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
lithium	B
concomitantly	O
with	O
drugs	O
which	O
cause	O
elimination	O
of	O
sodium	O
,	O
including	O
ACE	B
inhibitors	I
.	O

It	O
is	O
recommended	O
that	O
serum	O
lithium	B
levels	O
be	O
monitored	O
frequently	O
if	O
enalapril	B
is	O
administered	O
concomitantly	O
with	O
lithium	B
.	O

If	O
the	O
usual	O
amounts	O
of	O
nondepolarizing	O
relaxants	O
are	O
given	O
,	O
the	O
time	O
for	O
recovery	O
from	O
neuromuscular	O
blockade	O
will	O
be	O
longer	O
in	O
the	O
presence	O
of	O
Enflurane	B
than	O
when	O
halothane	B
or	O
nitrous	B
oxide	I
with	O
a	O
balanced	O
technique	O
are	O
used	O
.	O

Antiretroviral	B
Agents	I
:	O
No	O
drug	O
interactions	O
with	O
other	O
antiretroviral	B
medications	I
have	O
been	O
identified	O
that	O
would	O
warrant	O
alteration	O
of	O
either	O
the	O
enfuvirtide	B
dose	O
or	O
the	O
dose	O
of	O
the	O
other	O
antiretroviral	B
medication	I
.	O

Bismuth	B
:	O
Bismuth	B
subsalicylate	I
,	O
given	O
concomitantly	O
with	O
enoxacin	B
or	O
60	O
minutes	O
following	O
enoxacin	B
administration	O
,	O
decreased	O
enoxacin	B
bioavailability	O
by	O
approximately	O
25	O
%	O
.	O

Thus	O
,	O
concomitant	O
administration	O
of	O
enoxacin	B
and	O
bismuth	B
subsalicylate	I
should	O
be	O
avoided	O
.	O

Caffeine	B
:	O
Enoxacin	B
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
cytochrome	O
P	O
-	O
450	O
isozymes	O
responsible	O
for	O
the	O
metabolism	O
of	O
methylxanthines	B
.	O

In	O
a	O
multiple	O
-	O
dose	O
study	O
,	O
enoxacin	B
caused	O
a	O
dose	O
-	O
related	O
increase	O
in	O
the	O
mean	O
elimination	O
half	O
-	O
life	O
of	O
caffeine	B
,	O
thereby	O
decreasing	O
the	O
clearance	O
of	O
caffeine	B
by	O
up	O
to	O
80	O
%	O
and	O
leading	O
to	O
a	O
five	O
-	O
fold	O
increase	O
in	O
the	O
AUC	O
and	O
the	O
half	O
-	O
life	O
of	O
caffeine	B
.	O

Trough	O
plasma	O
enoxacin	B
levels	O
were	O
also	O
20	O
%	O
higher	O
when	O
caffeine	B
and	O
enoxacin	B
were	O
administered	O
concomitantly	O
.	O

Caffeine	B
-	O
related	O
adverse	O
effects	O
have	O
occurred	O
in	O
patients	O
consuming	O
caffeine	B
while	O
on	O
therapy	O
with	O
enoxacin	B
.	O

Cyclosporine	B
:	O
Elevated	O
serum	O
levels	O
of	O
cyclosporine	B
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
cyclosporine	B
with	O
other	O
members	O
of	O
the	O
quinolone	B
class	I
.	O

Digoxin	B
:	O
Enoxacin	B
may	O
raise	O
serum	O
digoxin	B
levels	O
in	O
some	O
individuals	O
.	O

If	O
signs	O
and	O
symptoms	O
suggestive	O
of	O
digoxin	B
toxicity	O
occur	O
when	O
enoxacin	B
and	O
digoxin	B
are	O
given	O
concomitantly	O
,	O
physicians	O
are	O
advised	O
to	O
obtain	O
serum	O
digoxin	B
levels	O
and	O
adjust	O
digoxin	B
doses	O
appropriately	O
.	O

Non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
agents	B
:	O
Seizures	O
have	O
been	O
reported	O
in	O
patients	O
taking	O
enoxacin	B
concomitantly	O
with	O
the	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
drug	B
fenbufen	I
.	O

Sucralfate	B
and	O
antacids	B
:	O
Quinolones	B
form	O
chelates	O
with	O
metal	O
cations	O
.	O

Therefore	O
,	O
administration	O
of	O
quinolones	B
with	O
antacids	B
containing	O
calcium	B
,	O
magnesium	B
,	O
or	O
aluminum	B
;	O

or	O
with	O
multivitamins	B
containing	O
zinc	B
may	O
substantially	O
interfere	O
with	O
drug	O
absorption	O
and	O
result	O
in	O
insufficient	O
plasma	O
and	O
tissue	O
quinolone	B
concentrations	O
.	O

Antacids	B
containing	O
aluminum	B
hydroxide	I
and	O
magnesium	B
hydroxide	I
reduce	O
the	O
oral	O
absorption	O
of	O
enoxacin	B
by	O
75	O
%	O
.	O

The	O
oral	O
bioavailability	O
of	O
enoxacin	B
is	O
reduced	O
by	O
60	O
%	O
with	O
coadministration	O
of	O
ranitidine	B
.	O

Theophylline	B
:	O
Enoxacin	B
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
cytochrome	O
P	O
-	O
450	O
isozymes	O
responsible	O
for	O
the	O
metabolism	O
of	O
methylxanthines	B
.	O

Enoxacin	B
interferes	O
with	O
the	O
metabolism	O
of	O
theophylline	B
resulting	O
in	O
a	O
42	O
%	O
to	O
74	O
%	O
dose	O
-	O
related	O
decrease	O
in	O
theophylline	B
clearance	O
and	O
a	O
subsequent	O
260	O
%	O
to	O
350	O
%	O
increase	O
in	O
serum	O
theophylline	B
levels	O
.	O

Theophylline	B
-	O
related	O
adverse	O
effects	O
have	O
occurred	O
in	O
patients	O
when	O
theophylline	B
and	O
enoxacin	B
were	O
coadministered	O
.	O

Warfarin	B
:	O
Quinolones	B
,	O
including	O
enoxacin	B
,	O
decrease	O
the	O
clearance	O
of	O
R	O
-	O
warfarin	B
,	O
the	O
less	O
active	O
isomer	O
of	O
racemic	O
warfarin	B
.	O

Enoxacin	B
does	O
not	O
affect	O
the	O
clearance	O
of	O
the	O
active	O
S	O
-	O
isomer	O
,	O
and	O
changes	O
in	O
clotting	O
time	O
have	O
not	O
been	O
observed	O
when	O
enoxacin	B
and	O
warfarin	B
were	O
coadministered	O
.	O

Nevertheless	O
,	O
the	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
test	O
should	O
be	O
monitored	O
when	O
warfarin	B
or	O
its	O
derivatives	O
and	O
enoxacin	B
are	O
given	O
concomitantly	O
.	O

These	O
agents	O
include	O
medications	O
such	O
as	O
:	O
anticoagulants	B
,	O
platelet	B
inhibitors	I
including	O
acetylsalicylic	B
acid	I
,	O
sali	O
-	O
cylates	O
,	O
NSAIDs	B
(	O
including	O
ketorolac	B
tromethamine	I
)	O
,	O
dipyridamole	B
,	O
or	O
sulfinpyrazone	B
.	O

In	O
vitro	O
studies	O
have	O
shown	O
no	O
binding	O
displacement	O
between	O
entacapone	B
and	O
other	O
highly	O
bound	O
drugs	O
,	O
such	O
as	O
warfarin	B
,	O
salicylic	B
acid	I
,	O
phenylbutazone	B
,	O
and	O
diazepam	B
.	O

Treatment	O
with	O
entacapone	B
coadministered	O
with	O
levodopa	B
/	O
dopa	B
decarboxylase	I
inhibitor	I
does	O
not	O
change	O
these	O
effects	O
.	O

No	O
interaction	O
was	O
noted	O
with	O
the	O
MAO	O
-	O
B	O
inhibitor	B
selegiline	I
in	O
two	O
multiple	O
-	O
dose	O
interaction	O
studies	O
when	O
entacapone	B
was	O
coadministered	O
with	O
a	O
levodopa	B
/	O
dopa	B
decarboxylase	I
inhibitor	I
(	O
n	O
=	O
29	O
)	O
.	O

More	O
than	O
600	O
Parkinsons	O
disease	O
patients	O
in	O
clinical	O
trials	O
have	O
used	O
selegiline	B
in	O
combination	O
with	O
entacapone	B
and	O
levodopa	B
/	O
dopa	B
decarboxylase	I
inhibitor	I
.	O

As	O
most	O
entacapone	B
excretion	O
is	O
via	O
the	O
bile	O
,	O
caution	O
should	O
be	O
exercised	O
when	O
drugs	O
known	O
to	O
interfere	O
with	O
biliary	O
excretion	O
,	O
glucuronidation	O
,	O
and	O
intestinal	O
beta	O
-	O
glucuronidase	O
are	O
given	O
concurrently	O
with	O
entacapone	B
.	O

These	O
include	O
probenecid	B
,	O
cholestyramine	B
,	O
and	O
some	O
antibiotics	B
(	O
e	O
.	O
g	O
.	O
erythromycin	B
,	O
rifamipicin	O
,	O
ampicillin	B
and	O
chloramphenicol	B
)	O
.	O

No	O
interaction	O
with	O
the	O
tricyclic	B
antidepressant	I
imipramine	I
was	O
shown	O
in	O
a	O
single	O
-	O
dose	O
study	O
with	O
entacapone	B
without	O
coadministered	O
levodopa	B
/	O
dopa	O
-	O
decarboxylase	O
inhibitor	B
.	O

Since	O
entecavir	B
is	O
primarily	O
eliminated	O
by	O
the	O
kidneys	O
,	O
coadministration	O
of	O
BARACLUDE	B
with	O
drugs	O
that	O
reduce	O
renal	O
function	O
or	O
compete	O
for	O
active	O
tubular	O
secretion	O
may	O
increase	O
serum	O
concentrations	O
of	O
either	O
entecavir	B
or	O
the	O
coadministered	O
drug	O
.	O

Coadministration	O
of	O
entecavir	B
with	O
lamivudine	B
,	O
adefovir	B
dipivoxil	I
,	O
or	O
tenofovir	B
disoproxil	I
fumarate	I
did	O
not	O
result	O
in	O
significant	O
drug	O
interactions	O
.	O

The	O
effects	O
of	O
coadministration	O
of	O
BARACLUDE	B
with	O
other	O
drugs	O
that	O
are	O
renally	O
eliminated	O
or	O
are	O
known	O
to	O
affect	O
renal	O
function	O
have	O
not	O
been	O
evaluated	O
,	O
and	O
patients	O
should	O
be	O
monitored	O
closely	O
for	O
adverse	O
events	O
when	O
BARACLUDE	B
is	O
coadministered	O
with	O
such	O
drugs	O
.	O

All	O
vasopressors	B
should	O
be	O
used	O
cautiously	O
in	O
patients	O
taking	O
monoamine	B
oxidase	I
(	O
MAO	O
)	O
inhibitors	B
.	O

Epinephrine	B
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
other	O
sympathomimetic	B
drugs	I
(	O
such	O
as	O
isoproterenol	B
)	O
because	O
of	O
possible	O
additive	O
effects	O
and	O
increased	O
toxicity	O
.	O

Administration	O
of	O
epinephrine	B
to	O
patients	O
receiving	O
cyclopropane	B
or	O
halogenated	B
hydrocarbon	I
general	I
anesthetics	I
such	O
as	O
halothane	B
which	O
sensitize	O
the	O
myocardium	O
,	O
may	O
induce	O
cardiac	O
arrhythmia	O
.	O
.	O

Epinephrine	B
also	O
should	O
be	O
used	O
cautiously	O
with	O
other	O
drugs	B
(	O
e	O
.	O
g	O
.	O
,	O
digitalis	B
,	O
glycosides	B
)	O
that	O
sensitize	O
the	O
myocardium	O
to	O
the	O
actions	O
of	O
sympathomimetic	B
drugs	I
.	O

Diuretic	B
agents	I
may	O
decrease	O
vascular	O
response	O
to	O
pressor	O
drugs	O
such	O
as	O
epinephrine	B
.	O

Epinephrine	B
may	O
antagonize	O
the	O
neuron	O
blockade	O
produced	O
by	O
guanethidine	B
resulting	O
in	O
decreased	O
antihypertensive	O
effect	O
and	O
requiring	O
increased	O
dosage	O
of	O
the	O
latter	O
.	O

Concomitant	O
use	O
of	O
ELLENCE	B
with	O
other	O
cardioactive	O
compounds	O
that	O
could	O
cause	O
heart	O
failure	O
(	O
e	O
.	O
g	O
.	O
,	O
calcium	B
channel	I
blockers	I
)	O
,	O
requires	O
close	O
monitoring	O
of	O
cardiac	O
function	O
throughout	O
treatment	O
.	O

Cimetidine	B
increased	O
the	O
AUC	O
of	O
epirubicin	B
by	O
50	O
%	O
.	O

Cimetidine	B
treatment	O
should	O
be	O
stopped	O
during	O
treatment	O
with	O
ELLENCE	B
.	O

A	O
pharmacokinetic	O
study	O
evaluating	O
the	O
administration	O
of	O
a	O
single	O
dose	O
of	O
INSPRA	B
100	O
mg	O
with	O
ketoconazole	B
200	O
mg	O
BID	O
,	O
a	O
potent	O
inhibitor	O
of	O
the	O
CYP3A4	O
pathway	O
,	O
showed	O
a	O
1	O
.	O
7	O
-	O
fold	O
increase	O
in	O
Cmax	O
of	O
eplerenone	B
and	O
a	O
5	O
.	O
4	O
-	O
fold	O
increase	O
in	O
AUC	O
of	O
eplerenone	B
.	O

Administration	O
of	O
eplerenone	B
with	O
other	O
CYP3A4	O
inhibitors	O
(	O
e	O
.	O
g	O
.	O
,	O
erythromycin	B
500	O
mg	O
BID	O
,	O
verapamil	B
240	O
mg	O
QD	O
,	O
saquinavir	B
1200	O
mg	O
TID	O
,	O
fluconazole	B
200	O
mg	O
QD	O
)	O
resulted	O
in	O
increases	O
in	O
Cmax	O
of	O
eplerenone	B
ranging	O
from	O
1	O
.	O
4	O
-	O
to	O
1	O
.	O
6	O
-	O
fold	O
and	O
AUC	O
from	O
2	O
.	O
0	O
-	O
to	O
2	O
.	O
9	O
-	O
fold	O
.	O

ACE	B
Inhibitors	I
and	O
Angiotensin	B
II	I
Receptor	I
Antagonists	I
(	O
Congestive	O
Heart	O
Failure	O
Post	O
-	O
Myocardial	O
Infarction	O
)	O
-	O
In	O
EPHESUS	O
,	O
3020	O
(	O
91	O
%	O
)	O
patients	O
receiving	O
INSPRA	B
25	O
to	O
50	O
mg	O
also	O
received	O
ACE	B
inhibitors	I
or	O
angiotensin	B
II	I
receptor	I
antagonists	I
(	O
ACEI	B
/	O
ARB	B
)	O
.	O

Rates	O
of	O
patients	O
with	O
maximum	O
potassium	O
levels	O
5	O
.	O
5	O
mEq	O
/	O
L	O
were	O
similar	O
regardless	O
of	O
the	O
use	O
of	O
ACEI	B
/	O
ARB	B
.	O

ACE	B
Inhibitors	I
and	O
Angiotensin	B
II	I
Receptor	I
Antagonists	I
(	O
Hypertension	O
)	O
-	O
In	O
clinical	O
studies	O
of	O
patients	O
with	O
hypertension	O
,	O
the	O
addition	O
of	O
INSPRA	B
50	O
to	O
100	O
mg	O
to	O
ACE	B
inhibitors	I
and	O
angiotensin	B
II	I
receptor	I
antagonists	I
increased	O
mean	O
serum	O
potassium	O
slightly	O
(	O
about	O
0	O
.	O
09	O
-	O
0	O
.	O
13	O
mEq	O
/	O
L	O
)	O
.	O

In	O
a	O
study	O
in	O
diabetics	O
with	O
microalbuminuria	O
INSPRA	B
200	O
mg	O
combined	O
with	O
the	O
ACE	B
inhibitor	I
enalapril	I
10	O
mg	O
increased	O
the	O
frequency	O
of	O
hyperkalemia	O
(	O
serum	O
potassium	O
5	O
.	O
5	O
mEq	O
/	O
L	O
)	O
from	O
17	O
%	O
on	O
enalapril	B
alone	O
to	O
38	O
%	O
.	O

Lithium	B
-	O
A	O
drug	O
interaction	O
study	O
of	O
eplerenone	B
with	O
lithium	B
has	O
not	O
been	O
conducted	O
.	O

Serum	O
lithium	B
levels	O
should	O
be	O
monitored	O
frequently	O
if	O
INSPRA	B
is	O
administered	O
concomitantly	O
with	O
lithium	B
.	O

Nonsteroidal	B
Anti	O
-	O
Inflammatory	O
Drugs	B
(	O
NSAIDs	B
)	O
-	O
A	O
drug	O
interaction	O
study	O
of	O
eplerenone	B
with	O
an	O
NSAID	B
has	O
not	O
been	O
conducted	O
.	O

The	O
administration	O
of	O
other	O
potassium	O
-	O
sparing	O
antihypertensives	B
with	O
NSAIDs	B
has	O
been	O
shown	O
to	O
reduce	O
the	O
antihypertensive	O
effect	O
in	O
some	O
patients	O
and	O
result	O
in	O
severe	O
hyperkalemia	O
in	O
patients	O
with	O
impaired	O
renal	O
function	O
.	O

Therefore	O
,	O
when	O
INSPRA	B
and	O
NSAIDs	B
are	O
used	O
concomitantly	O
,	O
patients	O
should	O
be	O
observed	O
to	O
determine	O
whether	O
the	O
desired	O
effect	O
on	O
blood	O
pressure	O
is	O
obtained	O
.	O

Additional	O
reductions	O
in	O
blood	O
pressure	O
may	O
occur	O
when	O
FLOLAN	B
is	O
administered	O
with	O
diuretics	B
,	O
antihypertensive	B
agents	I
,	O
or	O
other	O
vasodilators	B
.	O

When	O
other	O
antiplatelet	B
agents	I
or	O
anticoagulants	B
are	O
used	O
concomitantly	O
,	O
there	O
is	O
the	O
potential	O
for	O
FLOLAN	B
to	O
increase	O
the	O
risk	O
of	O
bleeding	O
.	O

However	O
,	O
patients	O
receiving	O
infusions	O
of	O
FLOLAN	B
in	O
clinical	O
trials	O
were	O
maintained	O
on	O
anticoagulants	B
without	O
evidence	O
of	O
increased	O
bleeding	O
.	O

In	O
clinical	O
trials	O
,	O
FLOLAN	B
was	O
used	O
with	O
digoxin	B
,	O
diuretics	B
,	O
anticoagulants	B
,	O
oral	O
vasodilators	B
,	O
and	O
supplemental	O
oxygen	B
.	O
In	O
a	O
pharmacokinetic	O
substudy	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
receiving	O
furosemide	B
or	O
digoxin	B
in	O
whom	O
therapy	O
with	O
FLOLAN	B
was	O
initiated	O
,	O
apparent	O
oral	O
clearance	O
values	O
for	O
furosemide	B
(	O
n	O
=	O
23	O
)	O
and	O
digoxin	B
(	O
n	O
=	O
30	O
)	O
were	O
decreased	O
by	O
13	O
%	O
and	O
15	O
%	O
,	O
respectively	O
,	O
on	O
the	O
second	O
day	O
of	O
therapy	O
and	O
had	O
returned	O
to	O
baseline	O
values	O
by	O
day	O
87	O
.	O

However	O
,	O
patients	O
on	O
digoxin	B
may	O
show	O
elevations	O
of	O
digoxin	B
concentrations	O
after	O
initiation	O
of	O
therapy	O
with	O
FLOLAN	B
,	O
which	O
may	O
be	O
clinically	O
significant	O
in	O
patients	O
prone	O
to	O
digoxin	B
toxicity	O
.	O

Eprosartan	B
has	O
been	O
shown	O
to	O
have	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
digoxin	B
and	O
the	O
pharmacodynamics	O
of	O
warfarin	B
and	O
glyburide	B
.	O

Because	O
eprosartan	B
is	O
not	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
system	O
,	O
inhibitors	O
of	O
CYP450	O
enzyme	O
would	O
not	O
be	O
expected	O
to	O
affect	O
its	O
metabolism	O
,	O
and	O
ketoconazole	B
and	O
fluconazole	B
,	O
potent	O
inhibitors	O
of	O
CYP3A	O
and	O
2C9	O
,	O
respectively	O
,	O
have	O
been	O
shown	O
to	O
have	O
no	O
effect	O
on	O
eprosartan	B
pharmacokinetics	O
.	O

Ranitidine	B
also	O
has	O
no	O
effect	O
on	O
eprosartan	B
pharmacokinetics	O
.	O

Eprosartan	B
(	O
up	O
to	O
400	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
or	O
800	O
mg	O
q	O
.	O
d	O
.	O
)	O
doses	O
have	O
been	O
safely	O
used	O
concomitantly	O
with	O
a	O
thiazide	B
diuretic	I
(	O
hydrochlorothiazide	B
)	O
.	O

Eprosartan	B
doses	O
of	O
up	O
to	O
300	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
have	O
been	O
safely	O
used	O
concomitantly	O
with	O
sustained	O
-	O
release	O
calcium	B
channel	I
blockers	I
(	O
sustained	O
-	O
release	O
nifedipine	B
)	O
with	O
no	O
clinically	O
significant	O
adverse	O
interactions	O
.	O

Enoxaparin	B
dosed	O
as	O
a	O
1	O
.	O
0	O
mg	O
/	O
kg	O
subcutaneous	O
injection	O
q12h	O
for	O
four	O
doses	O
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
eptifibatide	B
or	O
the	O
level	O
of	O
platelet	O
aggregation	O
in	O
healthy	O
adults	O
.	O

Mineral	B
oil	I
interferes	O
with	O
the	O
absorption	O
of	O
fat	O
-	O
soluble	O
vitamins	B
,	O
including	O
vitamin	B
D	I
preparations	I
.	O

Administration	O
of	O
thiazide	B
diuretics	I
to	O
hypoparathyroid	O
patients	O
who	O
are	O
concurrently	O
being	O
treated	O
with	O
ergocalciferol	B
may	O
cause	O
hypercalcemia	O
.	O

The	O
effects	O
of	O
ERGOMAR	B
may	O
be	O
potentiated	O
by	O
triacetyloleandomycin	B
which	O
inhibits	O
the	O
metabolism	O
of	O
ergotamine	B
.	O

The	O
pressor	O
effects	O
of	O
ERGOMAR	B
and	O
other	O
vasoconstrictor	B
drugs	I
can	O
combine	O
to	O
cause	O
dangerous	O
hypertension	O
.	O

Co	O
-	O
treatment	O
with	O
the	O
potent	O
CYP3A4	O
inhibitor	O
ketoconazole	B
increases	O
erlotinib	B
AUC	O
by	O
2	O
/	O
3	O
.	O

Caution	O
should	O
be	O
used	O
when	O
administering	O
or	O
taking	O
TARCEVA	B
with	O
ketoconazole	B
and	O
other	O
strong	O
CYP3A4	O
inhibitors	O
such	O
as	O
,	O
but	O
not	O
limited	O
to	O
,	O
atazanavir	B
,	O
clarithromycin	B
,	O
indinavir	B
,	O
itraconazole	B
,	O
nefazodone	B
,	O
nelfinavir	B
,	O
ritonavir	B
,	O
saquinavir	B
,	O
telithromycin	B
,	O
troleandomycin	B
(	O
TAO	B
)	O
,	O
and	O
voriconazole	B
.	O

Pre	O
-	O
treatment	O
with	O
the	O
CYP3A4	O
inducer	O
rifampicin	B
decreased	O
erlotinib	B
AUC	O
by	O
about	O
2	O
/	O
3	O
.	O

If	O
the	O
TARCEVA	B
dose	O
is	O
adjusted	O
upward	O
,	O
the	O
dose	O
will	O
need	O
to	O
be	O
reduced	O
upon	O
discontinuation	O
of	O
rifampicin	B
or	O
other	O
inducers	O
.	O

Other	O
CYP3A4	O
inducers	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
,	O
rifabutin	B
,	O
rifapentine	B
,	O
phenytoin	B
,	O
carbamazepine	B
,	O
phenobarbital	B
and	O
St	O
.	O
Johns	O
Wort	O
.	O

Patients	O
taking	O
warfarin	B
or	O
other	O
coumarin	O
-	O
derivative	O
anticoagulants	B
should	O
be	O
monitored	O
regularly	O
for	O
changes	O
in	O
prothrombin	O
time	O
or	O
INR	O

When	O
ertapenem	B
is	O
co	O
-	O
administered	O
with	O
probenecid	B
(	O
500	O
mg	O
p	O
.	O
o	O
.	O
every	O
6	O
hours	O
)	O
,	O
probenecid	B
competes	O
for	O
active	O
tubular	O
secretion	O
and	O
reduces	O
the	O
renal	O
clearance	O
of	O
ertapenem	B
.	O

Based	O
on	O
total	O
ertapenem	B
concentrations	O
,	O
probenecid	B
increased	O
the	O
AUC	O
by	O
25	O
%	O
and	O
reduced	O
the	O
plasma	O
and	O
renal	O
clearances	O
by	O
20	O
%	O
and	O
35	O
%	O
,	O
respectively	O
.	O

Because	O
of	O
the	O
small	O
effect	O
on	O
half	O
-	O
life	O
,	O
the	O
coadministration	O
with	O
probenecid	B
to	O
extend	O
the	O
half	O
-	O
life	O
of	O
ertapenem	B
is	O
not	O
recommended	O
.	O

In	O
vitro	O
studies	O
indicate	O
that	O
ertapenem	B
does	O
not	O
inhibit	O
P	O
-	O
glycoprotein	O
-	O
mediated	O
transport	O
of	O
digoxin	B
or	O
vinblastine	B
and	O
that	O
ertapenem	B
is	O
not	O
a	O
substrate	O
for	O
P	O
-	O
glycoprotein	O
-	O
mediated	O
transport	O
.	O

Erythromycin	B
use	O
in	O
patients	O
who	O
are	O
receiving	O
high	O
doses	O
of	O
theophylline	B
may	O
be	O
associated	O
with	O
an	O
increase	O
in	O
serum	O
theophylline	B
levels	O
and	O
potential	O
theophylline	B
toxicity	O
.	O

In	O
case	O
of	O
theophylline	B
toxicity	O
and	O
/	O
or	O
elevated	O
serum	O
theophylline	B
levels	O
,	O
the	O
dose	O
of	O
theophylline	B
should	O
be	O
reduced	O
while	O
the	O
patient	O
is	O
receiving	O
concomitant	O
erythromycin	B
therapy	O
.	O

Concomitant	O
administration	O
of	O
erythromycin	B
and	O
digoxin	B
has	O
been	O
reported	O
to	O
result	O
in	O
elevated	O
digoxin	B
serum	O
levels	O
.	O

There	O
have	O
been	O
reports	O
of	O
increased	O
anticoagulant	O
effects	O
when	O
erythromycin	B
and	O
oral	O
anticoagulants	B
were	O
used	O
concomitantly	O
.	O

Concurrent	O
use	O
of	O
erythromycin	B
and	O
ergotamine	B
or	O
dihydroergotamine	B
has	O
been	O
associated	O
in	O
some	O
patients	O
with	O
acute	O
ergot	O
toxicity	O
characterized	O
by	O
severe	O
peripheral	O
vasospasm	O
and	O
dysesthesia	O
.	O

Erythromycin	B
has	O
been	O
reported	O
to	O
decrease	O
the	O
clearance	O
of	O
triazolam	B
and	O
midazolam	B
and	O
thus	O
may	O
increase	O
the	O
pharmacologic	O
effect	O
of	O
these	O
benzodiazepines	B
.	O

There	O
have	O
been	O
reports	O
of	O
interactions	O
of	O
erythromycin	B
with	O
carbamazepine	B
,	O
cyclosporine	B
,	O
tacrolimus	B
,	O
hexobarbital	B
,	O
phenytoin	B
,	O
alfentanil	B
,	O
cisapride	B
,	O
disopyramide	B
,	O
lovastatin	B
,	O
bromocriptine	B
,	O
valproate	B
,	O
terfenadine	B
,	O
and	O
astemizole	B
.	O

Erythromycin	B
has	O
been	O
reported	O
to	O
significantly	O
alter	O
the	O
metabolism	O
of	O
nonsedating	O
antihistamines	B
terfenadine	I
and	O
astemizole	B
when	O
taken	O
concomitantly	O
.	O

In	O
addition	O
,	O
deaths	O
have	O
been	O
reported	O
rarely	O
with	O
concomitant	O
administration	O
of	O
terfenadine	B
and	O
erythromycin	B
.	O

There	O
have	O
been	O
postmarketing	O
reports	O
of	O
drug	O
interactions	O
when	O
erythromycin	B
is	O
coadministered	O
with	O
cisapride	B
,	O
resulting	O
in	O
QT	O
prolongation	O
,	O
cardiac	O
arrythmias	O
,	O
ventricular	O
tachycardia	O
,	O
ventricular	O
fibrulation	O
,	O
and	O
torsades	O
de	O
pointes	O
,	O
most	O
like	O
due	O
to	O
inhibition	O
of	O
hepatic	O
metabolism	O
of	O
cisapride	B
by	O
erythromycin	B
.	O

Patients	O
receiving	O
concomitant	O
lovastatin	B
and	O
erythromycin	B
should	O
be	O
carefully	O
monitored	O
;	O

Alcohol	B
-	O
Although	O
LEXAPRO	B
did	O
not	O
potentiate	O
the	O
cognitive	O
and	O
motor	O
effects	O
of	O
alcohol	B
in	O
a	O
clinical	O
trial	O
,	O
as	O
with	O
other	O
psychotropic	B
medications	I
,	O
the	O
use	O
of	O
alcohol	B
by	O
patients	O
taking	O
LEXAPRO	B
is	O
not	O
recommended	O
.	O

Monoamine	B
Oxidase	I
Inhibitors	I
(	O
MAOIs	B
)	O

Drugs	O
That	O
Interfere	O
With	O
Hemostasis	O
(	O
NSAIDs	B
,	O
Aspirin	B
,	O
Warfarin	B
,	O
etc	O
.	O
)	O

Epidemiological	O
studies	O
of	O
the	O
case	O
-	O
control	O
and	O
cohort	O
design	O
that	O
have	O
demonstrated	O
an	O
association	O
between	O
use	O
of	O
psychotropic	B
drugs	I
that	O
interfere	O
with	O
serotonin	O
reuptake	O
and	O
the	O
occurrence	O
of	O
upper	O
gastrointestinal	O
bleeding	O
have	O
also	O
shown	O
that	O
concurrent	O
use	O
of	O
an	O
NSAID	B
or	O
aspirin	B
potentiated	O
the	O
risk	O
of	O
bleeding	O
.	O

Cimetidine	B
-	O
In	O
subjects	O
who	O
had	O
received	O
21	O
days	O
of	O
40	O
mg	O
/	O
day	O
racemic	O
citalopram	B
,	O
combined	O
administration	O
of	O
400	O
mg	O
/	O
day	O
cimetidine	B
for	O
8	O
days	O
resulted	O
in	O
an	O
increase	O
in	O
citalopram	B
AUC	O
and	O
Cmax	O
of	O
43	O
%	O
and	O
39	O
%	O
,	O
respectively	O
.	O

Digoxin	B
-	O
In	O
subjects	O
who	O
had	O
received	O
21	O
days	O
of	O
40	O
mg	O
/	O
day	O
racemic	O
citalopram	B
,	O
combined	O
administration	O
of	O
citalopram	B
and	O
digoxin	B
(	O
single	O
dose	O
of	O
1	O
mg	O
)	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
either	O
citalopram	B
or	O
digoxin	B
.	O

Lithium	B
-	O
Coadministration	O
of	O
racemic	O
citalopram	B
(	O
40	O
mg	O
/	O
day	O
for	O
10	O
days	O
)	O
and	O
lithium	B
(	O
30	O
mmol	O
/	O
day	O
for	O
5	O
days	O
)	O
had	O
no	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
citalopram	B
or	O
lithium	B
.	O

Nevertheless	O
,	O
plasma	O
lithium	B
levels	O
should	O
be	O
monitored	O
with	O
appropriate	O
adjustment	O
to	O
the	O
lithium	B
dose	O
in	O
accordance	O
with	O
standard	O
clinical	O
practice	O
.	O

Because	O
lithium	B
may	O
enhance	O
the	O
serotonergic	O
effects	O
of	O
escitalopram	B
,	O
caution	O
should	O
be	O
exercised	O
when	O
LEXAPRO	B
and	O
lithium	B
are	O
coadministered	O
.	O

Pimozide	B
and	O
Celexa	B
-	O
In	O
a	O
controlled	O
study	O
,	O
a	O
single	O
dose	O
of	O
pimozide	B
2	O
mg	O
co	O
-	O
administered	O
with	O
racemic	O
citalopram	B
40	O
mg	O
given	O
once	O
daily	O
for	O
11	O
days	O
was	O
associated	O
with	O
a	O
mean	O
increase	O
in	O
QTc	O
values	O
of	O
approximately	O
10	O
msec	O
compared	O
to	O
pimozide	B
given	O
alone	O
.	O

Racemic	O
citalopram	B
did	O
not	O
alter	O
the	O
mean	O
AUC	O
or	O
Cmax	O
of	O
pimozide	B
.	O

Sumatriptan	B
-	O
There	O
have	O
been	O
rare	O
postmarketing	O
reports	O
describing	O
patients	O
with	O
weakness	O
,	O
hyperreflexia	O
,	O
and	O
incoordination	O
following	O
the	O
use	O
of	O
a	O
selective	B
serotonin	I
reuptake	I
inhibitor	I
(	O
SSRI	B
)	O
and	O
sumatriptan	B
.	O

If	O
concomitant	O
treatment	O
with	O
sumatriptan	B
and	O
an	O
SSRI	B
(	O
e	O
.	O
g	O
.	O
,	O
fluoxetine	B
,	O
fluvoxamine	B
,	O
paroxetine	B
,	O
sertraline	B
,	O
citalopram	B
,	O
escitalopram	B
)	O
is	O
clinically	O
warranted	O
,	O
appropriate	O
observation	O
of	O
the	O
patient	O
is	O
advised	O
.	O

Theophylline	B
-	O
Combined	O
administration	O
of	O
racemic	O
citalopram	B
(	O
40	O
mg	O
/	O
day	O
for	O
21	O
days	O
)	O
and	O
the	O
CYP1A2	O
substrate	O
theophylline	B
(	O
single	O
dose	O
of	O
300	O
mg	O
)	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
theophylline	B
.	O

The	O
effect	O
of	O
theophylline	B
on	O
the	O
pharmacokinetics	O
of	O
citalopram	B
was	O
not	O
evaluated	O
.	O

Warfarin	B
-	O
Administration	O
of	O
40	O
mg	O
/	O
day	O
racemic	O
citalopram	B
for	O
21	O
days	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
warfarin	B
,	O
a	O
CYP3A4	O
substrate	O
.	O

Carbamazepine	B
-	O
Combined	O
administration	O
of	O
racemic	O
citalopram	B
(	O
40	O
mg	O
/	O
day	O
for	O
14	O
days	O
)	O
and	O
carbamazepine	B
(	O
titrated	O
to	O
400	O
mg	O
/	O
day	O
for	O
35	O
days	O
)	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
carbamazepine	B
,	O
a	O
CYP3A4	O
substrate	O
.	O

Although	O
trough	O
citalopram	B
plasma	O
levels	O
were	O
unaffected	O
,	O
given	O
the	O
enzyme	O
-	O
inducing	O
properties	O
of	O
carbamazepine	B
,	O
the	O
possibility	O
that	O
carbamazepine	B
might	O
increase	O
the	O
clearance	O
of	O
escitalopram	B
should	O
be	O
considered	O
if	O
the	O
two	O
drugs	O
are	O
coadministered	O
.	O

Triazolam	B
-	O
Combined	O
administration	O
of	O
racemic	O
citalopram	B
(	O
titrated	O
to	O
40	O
mg	O
/	O
day	O
for	O
28	O
days	O
)	O
and	O
the	O
CYP3A4	O
substrate	O
triazolam	B
(	O
single	O
dose	O
of	O
0	O
.	O
25	O
mg	O
)	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
either	O
citalopram	B
or	O
triazolam	B
.	O

Ketoconazole	B
-	O
Combined	O
administration	O
of	O
racemic	O
citalopram	B
(	O
40	O
mg	O
)	O
and	O
ketoconazole	B
(	O
200	O
mg	O
)	O
decreased	O
the	O
Cmax	O
and	O
AUC	O
of	O
ketoconazole	B
by	O
21	O
%	O
and	O
10	O
%	O
,	O
respectively	O
,	O
and	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
citalopram	B
.	O

Ritonavir	B
-	O
Combined	O
administration	O
of	O
a	O
single	O
dose	O
of	O
ritonavir	B
(	O
600	O
mg	O
)	O
,	O
both	O
a	O
CYP3A4	O
substrate	O
and	O
a	O
potent	O
inhibitor	O
of	O
CYP3A4	O
,	O
and	O
escitalopram	B
(	O
20	O
mg	O
)	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
either	O
ritonavir	B
or	O
escitalopram	B
.	O

However	O
,	O
coadministration	O
of	O
escitalopram	B
(	O
20	O
mg	O
)	O
and	O
ritonavir	B
(	O
600	O
mg	O
)	O
,	O
a	O
potent	O
inhibitor	O
of	O
CYP3A4	O
,	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
escitalopram	B
.	O

Because	O
escitalopram	B
is	O
metabolized	O
by	O
multiple	O
enzyme	O
systems	O
,	O
inhibition	O
of	O
a	O
single	O
enzyme	O
may	O
not	O
appreciably	O
decrease	O
escitalopram	B
clearance	O
.	O

In	O
addition	O
,	O
steady	O
state	O
levels	O
of	O
racemic	O
citalopram	B
were	O
not	O
significantly	O
different	O
in	O
poor	O
metabolizers	O
and	O
extensive	O
CYP2D6	O
metabolizers	O
after	O
multiple	O
-	O
dose	O
administration	O
of	O
citalopram	B
,	O
suggesting	O
that	O
coadministration	O
,	O
with	O
escitalopram	B
,	O
of	O
a	O
drug	O
that	O
inhibits	O
CYP2D6	O
,	O
is	O
unlikely	O
to	O
have	O
clinically	O
significant	O
effects	O
on	O
escitalopram	B
metabolism	O
.	O

However	O
,	O
there	O
are	O
limited	O
in	O
vivo	O
data	O
suggesting	O
a	O
modest	O
CYP2D6	O
inhibitory	O
effect	O
for	O
escitalopram	B
,	O
i	O
.	O
e	O
.	O
,	O
coadministration	O
of	O
escitalopram	B
(	O
20	O
mg	O
/	O
day	O
for	O
21	O
days	O
)	O
with	O
the	O
tricyclic	B
antidepressant	I
desipramine	I
(	O
single	O
dose	O
of	O
50	O
mg	O
)	O
,	O
a	O
substrate	O
for	O
CYP2D6	O
,	O
resulted	O
in	O
a	O
40	O
%	O
increase	O
in	O
Cmax	O
and	O
a	O
100	O
%	O
increase	O
in	O
AUC	O
of	O
desipramine	B
.	O

Metoprolol	B
-	O
Administration	O
of	O
20	O
mg	O
/	O
day	O
LEXAPRO	B
for	O
21	O
days	O
in	O
healthy	O
volunteers	O
resulted	O
in	O
a	O
50	O
%	O
increase	O
in	O
Cmax	O
and	O
82	O
%	O
increase	O
in	O
AUC	O
of	O
the	O
beta	O
-	O
adrenergic	O
blocker	B
metoprolol	I
(	O
given	O
in	O
a	O
single	O
dose	O
of	O
100	O
mg	O
)	O
.	O

Coadministration	O
of	O
LEXAPRO	B
and	O
metoprolol	B
had	O
no	O
clinically	O
significant	O
effects	O
on	O
blood	O
pressure	O
or	O
heart	O
rate	O
.	O

Concomitant	O
Administration	O
with	O
Racemic	O
Citalopram	B
Citalopram	I
-	O
Since	O
escitalopram	B
is	O
the	O
active	O
isomer	O
of	O
racemic	O
citalopram	B
(	O
Celexa	B
)	O
,	O
the	O
two	O
agents	O
should	O
not	O
be	O
coadministered	O
.	O

Catecholamine	O
-	O
depleting	O
drugs	O
,	O
e	O
.	O
g	O
.	O
,	O
reserpine	B
,	O
may	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
beta	B
blocking	I
agents	I
.	O

Patients	O
treated	O
concurrently	O
with	O
BREVIBLOC	B
(	O
esmolol	B
HCl	I
)	O
and	O
a	O
catecholamine	O
depletor	O
should	O
therefore	O
be	O
closely	O
observed	O
for	O
evidence	O
of	O
hypotension	O
or	O
marked	O
bradycardia	O
,	O
which	O
may	O
result	O
in	O
vertigo	O
,	O
syncope	O
,	O
or	O
postural	O
hypotension	O
.	O

A	O
study	O
of	O
interaction	O
between	O
BREVIBLOC	B
and	O
warfarin	B
showed	O
that	O
concomitant	O
administration	O
of	O
BREVIBLOC	B
and	O
warfarin	B
does	O
not	O
alter	O
warfarin	B
plasma	O
levels	O
.	O

BREVIBLOC	B
concentrations	O
were	O
equivocally	O
higher	O
when	O
given	O
with	O
warfarin	B
,	O
but	O
this	O
is	O
not	O
likely	O
to	O
be	O
clinically	O
important	O
.	O

When	O
digoxin	B
and	O
BREVIBLOC	B
were	O
concomitantly	O
administered	O
intravenously	O
to	O
normal	O
volunteers	O
,	O
there	O
was	O
a	O
10	O
-	O
20	O
%	O
increase	O
in	O
digoxin	B
blood	O
levels	O
at	O
some	O
time	O
points	O
.	O

Digoxin	B
did	O
not	O
affect	O
BREVIBLOC	B
pharmacokinetics	O
.	O

When	O
intravenous	O
morphine	B
and	O
BREVIBLOC	B
were	O
concomitantly	O
administered	O
in	O
normal	O
subjects	O
,	O
no	O
effect	O
on	O
morphine	B
blood	O
levels	O
was	O
seen	O
,	O
but	O
BREVIBLOC	B
steady	O
-	O
state	O
blood	O
levels	O
were	O
increased	O
by	O
46	O
%	O
in	O
the	O
presence	O
of	O
morphine	B
.	O

The	O
effect	O
of	O
BREVIBLOC	B
on	O
the	O
duration	O
of	O
succinylcholine	B
-	O
induced	O
neuromuscular	O
blockade	O
was	O
studied	O
in	O
patients	O
undergoing	O
surgery	O
.	O

The	O
onset	O
of	O
neuromuscular	O
blockade	O
by	O
succinylcholine	B
was	O
unaffected	O
by	O
BREVIBLOC	B
,	O
but	O
the	O
duration	O
of	O
neuromuscular	O
blockade	O
was	O
prolonged	O
from	O
5	O
minutes	O
to	O
8	O
minutes	O
.	O

Although	O
the	O
interactions	O
observed	O
in	O
these	O
studies	O
do	O
not	O
appear	O
to	O
be	O
of	O
major	O
clinical	O
importance	O
,	O
BREVIBLOC	B
should	O
be	O
titrated	O
with	O
caution	O
in	O
patients	O
being	O
treated	O
concurrently	O
with	O
digoxin	B
,	O
morphine	B
,	O
succinylcholine	B
or	O
warfarin	B
.	O

Caution	O
should	O
be	O
exercised	O
when	O
considering	O
the	O
use	O
of	O
BREVIBLOC	B
and	O
verapamil	B
in	O
patients	O
with	O
depressed	O
myocardial	O
function	O
.	O

Additionally	O
,	O
BREVIBLOC	B
should	O
not	O
be	O
used	O
to	O
control	O
supraventricular	O
tachycardia	O
in	O
the	O
presence	O
of	O
agents	O
which	O
are	O
vasoconstrictive	O
and	O
inotropic	O
such	O
as	O
dopamine	B
,	O
epinephrine	B
,	O
and	O
norepinephrine	B
because	O
of	O
the	O
danger	O
of	O
blocking	O
cardiac	O
contractility	O
when	O
systemic	O
vascular	O
resistance	O
is	O
high	O
.	O

Drug	O
interaction	O
studies	O
have	O
shown	O
that	O
esomeprazole	B
does	O
not	O
have	O
any	O
clinically	O
significant	O
interactions	O
with	O
phenytoin	B
,	O
warfarin	B
,	O
quinidine	B
,	O
clarithromycin	B
or	O
amoxicillin	B
.	O

Post	O
-	O
marketing	O
reports	O
of	O
changes	O
in	O
prothrombin	O
measures	O
have	O
been	O
received	O
among	O
patients	O
on	O
concomitant	O
warfarin	B
and	O
esomeprazole	B
therapy	O
.	O

Patients	O
treated	O
with	O
proton	B
pump	I
inhibitors	I
and	O
warfarin	B
concomitantly	O
may	O
need	O
to	O
be	O
monitored	O
for	O
increases	O
in	O
INR	O
and	O
prothrombin	O
time	O
.	O

Esomeprazole	B
may	O
potentially	O
interfere	O
with	O
CYP2C19	O
,	O
the	O
major	O
esomeprazole	B
metabolizing	O
enzyme	O
.	O

Coadministration	O
of	O
esomeprazole	B
30	O
mg	O
and	O
diazepam	B
,	O
a	O
CYP2C19	O
substrate	O
,	O
resulted	O
in	O
a	O
45	O
%	O
decrease	O
in	O
clearance	O
of	O
diazepam	B
.	O

Therefore	O
,	O
esomeprazole	B
may	O
interfere	O
with	O
the	O
absorption	O
of	O
drugs	O
where	O
gastric	O
pH	O
is	O
an	O
important	O
determinant	O
of	O
bioavailability	O
(	O
eg	O
,	O
ketoconazole	B
,	O
iron	B
salts	O
and	O
digoxin	B
)	O
.	O

Coadministration	O
of	O
oral	O
contraceptives	B
,	O
diazepam	B
,	O
phenytoin	B
,	O
or	O
quinidine	B
did	O
not	O
seem	O
to	O
change	O
the	O
pharmacokinetic	O
profile	O
of	O
esomeprazole	B
.	O

Concomitant	O
administration	O
of	O
clarithromycin	B
with	O
pimozide	B
is	O
contraindicated	O
.	O

The	O
action	O
of	O
the	O
benzodiazepines	B
may	O
be	O
potentiated	O
by	O
anticonvulsants	B
,	O
antihistamines	B
,	O
alcohol	B
,	O
barbiturates	B
,	O
monoamine	B
oxidase	I
inhibitors	I
,	O
narcotics	B
,	O
phenothiazines	B
,	O
psychotropic	B
medications	I
,	O
or	O
other	O
drugs	O
that	O
produce	O
CNS	O
depression	O
.	O

While	O
no	O
in	O
vivo	O
drug	O
-	O
drug	O
interaction	O
studies	O
were	O
conducted	O
between	O
estazolam	B
and	O
inducers	O
of	O
CYP3A	O
,	O
compounds	O
that	O
are	O
potent	O
CYP3A	O
inducers	O
(	O
such	O
as	O
carbamazepine	B
,	O
phenytoin	B
,	O
rifampin	B
,	O
and	O
barbiturates	B
)	O
would	O
be	O
expected	O
to	O
decrease	O
estazolam	B
concentrations	O
.	O

Estazolam	B
:	O
Interaction	O
with	O
Drugs	O
that	O
Inhibit	O
Metabolism	O
via	O
Cytochrome	O
P450	O
3A	O
(	O
CYP3A	O
)	O
:	O
The	O
metabolism	O
of	O
estazolam	B
to	O
the	O
major	O
circulating	O
metabolite	O
4	O
-	O
hydroxy	O
-	O
estazolam	B
and	O
the	O
metabolism	O
of	O
other	O
triazolobenzodiazepines	B
is	O
catalyzed	O
by	O
CYP3A	O
.	O

Consequently	O
,	O
estazolam	B
should	O
be	O
avoided	O
in	O
patients	O
receiving	O
ketoconazole	B
and	O
itraconazole	B
,	O
which	O
are	O
very	O
potent	O
inhibitors	O
of	O
CYP3A	O
.	O

The	O
following	O
are	O
examples	O
of	O
drugs	O
known	O
to	O
inhibit	O
the	O
metabolism	O
of	O
other	O
related	O
benzodiazepines	B
,	O
presumably	O
through	O
inhibition	O
of	O
CYP3A	O
:	O
nefazodone	B
,	O
fluvoxamine	B
,	O
cimetidine	B
,	O
diltiazem	B
,	O
isoniazide	B
,	O
and	O
some	O
macrolide	B
antibiotics	I
.	O

Drug	O
Interaction	O
with	O
Fluoxetine	B
:	O
A	O
multiple	O
-	O
dose	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
effect	O
of	O
fluoxetine	B
20	O
mg	O
BID	O
on	O
the	O
pharmacokinetics	O
of	O
estazolam	B
2	O
mg	O
QHS	O
after	O
seven	O
days	O
.	O

The	O
pharmacokinetics	O
of	O
estazolam	B
(	O
Cmax	O
and	O
AUC	O
)	O
were	O
not	O
affected	O
during	O
multiple	O
-	O
dose	O
fluoxetine	B
,	O
suggesting	O
no	O
clinically	O
significant	O
pharmacokinetic	O
interaction	O
.	O

Estazolam	B
:	O
Interaction	O
with	O
Other	O
Drugs	O
that	O
are	O
Metabolized	O
by	O
Cytochrome	O
P450	O
(	O
CYP	O
)	O
:	O
At	O
clinically	O
relevant	O
concentrations	O
,	O
in	O
vitro	O
studies	O
indicate	O
that	O
estazolam	B
(	O
0	O
.	O
6	O
M	O
)	O
was	O
not	O
inhibitory	O
towards	O
the	O
major	O
cytochrome	O
P450	O
isoforms	O
CYP1A2	O
,	O
CYP2A6	O
,	O
CYP2C9	O
,	O
CYP2C19	O
,	O
CYP2D6	O
,	O
CYP2E1	O
,	O
and	O
CYP3A	O
.	O

Other	O
binding	O
proteins	O
may	O
be	O
elevated	O
in	O
serum	O
,	O
i	O
.	O
e	O
.	O
,	O
corticosteroid	O
binding	O
globulin	O
(	O
CBG	O
)	O
,	O
sex	B
hormone	O
-	O
binding	O
globulin	O
(	O
SHBG	O
)	O
,	O
leading	O
to	O
increased	O
total	O
circulating	O
corticosteroids	B
and	O
sex	B
steroids	I
,	O
respectively	O
.	O

Milk	O
,	O
milk	O
products	O
,	O
and	O
calcium	B
-	O
rich	O
foods	O
or	O
drugs	O
may	O
impair	O
the	O
absorption	O
of	O
EMCYT	B
.	O

CNS	O
-	O
Active	O
Drugs	O
Ethanol	B
An	O
additive	O
effect	O
on	O
psychomotor	O
performance	O
was	O
seen	O
with	O
coadministration	O
of	O
eszopiclone	B
and	O
ethanol	B
0	O
.	O
70	O
g	O
/	O
kg	O
for	O
up	O
to	O
4	O
hours	O
after	O
ethanol	B
administration	O
.	O

Paroxetine	B
:	O
Coadministration	O
of	O
single	O
doses	O
of	O
eszopiclone	B
3	O
mg	O
and	O
paroxetine	B
20	O
mg	O
daily	O
for	O
7	O
days	O
produced	O
no	O
pharmacokinetic	O
or	O
pharmacodynamic	O
interaction	O
.	O

Lorazepam	B
:	O
Coadministration	O
of	O
single	O
doses	O
of	O
eszopiclone	B
3	O
mg	O
and	O
lorazepam	B
2	O
mg	O
did	O
not	O
have	O
clinically	O
relevant	O
effects	O
on	O
the	O
pharmacodynamics	O
or	O
pharmacokinetics	O
of	O
either	O
drug	O
.	O

Olanzapine	B
:	O
Coadministration	O
of	O
eszopiclone	B
3	O
mg	O
and	O
olanzapine	B
10	O
mg	O
produced	O
a	O
decrease	O
in	O
DSST	O
scores	O
.	O

Drugs	O
That	O
Inhibit	O
CYP3A4	O
(	O
Ketoconazole	B
)	O
CYP3A4	O
is	O
a	O
major	O
metabolic	O
pathway	O
for	O
elimination	O
of	O
eszopiclone	B
.	O

The	O
AUC	O
of	O
eszopiclone	B
was	O
increased	O
2	O
.	O
2	O
-	O
fold	O
by	O
coadministration	O
of	O
ketoconazole	B
,	O
a	O
potent	O
inhibitor	O
of	O
CYP3A4	O
,	O
400	O
mg	O
daily	O
for	O
5	O
days	O
.	O

Other	O
strong	O
inhibitors	O
of	O
CYP3A4	O
(	O
e	O
.	O
g	O
.	O
,	O
itraconazole	B
,	O
clarithromycin	B
,	O
nefazodone	B
,	O
troleandomycin	B
,	O
ritonavir	B
,	O
nelfinavir	B
)	O
would	O
be	O
expected	O
to	O
behave	O
similarly	O
.	O

Drugs	O
That	O
Induce	O
CYP3A4	O
(	O
Rifampicin	B
)	O
Racemic	O
zopiclone	B
exposure	O
was	O
decreased	O
80	O
%	O
by	O
concomitant	O
useof	O
rifampicin	B
,	O
a	O
potent	O
inducer	O
of	O
CYP3A4	O
.	O

Drugs	O
With	O
A	O
Narrow	O
Therapeutic	O
Index	O
Digoxin	B
A	O
single	O
dose	O
of	O
eszopiclone	B
3	O
mg	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
digoxin	B
measured	O
at	O
steady	O
state	O
following	O
dosing	O
of	O
0	O
.	O
5	O
mg	O
twice	O
daily	O
for	O
one	O
day	O
and	O
0	O
.	O
25	O
mg	O
daily	O
for	O
the	O
next	O
6	O
days	O
.	O

Warfarin	B
:	O
Eszopiclone	B
3	O
mg	O
administered	O
daily	O
for	O
5	O
days	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
(	O
R	O
)	O
-	O
or	O
(	O
S	O
)	O
-	O
warfarin	B
,	O
nor	O
were	O
there	O
any	O
changes	O
in	O
the	O
pharmacodynamic	O
profile	O
(	O
prothrombin	O
time	O
)	O
following	O
a	O
single	O
25	O
mg	O
oral	O
dose	O
of	O
warfarin	B

However	O
,	O
it	O
was	O
observed	O
that	O
the	O
pharmacokinetics	O
of	O
ENBREL	B
was	O
unaltered	O
by	O
concomitant	O
methotrexate	B
in	O
rheumatoid	O
arthritis	O
patients	O
.	O

In	O
a	O
study	O
in	O
which	O
patients	O
with	O
active	O
RA	O
were	O
treated	O
for	O
up	O
to	O
24	O
weeks	O
with	O
concurrent	O
ENBREL	B
and	O
anakinra	B
therapy	O
,	O
a	O
7	O
%	O
rate	O
of	O
serious	O
infections	O
was	O
observed	O
,	O
which	O
was	O
higher	O
than	O
that	O
observed	O
with	O
ENBREL	B
alone	O
(	O
0	O
%	O
)	O
.	O

Two	O
percent	O
of	O
patients	O
treated	O
concurrently	O
with	O
ENBREL	B
and	O
anakinra	B
developed	O
neutropenia	O
(	O
ANC	O
1	O
x	O
109	O
/	O
L	O
)	O
.	O

Patients	O
in	O
a	O
clinical	O
study	O
who	O
were	O
on	O
established	O
therapy	O
with	O
sulfasalazine	B
,	O
to	O
which	O
ENBREL	B
was	O
added	O
,	O
were	O
noted	O
to	O
develop	O
a	O
mild	O
decrease	O
in	O
mean	O
neutrophil	O
counts	O
in	O
comparison	O
to	O
groups	O
treated	O
with	O
either	O
ENBREL	B
CI	O
or	O
sulfasalazine	B
alone	O
.	O

Lithium	B
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	B
because	O
they	O
reduce	O
its	O
renal	O
clearance	O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B
toxicity	O
.	O

EDECRIN	B
may	O
increase	O
the	O
ototoxic	O
potential	O
of	O
other	O
drugs	O
such	O
as	O
aminoglycoside	B
and	O
some	O
cephalosporin	B
antibiotics	I
.	O

A	O
number	O
of	O
drugs	O
,	O
including	O
ethacrynic	B
acid	I
,	O
have	O
been	O
shown	O
to	O
displace	O
warfarin	B
from	O
plasma	O
protein	O
;	O

In	O
some	O
patients	O
,	O
the	O
administration	O
of	O
a	O
non	O
-	O
steroidal	B
antiinflammatory	I
agent	I
can	O
reduce	O
the	O
diuretic	O
,	O
natriuretic	O
,	O
and	O
antihypertensive	O
effects	O
of	O
loop	B
,	O
potassium	O
-	O
sparing	B
and	O
thiazide	B
diuretics	I
.	O

Therefore	O
,	O
when	O
EDECRIN	B
and	O
non	O
-	O
steroidal	B
anti	O
-	O
inflammatory	B
agents	I
are	O
used	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	B
is	O
obtained	O
.	O

The	O
results	O
of	O
a	O
study	O
of	O
coadministration	O
of	O
ethambutol	B
(	O
50	O
mg	O
/	O
kg	O
)	O
with	O
an	O
aluminum	B
hydroxide	I
containing	O
antacid	B
to	O
13	O
patients	O
with	O
tuberculosis	O
showed	O
a	O
reduction	O
of	O
mean	O
serum	O
concentrations	O
and	O
urinary	O
excretion	O
of	O
ethambutol	B
of	O
approximately	O
20	O
%	O
and	O
13	O
%	O
,	O
respectively	O
,	O
suggesting	O
that	O
the	O
oral	O
absorption	O
of	O
ethambutol	B
may	O
be	O
reduced	O
by	O
these	O
antacid	B
products	I
.	O

It	O
is	O
recommended	O
to	O
avoid	O
concurrent	O
administration	O
of	O
ethambutol	B
with	O
aluminum	B
hydroxide	I
containing	O
antacids	B
for	O
at	O
least	O
4	O
hours	O
following	O
ethambutol	B
administration	O
.	O

Dicumarol	B
and	O
warfarin	B
may	O
decrease	O
hypoprothrombinemic	O
effect	O
.	O

Other	O
depressasnts	O
such	O
as	O
alcohol	B
,	O
barbiturates	B
,	O
and	O
MAOIs	B
may	O
enhance	O
CNS	O
depression	O
when	O
administered	O
with	O
ethchlorvynol	B
.	O

May	O
interact	O
with	O
addictive	O
medications	O
,	O
especially	O
central	B
nervous	I
system	I
(	O
CNS	O
)	O
depressants	B
with	O
habituating	O
potential	O
(	O
prolonged	O
concurrent	O
use	O
may	O
increase	O
the	O
risk	O
of	O
habituation	O
)	O
,	O
alcohol	B
or	O
CNS	O
depression	O
producing	O
medications	O
(	O
concurrent	O
use	O
may	O
increase	O
the	O
CNS	O
depressant	O
effects	O
of	O
either	O
these	O
medications	O
or	O
ethinamate	B
)	O
.	O

Certain	O
endocrine	O
and	O
liver	O
function	O
tests	O
may	O
be	O
affected	O
by	O
estrogen	B
-	O
containing	O
oral	O
contraceptives	B
.	O

Trecator	B
has	O
been	O
found	O
to	O
temporarily	O
raise	O
serum	O
concentrations	O
of	O
isoniazid	B
.	O

Trecator	B
may	O
potentiate	O
the	O
adverse	O
effects	O
of	O
other	O
antituberculous	B
drugs	I
administered	O
concomitantly	O
.	O

In	O
particular	O
,	O
convulsions	O
have	O
been	O
reported	O
when	O
ethionamide	B
is	O
administered	O
with	O
cycloserine	B
and	O
special	O
care	O
should	O
be	O
taken	O
when	O
the	O
treatment	O
regimen	O
includes	O
both	O
of	O
these	O
drugs	O
.	O

Ethopropazine	B
may	O
interact	O
with	O
alcohol	B
or	O
other	O
CNS	B
depressants	I
,	O
causing	O
increased	O
sedative	O
effects	O
.	O

It	O
may	O
also	O
interact	O
with	O
amantadine	B
or	O
other	O
anticholinergic	B
drugs	I
or	O
MAOIs	B
,	O
which	O
may	O
intensify	O
the	O
anticholinergic	B
action	O
.	O

Ethopropazine	B
can	O
interact	O
with	O
chlorpromazine	B
,	O
increasing	O
the	O
metabolism	O
of	O
chlorpromazine	B
.	O

Since	O
Zarontin	B
(	O
ethosuximide	B
)	O
may	O
interact	O
with	O
concurrently	O
administered	O
antiepileptic	B
drugs	I
,	O
periodic	O
serum	O
level	O
determinations	O
of	O
these	O
drugs	B
may	O
be	O
necessary	O
(	O
eg	O
,	O
ethosuximide	B
may	O
elevate	O
phenytoin	B
serum	O
levels	O
and	O
valproic	B
acid	I
has	O
been	O
reported	O
to	O
both	O
increase	O
and	O
decrease	O
ethosuximide	B
levels	O
)	O
.	O

Considerable	O
caution	O
should	O
be	O
exercised	O
if	O
PEGANONE	B
is	O
administered	O
concurrently	O
with	O
Phenurone	B
(	O
phenacemide	B
)	O
since	O
paranoid	O
symptoms	O
have	O
been	O
reported	O
during	O
therapy	O
with	O
this	O
combination	O
.	O

A	O
two	O
-	O
way	O
interaction	O
between	O
the	O
hydantoin	B
antiepileptic	I
,	O
phenytoin	B
,	O
and	O
the	O
coumarin	B
anticoagulants	O
has	O
been	O
suggested	O
.	O

Presumably	O
,	O
phenytoin	B
acts	O
as	O
a	O
stimulator	O
of	O
coumarin	B
metabolism	O
and	O
has	O
been	O
reported	O
to	O
cause	O
decreased	O
serum	O
levels	O
of	O
the	O
coumarin	B
anticoagulants	I
and	O
increased	O
prothrombin	O
-	O
proconvertin	O
concentrations	O
.	O

Conversely	O
,	O
the	O
coumarin	B
anticoagulants	I
have	O
been	O
reported	O
to	O
increase	O
the	O
serum	O
levels	O
and	O
prolong	O
the	O
serum	O
half	O
-	O
life	O
of	O
phenytoin	B
by	O
inhibiting	O
its	O
metabolism	O
.	O

Although	O
there	O
is	O
no	O
documentation	O
of	O
such	O
,	O
a	O
similar	O
interaction	O
between	O
ethotoin	B
and	O
the	O
coumarin	B
anticoagulants	I
may	O
occur	O
.	O

Caution	O
is	O
therefore	O
advised	O
when	O
administering	O
PEGANONE	B
to	O
patients	O
receiving	O
coumarin	B
anticoagulants	I
.	O

